

Early and late coronary stent thrombosis of sirolimus-eluting stents in routine clinical practice: data from a large two

Lancet, The

369, 667-678

DOI: [10.1016/s0140-6736\(07\)60314-6](https://doi.org/10.1016/s0140-6736(07)60314-6)

Citation Report

#	ARTICLE	IF	CITATIONS
3	Uterine mesothelioma. American Journal of Obstetrics and Gynecology, 1979, 135, 162.	0.7	3
4	The molecular mechanisms of congenital hypofibrinogenaemia. Cellular and Molecular Life Sciences, 2004, 61, 1427-38.	2.4	51
5	Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angiography. Heart, 2006, 93, 1533-1536.	1.2	40
6	Drug-Eluting Stent Thrombosis vs Bare Metal Stent Restenosis: Finding the Lesser of Two Evils. The American Heart Hospital Journal, 2007, 5, 151-154.	0.2	1
7	Offsetting Impact of Thrombosis and Restenosis on the Occurrence of Death and Myocardial Infarction After Paclitaxel-Eluting and Bare Metal Stent Implantation. Circulation, 2007, 115, 2842-2847.	1.6	162
9	Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives. Expert Review of Cardiovascular Therapy, 2007, 5, 939-953.	0.6	1
10	Drug-Eluting Stents: Can We Move Beyond Stent Thrombosis?. The American Heart Hospital Journal, 2007, 5, 155-158.	0.2	2
11	Drug-Eluting Stents. Circulation, 2007, 116, 696-699.	1.6	20
12	Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angiography. Heart, 2007, 93, 1353-1356.	1.2	23
13	Late Coronary Stent Thrombosis. Circulation, 2007, 116, 1952-1965.	1.6	218
14	(Active) stents are no panacea, a deja-vu. European Heart Journal, 2007, 28, 653-654.	1.0	4
15	Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. European Heart Journal, 2007, 28, 2706-2713.	1.0	337
16	Emerging Endovascular Therapies for Symptomatic Intracranial Atherosclerotic Disease. Stroke, 2007, 38, 2391-2396.	1.0	31
17	The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis. Country Review Ukraine, 2007, 9, D10-D19.	0.8	1
18	Does prolonged clopidogrel therapy improve outcome in patients with drug-eluting or bare-metal stents?. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 302-303.	3.3	1
19	Risk profiling patients for selective use of drug-eluting stents is warranted. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 346-347.	3.3	1
20	Drug-Eluting Stents: The Next Chapter of the Coronary Stent Saga. The American Heart Hospital Journal, 2007, 5, 173-176.	0.2	0
21	Controversies Surrounding the Use of Drug-Eluting Stents. The American Heart Hospital Journal, 2007, 5, 141-145.	0.2	0

#	ARTICLE	IF	CITATIONS
22	Drug-Eluting Stents: Some Thoughts From Old Europe. <i>The American Heart Hospital Journal</i> , 2007, 5, 135-137.	0.2	5
23	The Risks and Benefits of Drug-Eluting Stents. <i>The American Heart Hospital Journal</i> , 2007, 5, 146-150.	0.2	0
24	The Enigma of Drug-Eluting Stents. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 2028.	3.8	18
25	Response to Letter Regarding Article, "Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization". <i>Circulation</i> , 2007, 116, .	1.6	2
26	Letter by Testa et al Regarding Article, "Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization". <i>Circulation</i> , 2007, 116, e549; author reply e550.	1.6	2
27	Drug-Eluting Stent Update 2007. <i>Circulation</i> , 2007, 116, 961-968.	1.6	58
28	Vascular Responses to Drug Eluting Stents. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1500-1510.	1.1	826
29	Current Status and Future Trends in Drug-Eluting Stents. <i>The American Heart Hospital Journal</i> , 2007, 5, 165-168.	0.2	1
31	Clinical Outcomes and Stent Thrombosis Following Off-Label Use of Drug-Eluting Stents. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 2001.	3.8	311
34	The conundrum of late and very late stent thrombosis following drug-eluting stent implantation. <i>Current Opinion in Cardiology</i> , 2007, 22, 565-571.	0.8	31
35	Update on drug-eluting stents: as good as it gets?. <i>Clinical Medicine</i> , 2007, 7, 401-404.	0.8	0
36	Cost-effectiveness of sirolimus-eluting stents compared with vascular brachytherapy for the treatment of in-stent restenosis. <i>American Heart Journal</i> , 2007, 154, 1221-1227.	1.2	4
37	The rise and fall of drug-eluting stents: Time trend analysis in 13647 consecutive patients undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2007, 154, e37.	1.2	4
38	Thrombosis: the last frontier of coronary stenting?. <i>Lancet, The</i> , 2007, 369, 619-621.	6.3	18
39	Risks associated with drug-eluting stents. <i>Lancet, The</i> , 2007, 369, 1785.	6.3	0
40	Risks associated with drug-eluting stents. <i>Lancet, The</i> , 2007, 369, 1785.	6.3	0
41	Drug-eluting stents and late stent thrombosis. <i>Lancet, The</i> , 2007, 370, 914-915.	6.3	27
42	Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. <i>Lancet, The</i> , 2007, 370, 937-948.	6.3	1,329

#	ARTICLE	IF	CITATIONS
43	Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysis. <i>Lancet, The</i> , 2007, 370, 1552-1559.	6.3	91
45	DES use complicated by late stent thrombosis. <i>Reactions Weekly</i> , 2007, &NA;, 1.	0.0	0
46	Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. <i>British Journal of Anaesthesia</i> , 2007, 99, 316-328.	1.5	286
47	Clinical End Points in Coronary Stent Trials. <i>Circulation</i> , 2007, 115, 2344-2351.	1.6	4,993
48	A Cause for Concern. <i>Circulation</i> , 2007, 115, 1440-1455.	1.6	724
49	As Time Goes By. <i>Journal of the American College of Cardiology</i> , 2007, 50, 128-137.	1.2	44
50	Late and Very Late Thrombosis of Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2007, 50, 119-127.	1.2	117
51	Angiographic Stent Thrombosis After Routine Use of Drug-Eluting Stents in ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 573-583.	1.2	447
52	President's Page: Drug-Eluting Stents in Contemporary Practice—A Call for a Real-World, Open-Entry, Device-Tracking Registry. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2223-2226.	1.2	5
53	“Crying Fire in a Theater” or a “Confirmatory Sighting”? Editorials published in the <i>Journal of the American College of Cardiology</i> reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. <i>Journal of the American College of Cardiology</i> , 2007, 50, 268-269.	1.2	7
54	Stent Thrombosis, Myocardial Infarction, and Death After Drug-Eluting and Bare-Metal Stent Coronary Interventions. <i>Journal of the American College of Cardiology</i> , 2007, 50, 463-470.	1.2	229
55	A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1373-1380.	1.2	307
56	Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 1064-1074.	0.7	62
57	Late stent thrombosis—The “vulnerable” stent. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 54-56.	0.7	4
58	Dual drug release from stents—Will we be happy with thing one and thing two?. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 880-880.	0.7	0
59	Clinical Use of Sirolimus-Eluting Stents. <i>Cardiovascular Drug Reviews</i> , 2007, 25, 316-332.	4.4	8
60	Angiographic and Procedural Correlates of Stent Thrombosis after Intracoronary Implantation of Drug-Eluting Stents. <i>Journal of Interventional Cardiology</i> , 2007, 20, 307-313.	0.5	30
61	Comparison of Three-Year Clinical Outcome of Sirolimus- and Paclitaxel-Eluting Stents Versus Bare Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction (from the RESEARCH and) <i>Tj ETQq1 1 0.7874314 rgBii/Over</i>	0.5	30

#	ARTICLE	IF	CITATIONS
62	Late Stent Thrombosis: Problem or Not?. American Journal of Cardiology, 2007, 99, 1020-1023.	0.7	7
63	Impact of In-Stent Restenosis on Death and Myocardial Infarction. American Journal of Cardiology, 2007, 100, 1109-1113.	0.7	20
64	Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Duration, Resistance, Alternatives, and Management of Surgical Patients. American Journal of Cardiology, 2007, 100, S18-S25.	0.7	28
65	Stents coronaires et anti-agrégants plaquettaires. Annales De Cardiologie Et D'Angéiologie, 2007, 56, S53-S62.	0.3	0
66	Situación actual de los stents liberadores de fármacos: nuevos desafíos y nuevas dudas. Introducción. Revista Española De Cardiología Suplementos, 2007, 7, 1E-7E.	0.2	0
67	Coronary stent healing, endothelialisation and the role of co-medication. Netherlands Heart Journal, 2007, 15, 395-396.	0.3	9
68	The risk of drug-eluting stent thrombosis with noncardiac surgery. Current Cardiology Reports, 2007, 9, 406-411.	1.3	15
69	Stenttrombose: vroege en late trombose bij sirolimus- en paclitaxel-eluting stents. Medisch-farmaceutische Mededelingen, 2007, 45, 242-243.	0.0	0
72	Vascular Pathology of Drug-Eluting Stents. Herz, 2007, 32, 274-280.	0.4	48
76	Sirolimus-Eluting Versus Bare-Metal Stents for the Reduction of Coronary Restenosis. Herz, 2007, 32, 650-655.	0.4	3
77	The Paclitaxel-Eluting Coroflex <sup>®</sup> Please Stent Pilot Study (PECOPS I). Clinical Research in Cardiology, 2007, 96, 803-811.	1.5	10
78	Drug-eluting stents: What is the balance of risks and benefits?. Current Cardiovascular Risk Reports, 2007, 1, 279-283.	0.8	0
80	The 5 Ts of Bifurcation Intervention: Type, Technique, Two Stents, T-Stenting, Trials. JACC: Cardiovascular Interventions, 2008, 1, 366-368.	1.1	12
81	Drug-Eluting Coronary Stent Very Late Thrombosis Revisited. Herz, 2008, 33, 334-342.	0.4	25
83	Standortbestimmung der Drug-Eluting-Stents ein Jahr nach Beginn der Sicherheitsdiskussion. Clinical Research in Cardiology Supplements, 2008, 3, 85-89.	2.0	0
84	Antiplatelet therapy in the era of late stent thrombosis. Current Treatment Options in Cardiovascular Medicine, 2008, 10, 12-17.	0.4	4
85	Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clinical Research in Cardiology, 2008, 97, 773-781.	1.5	227
87	Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy. Thrombosis Journal, 2008, 6, 1.	0.9	30

#	ARTICLE	IF	CITATIONS
88	Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer-coated sirolimus-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 177-183.	0.7	24
89	High incidence of recurrent in stent thrombosis after successful treatment of a first in stent thrombosis. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 470-478.	0.7	25
90	Six-Month Comparison of Coronary Endothelial Dysfunction Associated With Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 65-71.	1.1	83
91	Optical Coherence Tomography. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 174-175.	1.1	12
92	Impact of Drug-Eluting Stents Among Insulin-Treated Diabetic Patients. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 139-147.	1.1	49
94	Stent Thrombosis, Clinical Events, and Influence of Prolonged Clopidogrel Use After Placement of Drug-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 494-503.	1.1	84
95	Reprogramming the cell cycle machinery to treat cardiovascular disease. <i>Current Opinion in Pharmacology</i> , 2008, 8, 193-201.	1.7	12
96	Restenosis begets restenosis: implications for stent selection. <i>Netherlands Heart Journal</i> , 2008, 16, 376-381.	0.3	1
97	Use of Drug-Eluting Stents in Saphenous Vein Aortocoronary Bypass Graft Lesions: A Critical Appraisal. <i>Journal of Interventional Cardiology</i> , 2008, 21, 151-157.	0.5	13
98	Percutaneous Treatment of a Coronary Aneurysm by Stent Graft and Drug-Eluting Stent Implantation: A Potential Method to Reduce Stent Graft Restenosis. <i>Journal of Interventional Cardiology</i> , 2008, 21, 325-328.	0.5	8
99	A small molecule CXCR4 antagonist inhibits neointima formation and smooth muscle progenitor cell mobilization after arterial injury. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1812-1815.	1.9	41
100	Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008, 33, 591-601.	0.7	22
101	Functional Effects of High Clopidogrel Maintenance Dosing in Patients With Inadequate Platelet Inhibition on Standard Dose Treatment. <i>American Journal of Cardiology</i> , 2008, 101, 440-445.	0.7	72
102	Long-Term (>3 Years) Outcome and Predictors of Clinical Events After Insertion of Sirolimus-Eluting Stent in One or More Native Coronary Arteries (from the Israeli Arm of the e-Cypher Registry). <i>American Journal of Cardiology</i> , 2008, 101, 953-959.	0.7	16
103	Four-Year Clinical Follow-Up of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital Registry. <i>American Journal of Cardiology</i> , 2008, 101, 1105-1111.	0.7	35
104	Rates of Stent Thrombosis in Bare-Metal Versus Drug-Eluting Stents (from a Large Australian) <a href="#">Tj ETQq1 1 0.784314 rgBT /Overlock 10</a>	0.7	29
105	Observations and Outcomes of Definite and Probable Drug-Eluting Stent Thrombosis Seen at a Single Hospital in a Four-Year Period. <i>American Journal of Cardiology</i> , 2008, 102, 298-303.	0.7	48
106	The Question of Drug-Eluting Stent Safety: Then and Now. <i>American Journal of Cardiology</i> , 2008, 102, 12J-17J.	0.7	8

#	ARTICLE	IF	CITATIONS
107	Safety and Efficacy Update on First-Generation Drug-Eluting Stents. American Journal of Cardiology, 2008, 102, 18J-23J.	0.7	5
108	Platelet function in intravascular device implant-induced intimal injury. Cardiovascular Revascularization Medicine, 2008, 9, 78-87.	0.3	13
111	Thrombus causes fluctuations in arterial drug delivery from intravascular stents. Journal of Controlled Release, 2008, 131, 173-180.	4.8	50
112	The future of drug-eluting stents. Pharmacological Research, 2008, 57, 171-180.	3.1	100
116	Use of drug eluting stents: expert consensus of the French Society of Cardiology. Archives of Cardiovascular Diseases, 2008, 101, 190-193.	0.7	4
117	Long-Term Results With the Off-Label Use of Paclitaxel-Eluting Stents. Revista Espanola De Cardiologia (English Ed ), 2008, 61, 695-704.	0.4	4
118	Long-Term Follow-Up Evaluation After Sirolimus-Eluting Stent Implantation by Optical Coherence Tomography. Journal of the American College of Cardiology, 2008, 51, 968-969.	1.2	83
119	The Left Main Facts: Faced, Spun, But Alas Too Few. Journal of the American College of Cardiology, 2008, 51, 893-898.	1.2	12
120	Drug-Eluting Stent Thrombosis. Journal of the American College of Cardiology, 2008, 51, 986-990.	1.2	293
121	A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease. Journal of the American College of Cardiology, 2008, 51, 1543-1552.	1.2	109
122	Balancing the Risks of Restenosis and Stent Thrombosis in Bare-Metal Versus Drug-Eluting Stents. Journal of the American College of Cardiology, 2008, 51, 1844-1853.	1.2	66
123	Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2008, 51, 2212-2219.	1.2	160
124	The Year in Interventional Cardiology. Journal of the American College of Cardiology, 2008, 51, 2355-2369.	1.2	2
126	A Randomized Comparison of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus. Journal of the American College of Cardiology, 2008, 52, 727-733.	1.2	78
127	Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice. Journal of the American College of Cardiology, 2008, 52, 1134-1140.	1.2	468
128	Multivessel Coronary Revascularization in Patients With and Without Diabetes Mellitus. Journal of the American College of Cardiology, 2008, 52, 1957-1967.	1.2	112
129	Very Late Drug-eluting Stent Thrombosis. Heart Lung and Circulation, 2008, 17, 144-145.	0.2	0
130	Stent thrombosis in 2008: Definition, predictors, prognosis and treatment. Archives of Cardiovascular Diseases, 2008, 101, 769-777.	0.7	49

#	ARTICLE	IF	CITATIONS
131	Fully Biodegradable Coronary Stents. American Journal of Cardiovascular Drugs, 2008, 8, 305-314.	1.0	75
132	Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry. European Heart Journal, 2008, 29, 2108-2115.	1.0	99
133	Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. European Heart Journal, 2008, 30, 321-329.	1.0	108
134	In-stent restenosis and thrombosis 41 months after drug-eluting stent implantation. International Journal of Cardiology, 2008, 130, e111-e113.	0.8	5
135	Simultaneous subacute stent thrombosis of two sirolimus-eluting stents in a patient treated by ReoPro, thrombus aspiration and triple anti-platelet agents. International Journal of Cardiology, 2008, 130, e25-e29.	0.8	3
136	Treatment of diffuse in-stent restenosis with Drug-Eluting stents vs. intracoronary beta-radiation therapy: INDEED Study. International Journal of Cardiology, 2008, 131, 70-77.	0.8	16
137	Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry. International Journal of Cardiology, 2008, 130, 374-379.	0.8	20
138	Late thrombosis of paclitaxel-eluting stents: Long-term incidence, clinical consequences, and risk factors in a cohort of 604 patients. American Heart Journal, 2008, 155, 648-653.	1.2	27
139	Correlates of late and very late thrombosis of drug eluting stents. American Heart Journal, 2008, 156, 141-147.	1.2	31
140	Systemic exposure of everolimus after stent implantation: A pharmacokinetic study. American Heart Journal, 2008, 156, 751.e1-751.e7.	1.2	18
141	A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet, The, 2008, 371, 899-907.	6.3	655
142	Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet, The, 2008, 371, 2134-2143.	6.3	110
143	Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet, The, 2008, 372, 1163-1173.	6.3	607
144	Drug-eluting stents: is new necessarily better?. Lancet, The, 2008, 372, 1126-1128.	6.3	5
145	Coronary Artery Revascularisation : Past, Present and Future. Medical Journal Armed Forces India, 2008, 64, 154-157.	0.3	2
146	Safety of drug-coated stents. Expert Opinion on Drug Safety, 2008, 7, 597-606.	1.0	8
147	Drug-eluting stent thrombosis: A lesson in vascular biology. Canadian Journal of Cardiology, 2008, 24, 50C-55C.	0.8	2
148	Safety and Feasibility of Drug-eluting Stent Implantation at Vertebral Artery Origin: The First Case Series in Asians. Journal of the Formosan Medical Association, 2008, 107, 253-258.	0.8	21



#	ARTICLE	IF	CITATIONS
150	Off-label use of stents: bare-metal versus drug-eluting stents. Expert Review of Cardiovascular Therapy, 2008, 6, 1095-1106.	0.6	1
151	Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. European Heart Journal, 2008, 30, 16-24.	1.0	99
152	A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. European Heart Journal, 2008, 29, 2202-2211.	1.0	183
153	Safety of drug-eluting stents. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 316-328.	3.3	18
154	Meta-Analysis Shows Similar Risk of Thrombosis After Drug-Eluting Stent, Bare-Metal Stent, or Angioplasty. Endothelium: Journal of Endothelial Cell Research, 2008, 15, 93-100.	1.7	6
155	<i>meta</i> -l-iodobenzylguanidine, an Inhibitor of Arginine-Dependent Mono(ADP-ribosyl)ation, Prevents Neointimal Hyperplasia. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 717-724.	1.3	6
156	Drug-eluting stents: a critique. Heart, 2008, 94, 145-152.	1.2	28
157	Very Late Stent Thrombosis After Dual Antiplatelet Therapy Discontinuation in a Patient with a History of Acute Stent Thrombosis. Annals of Pharmacotherapy, 2008, 42, 708-712.	0.9	8
158	Primary Percutaneous Coronary Intervention. Fundamental and Clinical Cardiology, 2008, , 91-117.	0.0	0
159	Cardiovascular Toxicology. , 0, , .		0
160	The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. European Heart Journal, 2008, 29, 1851-1857.	1.0	265
161	Biodegradable coating for drug-eluting stents--more than a facelift?. European Heart Journal, 2008, 29, 1930-1931.	1.0	21
162	Late drug-eluting stent thrombosis in unprotected left main coronary artery lesions--sometimes possible, but rarely definite or probable. European Heart Journal, 2008, 29, 2064-2066.	1.0	0
164	Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. European Heart Journal, 2008, 29, 1975-1982.	1.0	182
165	Late Stent Thrombosis After Drug-Eluting Stent Implantation for Acute Myocardial Infarction. Circulation, 2008, 118, 1117-1119.	1.6	44
166	Frequency and pattern of de-novo three-vessel and left main coronary artery disease; insights from single center enrolment in the SYNTAX study. European Journal of Cardio-thoracic Surgery, 2008, 34, 376-383.	0.6	16
167	Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2008, 299, 1903.	3.8	535
168	Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ: British Medical Journal, 2008, 337, a1331-a1331.	2.4	270

#	ARTICLE	IF	CITATIONS
169	Long-Term Clinical Outcomes After Drug-Eluting and Bare-Metal Stenting in Massachusetts. <i>Circulation</i> , 2008, 118, 1817-1827.	1.6	132
170	Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients. <i>Circulation</i> , 2008, 118, 1138-1145.	1.6	818
171	Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 226-232.	1.4	3
172	Hospital and operator variations in drug-eluting stent use: a multi-level analysis of 5967 consecutive patients in Scotland. <i>Journal of Public Health</i> , 2008, 30, 186-193.	1.0	10
173	Review: The safety of drug-eluting stents. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2008, 2, 43-52.	1.0	6
174	Outcomes Following Coronary Stenting in the Era of Bare-Metal vs the Era of Drug-Eluting Stents. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 2868.	3.8	96
175	Drug-Eluting Stents: A Review of Current Evidence on Clinical Effectiveness and Late Complications. <i>Scottish Medical Journal</i> , 2008, 53, 16-24.	0.7	3
176	Commentary on drug-eluting stents: to use or not to use--that is the question!. <i>Heart</i> , 2008, 94, 1648-1650.	1.2	1
177	Lack of Association Between Large Angiographic Late Loss and Low Risk of In-Stent Thrombus. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 20-27.	1.4	33
178	High Incidence of Intramural Thrombus After Overlapping Paclitaxel-Eluting Stent Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 28-35.	1.4	21
179	Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions. <i>Circulation</i> , 2008, 117, 923-930.	1.6	66
180	Long-Term Mortality After Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation Versus Coronary Artery Bypass Surgery for the Treatment of Multivessel Coronary Artery Disease. <i>Circulation</i> , 2008, 117, 2079-2086.	1.6	83
181	Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 103-110.	1.4	40
182	Commentary on drug-eluting stents: NICE technology appraisal guidance. <i>Heart</i> , 2008, 94, 1650-1652.	1.2	2
183	Risk Factors for In-Stent Restenosis After Vertebral Ostium Stenting. <i>Journal of Endovascular Therapy</i> , 2008, 15, 203-212.	0.8	46
184	Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 45-52.	1.4	16
185	Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 217-225.	1.4	15
186	Drug-eluting stents: do the risks really outweigh the benefits?. <i>Heart</i> , 2008, 94, 127-128.	1.2	7

#	ARTICLE	IF	CITATIONS
187	Local Delivery of Gene Vectors From Bare-Metal Stents by Use of a Biodegradable Synthetic Complex Inhibits In-Stent Restenosis in Rat Carotid Arteries. <i>Circulation</i> , 2008, 117, 2096-2103.	1.6	68
188	Drug-eluting stent safety: findings from preclinical studies. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1379-1391.	0.6	72
189	Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study. <i>European Heart Journal</i> , 2008, 29, 3011-3021.	1.0	47
190	Duration of antiplatelet therapy following intracoronary stenting: are changes needed?. <i>European Heart Journal Supplements</i> , 2008, 10, I25-I29.	0.0	5
191	Dual antiplatelet therapy in the drug-eluting stent era. <i>Country Review Ukraine</i> , 2008, 10, D38-D44.	0.8	2
192	Sirolimus-Eluting Stents Suppress Neointimal Formation Irrespective of Metallic Allergy. <i>Circulation Journal</i> , 2008, 72, 893-896.	0.7	20
193	Pro-healing drug-eluting stents: a role for antioxidants?. <i>Clinical Science</i> , 2008, 114, 265-273.	1.8	15
194	Management of Antiplatelet Therapy for Non-Cardiac Surgery. , 0, , 251-264.		0
195	Antiplatelet Therapy and Coronary Stents. , 0, , 265-279.		0
196	Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention. <i>Anesthesia and Analgesia</i> , 2008, 107, 552-569.	1.1	62
198	Systemic Immunosuppressive Therapy with Oral Sirolimus after Bare Metal Stent Implantation: The Missing Alternative in the Prevention of Coronary Restenosis after Percutaneous Coronary Interventions. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2008, 3, 201-208.	1.5	5
199	Outcome observations with drug-eluting stents. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 110-112.	0.6	1
200	Sirolimus-eluting stent implantation for bare-metal in-stent restenosis: is there any evidence for a late catch-up phenomenon?. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 783-788.	0.6	12
201	Incidence of thrombosis after implantation of drug-eluting stents in patients with coronary artery disease. <i>Chinese Medical Journal</i> , 2008, 121, 2144-2147.	0.9	2
203	Long term efficacy and safety of Chinese made sirolimus eluting stents: results, including off label usage, from two centres over three years. <i>Chinese Medical Journal</i> , 2008, 121, 1670-1674.	0.9	8
204	Acute coronary syndrome is an independent risk factor for late incomplete stent apposition after sirolimus-eluting stent implantation. <i>Chinese Medical Journal</i> , 2008, 121, 2504-2508.	0.9	3
205	Advances in drug eluting stents &ndash; focus on the Endeavor&reg; zotarolimus stent. <i>Medical Devices: Evidence and Research</i> , 0, , 1.	0.4	0
206	Clopidogrel and the prevention of cardiovascular events. <i>British Journal of Cardiac Nursing</i> , 2008, 3, 15-21.	0.0	0

#	ARTICLE	IF	CITATIONS
207	Outcomes after percutaneous coronary intervention in contemporary Australian practice: insights from a large multicentre registry. <i>Medical Journal of Australia</i> , 2008, 189, 423-428.	0.8	23
208	Why we need a national registry in interventional cardiology. <i>Medical Journal of Australia</i> , 2008, 189, 223-227.	0.8	11
209	Diabetes mellitus: a prothrombotic state. Implications for outcomes after coronary revascularization. <i>Vascular Health and Risk Management</i> , 2009, 5, 101.	1.0	11
210	Les stents pharmacoactifs. <i>Sang Thrombose Vaisseaux</i> , 2009, 21, 373-383.	0.1	0
211	Very Late Thrombosis of a Drug-Eluting Stent After Discontinuation of Dual Antiplatelet Therapy in a Patient Treated With Both Drug-Eluting and Bare-Metal Stents. <i>Korean Circulation Journal</i> , 2009, 39, 205.	0.7	9
212	Stenting versus Bypass Surgery for the Treatment of Left Main Coronary Artery Disease. <i>Yonsei Medical Journal</i> , 2009, 50, 739.	0.9	4
213	Emprego do stent farmacológico Supralimus™, com sirolimus e polímero absorvível, no tratamento de pacientes com síndrome coronária aguda submetidos a intervenção coronária percutânea. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2009, 17, 491-497.	0.1	0
214	Impact of Intravascular Ultrasound Guidance on Long-Term Mortality in Stenting for Unprotected Left Main Coronary Artery Stenosis. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 167-177.	1.4	452
215	Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis. <i>Circulation</i> , 2009, 119, 2986-2994.	1.6	451
216	Bioabsorbable Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 255-260.	1.4	233
217	Xience Vã, everolimus-eluting coronary stent. <i>Expert Review of Medical Devices</i> , 2009, 6, 219-229.	1.4	32
218	Mechanisms behind the Synergistic Effect of Sirolimus and Imatinib in Preventing Restenosis after Intimal Injury. <i>Journal of Vascular Research</i> , 2009, 46, 240-252.	0.6	6
219	Intimal Dissection Causing Late Thrombosis of a Covered Stent. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 359-360.	1.4	5
220	Differential Healing After Sirolimus, Paclitaxel, and Bare Metal Stent Placement in Combination With Peroxisome Proliferator-Activator Receptor Î³ Agonists. <i>Circulation Research</i> , 2009, 105, 1003-1012.	2.0	24
221	Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents. <i>Circulation</i> , 2009, 119, 687-698.	1.6	172
222	C-Reactive Protein and the Risk of Stent Thrombosis and Cardiovascular Events After Drug-Eluting Stent Implantation. <i>Circulation</i> , 2009, 120, 1987-1995.	1.6	100
223	Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation. <i>Circulation</i> , 2009, 119, 987-995.	1.6	345
224	Three-Year Outcomes After Sirolimus-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. <i>Circulation</i> , 2009, 120, 1866-1874.	1.6	101

#	ARTICLE	IF	CITATIONS
225	Update on dual antiplatelet therapy for percutaneous coronary intervention. <i>Heart</i> , 2009, 95, 861-865.	1.2	3
226	Drug eluting or bare metal stent for acute myocardial infarction: an issue of safety?. <i>European Heart Journal</i> , 2009, 30, 1828-1830.	1.0	11
227	Are drug-eluting stents safe in the long term?. <i>Cmaj</i> , 2009, 180, 154-155.	0.9	6
228	Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. <i>European Heart Journal</i> , 2009, 30, 2714-2721.	1.0	224
229	Antiplatelet Agents in the Perioperative Period. <i>Archives of Surgery</i> , 2009, 144, 69.	2.3	80
230	Long-Term Safety and Efficacy of Drug-Eluting versus Bare-Metal Stents in Sweden. <i>New England Journal of Medicine</i> , 2009, 360, 1933-1945.	13.9	223
231	Two-year follow-up after percutaneous coronary intervention with titanium-nitride-oxide-coated stents versus paclitaxel-eluting stents in acute myocardial infarction. <i>Annals of Medicine</i> , 2009, 41, 599-607.	1.5	24
232	Time does not heal every wound: Coronary stent thrombosis of a bare-metal stent more than one decade after its implantation. <i>Platelets</i> , 2009, 20, 594-597.	1.1	1
233	Comparative Studies on the Mechanisms of Action of Four Polysaccharides on Arterial Restenosis. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2009, 20, 689-702.	1.9	8
234	Percutaneous Coronary Intervention Outcomes in a Low-Volume Center. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 671-677.	0.9	7
235	Treatment of Acute Myocardial Infarction With Sirolimus-Eluting Stents Results in Chronic Endothelial Dysfunction in the Infarct-Related Coronary Artery. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 384-391.	1.4	19
236	Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II). <i>Heart</i> , 2009, 95, 1061-1066.	1.2	21
237	Temporal Changes in Coronary Revascularization Procedures, Outcomes, and Costs in the Bare-Metal Stent and Drug-Eluting Stent Eras. <i>Circulation</i> , 2009, 119, 952-961.	1.6	47
238	First-in-man use of polymer-free valsartan-eluting stents in small coronary vessels: a comparison to polymer-free rapamycin (2%)-eluting stents. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2009, 10, 91-95.	1.0	5
239	Restenosis Revisited. <i>Circulation Research</i> , 2009, 104, 823-825.	2.0	7
240	Drug-eluting stent thrombosis. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2009, 3, 45-52.	1.0	25
241	Drug-Eluting Stent Thrombosis in Routine Clinical Practice. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 285-293.	1.4	77
242	Stent Thrombosis in Sweden. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 401-408.	1.4	121

#	ARTICLE	IF	CITATIONS
243	Bioabsorbable Material Containing Phosphorylcholine Group-Rich Surfaces for Temporary Scaffolding of the Vessel Wall. <i>Tissue Engineering - Part C: Methods</i> , 2009, 15, 125-133.	1.1	13
244	Early Stent Thrombosis. <i>Circulation</i> , 2009, 119, 657-659.	1.6	57
245	Percutaneous Coronary Intervention With Stent Implantation Versus Coronary Artery Bypass Surgery for Treatment of Left Main Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 59-68.	1.4	57
246	Coronary aneurysm associated with coronary perforation after sirolimus-eluting stents implantation: Close follow-up exceeding 2 years by coronary 3-dimensional computed tomography. <i>Journal of Cardiology</i> , 2009, 54, 115-120.	0.8	3
247	Improved cardiac function after sirolimus-eluting stent placement in diabetic patients by pioglitazone: Combination therapy with statin. <i>Journal of Cardiology</i> , 2009, 53, 402-409.	0.8	7
248	Comparison of Drug-Eluting Stents and Bare-Metal Stents for the Treatment of Unprotected Left Main Coronary Artery Disease in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2009, 103, 187-193.	0.7	36
249	Comparison of Six-Month Outcomes for Primary Percutaneous Revascularization for Acute Myocardial Infarction With Drug-Eluting Versus Bare Metal Stents (from the APEX-AMI Study). <i>American Journal of Cardiology</i> , 2009, 103, 181-186.	0.7	11
250	Three-Year Survival Following Multivessel Percutaneous Coronary Intervention With Bare-Metal or Drug-Eluting Stents in Unselected Patients. <i>American Journal of Cardiology</i> , 2009, 103, 203-211.	0.7	12
251	Comparison of Outcomes of Drug-Eluting Stents Versus Bare-Metal Stents in Nonstent Proximal Left Anterior Descending Coronary Arteries. <i>American Journal of Cardiology</i> , 2009, 103, 496-500.	0.7	6
252	Prognostic Influence of Diabetes Mellitus on Long-Term Clinical Outcomes and Stent Thrombosis After Drug-Eluting Stent Implantation in Asian Patients. <i>American Journal of Cardiology</i> , 2009, 103, 646-652.	0.7	26
253	Temporal Relation Between Clopidogrel Cessation and Stent Thrombosis After Drug-Eluting Stent Implantation. <i>American Journal of Cardiology</i> , 2009, 103, 801-805.	0.7	61
254	Optical Coherence Tomographic Results at Six-Month Follow-Up Evaluation of the CATANIA Coronary Stent System With NanoThin Polyethylene-F Surface Modification (from the Assessment of The Latest) <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i> 1551-1555.	0.7	20
257	Extremely late drug-eluting stent thrombosis: 2037 days after deployment. <i>Cardiovascular Revascularization Medicine</i> , 2009, 10, 55-57.	0.3	20
258	Recurrent very late drug-eluting stent thrombosis. <i>Cardiovascular Revascularization Medicine</i> , 2009, 10, 130-135.	0.3	3
259	The Current Status of Coronary Drug-Eluting Stents. <i>Tzu Chi Medical Journal</i> , 2009, 21, 18-27.	0.4	1
260	Antiplatelet drug response variability and the role of platelet function testing: A practical guide for interventional cardiologists. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 1-14.	0.7	36
261	A comparison of the mechanical performance characteristics of seven drug-eluting stent systems. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 350-360.	0.7	68
262	Differences of platelet adhesion and thrombus activation on amorphous silicon carbide, magnesium alloy, stainless steel, and cobalt chromium stent surfaces. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 488-496.	0.7	46

#	ARTICLE	IF	CITATIONS
263	Paclitaxel-eluting balloon: From bench to bed. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 643-652.	0.7	58
264	Multivessel drug-eluting stenting and impact of diabetes mellitus—A report from the EVENT registry. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 874-880.	0.7	10
265	The paclitaxel-eluting coroflex, please stent study (PECOPS I): The 3-year clinical follow-up. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 674-682.	0.7	6
266	Antiplatelet therapy discontinuation following drug-eluting stent placement: Dangers, reasons, and management recommendations. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 1047-1054.	0.7	37
267	Impact of intravascular ultrasound guidance in patients with acute myocardial infarction undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 86-92.	0.7	27
268	Clinical safety and efficacy of a novel thin-strut cobalt-chromium coronary stent system: Results of the real world Coroflex Blue Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 78-85.	0.7	17
269	Comparison of 2-year clinical outcomes with sirolimus and paclitaxel-eluting stents for patients with diabetes: Results of the Registro Regionale Angioplastiche Emilia-Romagna Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 327-334.	0.7	4
270	Periprocedural antithrombotic management: A review of the literature and practical approach for the hospitalist physician. <i>Journal of Hospital Medicine</i> , 2009, 4, 551-559.	0.7	9
271	The risk of definitive stent thrombosis is increased after off-label stent implantation irrespective of drug-eluting stent or bare-metal stent use. <i>Clinical Research in Cardiology</i> , 2009, 98, 549-554.	1.5	18
272	The evolution of cardiovascular stent materials and surfaces in response to clinical drivers: A review. <i>Acta Biomaterialia</i> , 2009, 5, 945-958.	4.1	245
273	The Risk of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Bare-Metal and Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 534-541.	1.1	134
274	Early changes in local hemostasis activation following percutaneous coronary intervention in stable angina patients: a comparison between drug-eluting and bare metal stents. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 333-341.	1.0	10
275	Drug-eluting stents versus bypass surgery for multivessel coronary disease. <i>Current Cardiovascular Risk Reports</i> , 2009, 3, 331-338.	0.8	1
276	Emergent coronary artery bypass grafting for cardiogenic shock caused by very late drug-eluting stent thrombosis. <i>General Thoracic and Cardiovascular Surgery</i> , 2009, 57, 609-611.	0.4	1
277	Grayscale intravascular ultrasound: Current concepts in percutaneous coronary interventions. <i>Current Cardiovascular Imaging Reports</i> , 2009, 2, 259-267.	0.4	0
278	Effect of balloon inflation time on expansion of sirolimus-eluting stent. <i>Heart and Vessels</i> , 2009, 24, 335-339.	0.5	17
279	Resolution of late sirolimus-eluting stent thrombosis after tirofiban treatment. <i>Heart and Vessels</i> , 2009, 24, 388-390.	0.5	4
280	Are Drug-Eluting Stents Safe?: Definitely! Or Probably? Or Possibly? Or Maybe Not Yet?. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 127-130.	2.3	3

#	ARTICLE	IF	CITATIONS
281	Drug-Eluting Stents Are Safe. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 130-132.	2.3	2
282	Performance of Everolimus-Eluting Stents: Pooled Analysis from the SPIRIT Trials. <i>Journal of Interventional Cardiology</i> , 2009, 22, .	0.5	3
283	Treating Coronary Bifurcations: Neither Rhyme nor Reason?. <i>Journal of Interventional Cardiology</i> , 2009, 22, 257-260.	0.5	0
284	Experimental Evaluation of a New Antithrombogenic Stent Using Ion Beam Surface Modification. <i>Artificial Organs</i> , 2009, 33, 456-463.	1.0	9
285	Cost-Effectiveness of Drug-Eluting Stents in a US Medicare Setting: A Cost-Utility Analysis with 3-Year Clinical Follow-Up Data. <i>Value in Health</i> , 2009, 12, 649-656.	0.1	28
286	First-in-Man 1-Year Clinical Outcomes of the Catania Coronary Stent System With Nanothin Polyzene-F in De Novo Native Coronary Artery Lesions. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 197-204.	1.1	30
287	Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in "Real-World" Practice. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 303-309.	1.1	73
288	A Randomized Optical Coherence Tomography Study of Coronary Stent Strut Coverage and Luminal Protrusion With Rapamycin-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 437-444.	1.1	62
289	A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 524-531.	1.1	56
290	Drug-Eluting Stent Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 583-593.	1.1	110
291	Drug-Eluting Stents and the Use of Percutaneous Coronary Intervention Among Patients With Class I Indications for Coronary Artery Bypass Surgery Undergoing Index Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 614-621.	1.1	31
292	No Association of Chromosome 9p21.3 Variation With Clinical and Angiographic Outcomes After Placement of Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1149-1155.	1.1	29
293	Safety and Effectiveness of the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1227-1235.	1.1	57
294	3-Year Clinical Follow-Up of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1190-1198.	1.1	89
295	The First-Generation Drug-Eluting Stents and Coronary Endothelial Dysfunction. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1169-1177.	1.1	85
296	Late Safety, Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1208-1218.	1.1	57
297	Late stent thrombosis, endothelialisation and drug-eluting stents. <i>Netherlands Heart Journal</i> , 2009, 17, 177-180.	0.3	24
298	Antioxidant enzyme gene transfer for ischemic diseases. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 351-363.	6.6	64



#	ARTICLE	IF	CITATIONS
299	Safety and Efficacy of Drug-Eluting and Bare Metal Stents. <i>Circulation</i> , 2009, 119, 3198-3206.	1.6	794
300	Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Libertel-Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 188-195.	1.4	144
302	Cost-effectiveness analyses of drug eluting stents versus bare metal stents: A systematic review of the literature. <i>Health Policy</i> , 2009, 91, 107-120.	1.4	24
303	Impact of P2Y12 Inhibitory Effects Induced by Clopidogrel on Platelet Procoagulant Activity in Type 2 Diabetes Mellitus Patients. <i>Thrombosis Research</i> , 2009, 124, 318-322.	0.8	37
304	Low-dose paclitaxel elution by novel bioerodible sol-gel coating on stents inhibits neointima with low toxicity in porcine coronary arteries. <i>International Journal of Cardiology</i> , 2009, 135, 93-101.	0.8	12
305	Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome. <i>American Heart Journal</i> , 2009, 157, 375-382.	1.2	45
307	Incidence of stent thrombosis and adverse cardiac events 5 years after sirolimus stent implantation in clinical practice. <i>American Heart Journal</i> , 2009, 157, 883-888.	1.2	19
308	The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents. <i>American Heart Journal</i> , 2009, 157, 899-907.	1.2	35
309	SPIRIT IV trial design: A large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. <i>American Heart Journal</i> , 2009, 158, 520-526.e2.	1.2	41
310	Are we sure we have taken the best from clopidogrel?. <i>American Heart Journal</i> , 2009, 158, e59.	1.2	0
311	Drug-eluting stents: A study of international practice. <i>American Heart Journal</i> , 2009, 158, 576-584.	1.2	14
312	Rationale and design of the Patient Related Outcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. <i>American Heart Journal</i> , 2009, 158, 902-909.e5.	1.2	42
313	Comprehensive Meta-Analysis on Drug-Eluting Stents versus Bare-Metal Stents during Extended Follow-up. <i>American Journal of Medicine</i> , 2009, 122, 581.e1-581.e10.	0.6	77
314	Intravascular ultrasound-guided percutaneous coronary interventions in contemporary practice. <i>Archives of Cardiovascular Diseases</i> , 2009, 102, 143-151.	0.7	12
315	Comparative analysis of neointimal coverage with paclitaxel and zotarolimus drug-eluting stents, using optical coherence tomography 6 months after implantation. <i>Archives of Cardiovascular Diseases</i> , 2009, 102, 617-624.	0.7	17
316	The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography. <i>International Journal of Cardiology</i> , 2009, 134, 180-188.	0.8	123
317	Outcome of Drug-Eluting Versus Bare-Metal Stenting Used According to On- and Off-Label Criteria. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1389-1398.	1.2	32
318	Predictors of Coronary Stent Thrombosis. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1399-1409.	1.2	641

#	ARTICLE	IF	CITATIONS
319	Five-Year Follow-Up After Sirolimus-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1488-1497.	1.2	194
320	Combining Antiplatelet and Anticoagulant Therapies. <i>Journal of the American College of Cardiology</i> , 2009, 54, 95-109.	1.2	140
321	Long-Term Clinical Outcomes of Sirolimus- Versus Paclitaxel-Eluting Stents for Patients With Unprotected Left Main Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2009, 54, 853-859.	1.2	42
322	5-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2009, 54, 894-902.	1.2	142
323	The Everolimus-Eluting Stent in Real-World Patients. <i>Journal of the American College of Cardiology</i> , 2009, 54, 269-276.	1.2	63
324	Incidence and Predictors of Drug-Eluting Stent Fracture in Human Coronary Artery. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1924-1931.	1.2	229
325	Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2009, 360, 961-972.	13.9	3,634
327	Myocardial Cleft: An Anatomical Anomaly to Bear in Mind. <i>Revista Espanola De Cardiologia (English Ed)</i> Tj ETQq1 1 0,784314,rgBT /Over	0.4	1
328	Characteristics and Outcome of Angiographically Confirmed Stent Thrombosis. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 833-834.	0.4	0
329	Safety and Efficacy of Coronary Drug-Eluting Stents in Octogenarians. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 1250-1259.	0.4	5
330	Correlation of Intravascular Ultrasound Findings With Histopathological Analysis of Thrombus Aspirates in Patients With Very Late Drug-Eluting Stent Thrombosis. <i>Circulation</i> , 2009, 120, 391-399.	1.6	441
331	A review of current devices and a look at new technology: drug-eluting stents. <i>Expert Review of Medical Devices</i> , 2009, 6, 33-42.	1.4	60
332	An Appraisal of Dual Antiplatelet Therapy with Clopidogrel and Aspirin for Prevention of Cardiovascular Events. <i>Journal of the American Board of Family Medicine</i> , 2009, 22, 51-56.	0.8	18
333	Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction. <i>Applied Health Economics and Health Policy</i> , 2009, 7, 19-29.	1.0	9
334	Cost Effectiveness of Drug-Eluting Stents In Belgian Practice. <i>Pharmacoeconomics</i> , 2009, 27, 313-327.	1.7	14
335	Caracterizaci3n y pron3stico de la trombosis del stent comprobada angiogr3ficamente. <i>Revista Espanola De Cardiologia</i> , 2009, 62, 220-223.	0.6	6
337	Hendidura mioc3rdica: una alteraci3n anat3mica para tener en cuenta. <i>Revista Espanola De Cardiologia</i> , 2009, 62, 831-833.	0.6	2
338	Caracterizaci3n y pron3stico de la trombosis del stent comprobada angiogr3ficamente. <i>Revista Espanola De Cardiologia</i> , 2009, 62, 833-834.	0.6	0

#	ARTICLE	IF	CITATIONS
340	Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 375-388.	2.2	53
341	Advances in stent drug delivery: the future is in bioabsorbable stents. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 113-126.	2.4	64
342	Three-year prognosis of Japanese patients with ST-elevation myocardial infarction treated with sirolimus-eluting stents. <i>Coronary Artery Disease</i> , 2009, 20, 422-427.	0.3	11
343	A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) – study design and rationale. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 192-199.	0.6	5
344	Advanced Neointimal Growth is Not Associated With a Low Risk of In-Stent Thrombus Optical Coherence Tomographic Findings After First-Generation Drug-Eluting Stent Implantation. <i>Circulation Journal</i> , 2009, 73, 1627-1634.	0.7	26
345	Chest Pain without Significant Coronary Stenosis after Implantation of Sirolimus-Eluting Stents. <i>Internal Medicine</i> , 2009, 48, 213-217.	0.3	3
346	1. Overview of First-Generation Drug-Eluting Stent and Future Generation. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2009, 98, 336-342.	0.0	0
347	Use of drug-eluting stents for patients with coronary heart disease. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2009, 22, 30-34.	0.1	5
348	Latest on the pathology of drug-eluting stents. <i>Interventional Cardiology</i> , 2009, 1, 165-174.	0.0	3
349	Efficacy of Abciximab for Patients Undergoing Balloon Angioplasty Data From Japanese Evaluation of c7E3 Fab for Elective and Primary PCI Organization in Randomized Trial (JEPPORT). <i>Circulation Journal</i> , 2009, 73, 145-151.	0.7	31
350	Bare metal or drug-eluting stent implantation in last remaining vessel PCI?. <i>Acta Cardiologica</i> , 2009, 64, 281-285.	0.3	0
351	Repeat late in-stent-stenosis after an interval of four years in the same lesion after bare-metal and drug-eluting stent: a case report. <i>Cases Journal</i> , 2009, 2, 9407.	0.4	1
352	Conference Scene: A congress report. <i>Interventional Cardiology</i> , 2009, 1, 161-164.	0.0	1
353	Predictors of Early Discontinuation of Dual-Antiplatelet Therapy: Room for Improvement. <i>Circulation</i> , 2010, 122, 946-948.	1.6	3
354	Stent Thrombosis and Duration of Dual Antiplatelet Therapy. <i>Current Pharmaceutical Design</i> , 2010, 16, 4052-4063.	0.9	7
355	Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials. <i>European Heart Journal</i> , 2010, 31, 1071-1078.	1.0	26
356	Drug-eluting stents for acute coronary syndromes: should the labeling be expanded?. <i>Interventional Cardiology</i> , 2010, 2, 249-252.	0.0	0
357	Vertebral Artery Origin Stents Revisited. <i>Neurosurgery</i> , 2010, 67, 41-48.	0.6	22

#	ARTICLE	IF	CITATIONS
358	Rapid Evaluation of Vessel HEaling After AngiopLasty (REVEAL) trial: rationale, objectives and design. Journal of Cardiovascular Medicine, 2010, 11, 53-58.	0.6	5
359	Management of patients with coronary stents in the ICU. Current Opinion in Critical Care, 2010, 16, 426-431.	1.6	1
360	Zotarolimus-eluting versus sirolimus-eluting coronary stent implantation. Interventional Cardiology, 2010, 2, 807-812.	0.0	2
361	Acute Coronary Syndrome: Insight From Angioscopy. Circulation Journal, 2010, 74, 411-417.	0.7	36
362	DESIGN IMPLICATIONS FOR ENDOVASCULAR STENTS AND THE ENDOTHELIUM. , 2010, , 291-312.		2
363	In-stent thrombosis after 68 months of implantation inspite of continuous dual antiplatelet therapy: a case report. Cases Journal, 2010, 3, 68.	0.4	6
364	Coronary Angioscopic Evaluation for Serial Changes of Luminal Appearance After Pharmacological and Catheter Interventions. Circulation Journal, 2010, 74, 240-245.	0.7	15
365	Comparison of Different Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation. Circulation Journal, 2010, 74, 701-708.	0.7	88
366	Real World' Comparison of Drug-Eluting Stents vs Bare Metal Stents in the Treatment of Unselected Patients With Acute ST-Segment Elevation Myocardial Infarction. Circulation Journal, 2010, 74, 1111-1120.	0.7	20
367	Three-Month Dual Antiplatelet Therapy After Implantation of Zotarolimus-Eluting Stents - The DATE (Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent) Registry -. Circulation Journal, 2010, 74, 2314-2321.	0.7	28
368	Drug-Eluting Stents Are Not Indicated for Patients With Acute Coronary Syndrome - Should Drug-Eluting Stents Be Indicated for Patients With Acute Coronary Syndrome? (Con) -. Circulation Journal, 2010, 74, 2232-2238.	0.7	9
369	Application of Drug Eluting Stents to Clinical Practice in Japan. Circulation Journal, 2010, 74, 1532-1533.	0.7	0
370	STELLIUM 1: First-In-Man Follow-up Evaluation of Bioabsorbable Polymer-Coated Paclitaxel-Eluting Stent. Circulation Journal, 2010, 74, 2089-2096.	0.7	8
371	TWENTE Study: The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente: study design, rationale and objectives. Netherlands Heart Journal, 2010, 18, 360-364.	0.3	15
372	One-year clinical follow-up of a registry evaluating a percutaneous revascularisation strategy combining a pre-specified simple selection process with the use of a new thin-strut bare cobalt-chromium stent. Netherlands Heart Journal, 2010, 18, 486-492.	0.3	2
373	Long-term Clinical Outcomes of Drug-eluting Stents Vs Bare-metal Stents in Chinese Patients. Clinical Cardiology, 2010, 33, E22-9.	0.7	4
374	Impact of Stent Design on In-Stent Stenosis in a Rabbit Iliac Artery Model. CardioVascular and Interventional Radiology, 2010, 33, 565-575.	0.9	7
376	Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention. JACC: Cardiovascular Interventions, 2010, 3, 1229-1239.	1.1	42

#	ARTICLE	IF	CITATIONS
377	Plasma-induced nanopillars on bare metal coronary stent surface for enhanced endothelialization. <i>Acta Biomaterialia</i> , 2010, 6, 4589-4595.	4.1	44
378	Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , 2010, 99, 345-357.	1.5	34
379	Incidence and outcome of surgical procedures after sirolimus-eluting stent implantation: a report from the j-Cypher registry. <i>Cardiovascular Intervention and Therapeutics</i> , 2010, 25, 29-39.	1.2	22
380	Coronary Stent Thrombosis in the Current Era: Challenges and Opportunities for Treatment. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 46-57.	0.4	3
383	Secondary prevention strategies for coronary heart disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 8-24.	1.0	24
384	Revascularization for coronary artery disease in diabetes mellitus: Angioplasty, stents and coronary artery bypass grafting. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2010, 11, 75-86.	2.6	68
385	Lessons from the SYNTAX trial. <i>Journal of the Saudi Heart Association</i> , 2010, 22, 35-41.	0.2	3
386	Percutaneous coronary intervention. <i>Medicine</i> , 2010, 38, 438-445.	0.2	2
387	Repeated stent thrombosis after DES implantation and localized hypersensitivity to a stent implanted in the distal portion of a coronary aneurysm thought to be a sequela of Kawasaki disease: Autopsy report. <i>Pathology International</i> , 2010, 60, 112-118.	0.6	11
388	Angiographic Predictors of Recurrent Stent Thrombosis (from the Outcome of PCI for Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 38)	0.7	11
389	Comparison of Sirolimus-Eluting Stents With Paclitaxel-Eluting Stents in Saphenous Vein Graft Intervention (from a Multicenter Southern California Registry). <i>American Journal of Cardiology</i> , 2010, 106, 337-341.	0.7	16
390	Three-Year Outcomes Following Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in an Unselected Population With Coronary Artery Disease (from the REWARDS Registry). <i>American Journal of Cardiology</i> , 2010, 106, 504-510.	0.7	14
392	Patients under anti-platelet therapy. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2010, 24, 41-50.	1.7	13
393	Late drug-eluting stent thrombosis: importance of intravascular ultrasound. <i>Cardiovascular Revascularization Medicine</i> , 2010, 11, 52-56.	0.3	5
394	Fibrinolytic therapy for very late stent thrombosis—is it a viable option?. <i>Cardiovascular Revascularization Medicine</i> , 2010, 11, 264.e13-264.e15.	0.3	1
395	Combined drug release from biodegradable bilayer coating for endovascular stents. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2010, 93B, 375-385.	1.6	15
396	Outcomes of diabetics receiving bare-metal stents versus drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 473-481.	0.7	5
397	Recurrent very late thrombosis of drug-eluting stent: Optical coherence tomography findings. <i>Journal of Cardiology Cases</i> , 2010, 2, e166-e169.	0.2	0

#	ARTICLE	IF	CITATIONS
398	Incidence and Predictors of Very Late (≥4 Years) Major Cardiac Adverse Events in the DESIRE (Drug-Eluting Stents in the Real World)-Late Registry. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 12-18.	1.1	54
400	Impact of Multiple and Long Sirolimus-Eluting Stent Implantation on 3-Year Clinical Outcomes in the j-Cypher Registry. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 180-188.	1.1	55
401	Perioperative Management of Patients With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 131-142.	1.1	74
402	A Novel Paclitaxel-Eluting Stent With an Ultrathin Abluminal Biodegradable Polymer. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 431-438.	1.1	48
403	Thrombosis of Second-Generation Drug-Eluting Stents in Real Practice. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 911-919.	1.1	59
404	Percutaneous Coronary Intervention in Native Vessels With Angiographically Visible Thrombus. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 937-946.	1.1	3
405	Frequency and Predictors of Drug-Eluting Stent Use in Saphenous Vein Bypass Graft Percutaneous Coronary Interventions. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1068-1073.	1.1	59
406	Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1220-1228.	1.1	45
407	The Unrestricted Use of Sirolimus- and Paclitaxel-Eluting Stents Results in Better Clinical Outcomes During 6-Year Follow-Up Than Bare-Metal Stents. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1051-1058.	1.1	42
408	Long-Term Clinical Outcomes With Zotarolimus-Eluting Versus Bare-Metal Coronary Stents. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1240-1249.	1.1	42
409	A history of late and very late stent thrombosis is not associated with increased activation of the contact system, a case control study. <i>Thrombosis Journal</i> , 2010, 8, 6.	0.9	2
410	The Paclitaxel-Eluting Coroflex <sup>®</sup> Stent Study II (PECOPS II) Acute and 6-Month Clinical and Angiographic Follow-Up, 1-Year Clinical Follow-Up. <i>Journal of Interventional Cardiology</i> , 2010, 23, 160-166.	0.5	7
411	In-Hospital and 12-Month Postprocedural Clinical Outcome of Coronary Bifurcational Lesion Treatment with the Endeavor Stent. <i>Journal of Interventional Cardiology</i> , 2010, 23, 188-194.	0.5	3
412	Stent Thrombosis Following 2 Drug-Eluting Stent Implantations for Coronary Bifurcation Lesion: A Single-Center Analysis. <i>Journal of Interventional Cardiology</i> , 2010, 23, 346-351.	0.5	1
413	Protein C and/or Protein S Deficiency and Occurrence of Stent Thrombosis: A Hitherto Unrecognized Association. <i>Journal of Interventional Cardiology</i> , 2010, 23, 560-564.	0.5	5
414	Clinical characteristics and mid-term outcomes of acute myocardial infarction patients with prior cerebrovascular disease in an Asian population: Lessons from the Korea Acute Myocardial Infarction Registry. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2010, 37, 581-586.	0.9	12
415	Nanomedicine for the reduction of the thrombogenicity of stent coatings. <i>International Journal of Nanomedicine</i> , 2010, 5, 239.	3.3	29
416	Long-term Clinical Outcomes After Sirolimus-Eluting Stent Implantation in Dialysis Patients. <i>International Heart Journal</i> , 2010, 51, 92-97.	0.5	24

#	ARTICLE	IF	CITATIONS
417	THE MODERN ASPECTS OF CLOPIDOGREL USE. Rational Pharmacotherapy in Cardiology, 2010, 6, 185-191.	0.3	0
418	The Effect of Cilostazol on Stent Thrombosis After Drug-Eluting Stent Implantation. Korean Circulation Journal, 2010, 40, 10.	0.7	8
419	Imagerie de complications du stenting coronaire en tomographie par cohérence optique. Sang Thrombose Vaisseaux, 2010, 22, 017-025.	0.1	1
420	Coronary Stent Thrombosis in Patients With Chronic Renal Insufficiency. Angiology, 2010, 61, 297-303.	0.8	5
421	Very Long-Term (15 to 20 Years) Clinical and Angiographic Outcome After Coronary Bare Metal Stent Implantation. Circulation: Cardiovascular Interventions, 2010, 3, 468-475.	1.4	87
422	Paclitaxel-Eluting Versus Sirolimus-Eluting Stents in Diabetes Mellitus. Circulation: Cardiovascular Interventions, 2010, 3, 42-49.	1.4	13
423	Commentary: Vertebral Ostium Stenting: Unsolved Puzzle. Journal of Endovascular Therapy, 2010, 17, 241-242.	0.8	3
424	Drug-eluting balloon: new tool in the box. Expert Review of Medical Devices, 2010, 7, 381-388.	1.4	14
425	Cardiovascular stents. , 2010, , 173-216.		5
426	Bioresorbable Stents. Circulation, 2010, 122, 2236-2238.	1.6	8
427	Use of drug eluting stents in ST segment elevation myocardial infarction. Heart, 2010, 96, 1073-1077.	1.2	10
428	Comparisons of Baseline Demographics, Clinical Presentation, and Long-Term Outcome Among Patients With Early, Late, and Very Late Stent Thrombosis of Sirolimus-Eluting Stents. Circulation, 2010, 122, 52-61.	1.6	228
429	CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. European Heart Journal, 2010, 31, 3046-3053.	1.0	138
430	Letter by Dominguez-Rodriguez et al Regarding Article, "C-Reactive Protein and the Risk of Stent Thrombosis and Cardiovascular Events After Drug-Eluting Stent Implantation". Circulation, 2010, 122, e2; author reply e3.	1.6	0
431	Altered Plasma Fibrin Clot Properties Are Associated With In-Stent Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 276-282.	1.1	55
432	Drug-eluting balloons: what is their place on the interventionalist's shelf?. Heart, 2010, 96, 1257-1258.	1.2	11
433	Letter by Virmani et al Regarding Article, "Drug-Eluting Stents in Animals and Patients: Where Do We Stand Today?". Circulation, 2010, 121, e246; author reply e247.	1.6	3
434	Review Article: The New Concept of Interventional Heart Failure Therapy"Part 1: Electrical Therapy, Treatment of CAD, Fluid Removal, and Ventricular Support. Journal of Cardiovascular Pharmacology and Therapeutics, 2010, 15, 102-111.	1.0	7

#	ARTICLE	IF	CITATIONS
435	Why Observational Studies Should Be Among The Tools Used In Comparative Effectiveness Research. Health Affairs, 2010, 29, 1818-1825.	2.5	183
436	Strut Coverage and Vessel Wall Response to a New-Generation Paclitaxel-Eluting Stent With an Ultrathin Biodegradable Abluminal Polymer. Circulation: Cardiovascular Interventions, 2010, 3, 367-375.	1.4	64
437	Überwachung der Clopidogrel-Therapie mit Hilfe der Mehrfach-Elektroden Plättchen-Aggregometrie / Monitoring of clopidogrel treatment by multiple electrode platelet aggregometry. Laboratoriums Medizin, 2010, 34, 99-107.	0.1	2
438	Monitoring of clopidogrel treatment by multiple electrode platelet aggregometry 1 , 2. Laboratoriums Medizin, 2010, 34, -.	0.1	0
439	Late Vascular Responses From 2 to 4 Years After Implantation of Sirolimus-Eluting Stents. Circulation: Cardiovascular Interventions, 2010, 3, 476-483.	1.4	45
440	Clopidogrel hypersensitivity: clinical challenges and options for management. Expert Review of Clinical Pharmacology, 2010, 3, 553-561.	1.3	14
441	Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO Study. Heart, 2010, 96, 1291-1296.	1.2	257
442	Response to Letter Regarding Article, "C-Reactive Protein and the Risk of Stent Thrombosis and Cardiovascular Events After Drug-Eluting Stent Implantation"; Circulation, 2010, 122, .	1.6	0
443	Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-I) Trial. Circulation: Cardiovascular Interventions, 2010, 3, 556-564.	1.4	55
444	Prediction and prevention by progenitors? Stent thrombosis and EPCs. European Heart Journal, 2010, 31, 2569-2571.	1.0	4
445	Unravelling the endovascular microenvironment by optical coherence tomography. European Heart Journal, 2010, 31, 139-142.	1.0	12
446	Late device thrombosis after atrial septal defect closure. European Heart Journal, 2010, 31, 142-142.	1.0	11
447	Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy. European Heart Journal, 2010, 31, 1792-1801.	1.0	109
448	Circulating endothelial progenitor cell levels and function in patients who experienced late coronary stent thrombosis. European Heart Journal, 2010, 31, 2625-2632.	1.0	37
449	To beat or not to beat? From one size fits it all to an individual coronary revascularization strategy. European Heart Journal, 2010, 31, 2441-2443.	1.0	5
450	Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2010, 38, S1-S52.	0.6	405
451	Pathobiology of Stent Thrombosis after Drug-Eluting Stent Implantation. Current Pharmaceutical Design, 2010, 16, 4064-4071.	0.9	35
452	Current status of the Xience V <sup>®</sup> everolimus-eluting coronary stent system. Expert Review of Cardiovascular Therapy, 2010, 8, 1363-1374.	0.6	11



#	ARTICLE	IF	CITATIONS
453	Benefits of and safety concerns associated with drug-eluting coronary stents. Expert Review of Cardiovascular Therapy, 2010, 8, 449-470.	0.6	24
454	Everolimus-eluting stents: insights from the SPIRIT IV and COMPARE trials. Expert Review of Cardiovascular Therapy, 2010, 8, 1207-1210.	0.6	2
455	Efficiency of Drug Delivery to the Coronary Arteries in Swine Is Dependent on the Route of Administration: Assessment of Luminal, Intimal, and Adventitial Coronary Artery and Venous Delivery Methods. Journal of Vascular and Interventional Radiology, 2010, 21, 1555-1564.	0.2	14
456	Drug-Eluting Stents: Issues of Late Stent Thrombosis. Cardiology Clinics, 2010, 28, 97-105.	0.9	24
457	Diagnosis and Treatment of Complications of Coronary and Valvular Interventions. , 2010, , 255-269.		0
458	A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions. Journal of the American College of Cardiology, 2010, 55, 543-554.	1.2	217
459	Long-Term Effectiveness and Safety of Sirolimus Stent Implantation for Coronary In-Stent Restenosis. Journal of the American College of Cardiology, 2010, 55, 613-616.	1.2	21
460	Intravascular Ultrasound Findings in Patients With Very Late Stent Thrombosis After Either Drug-Eluting or Bare-Metal Stent Implantation. Journal of the American College of Cardiology, 2010, 55, 1936-1942.	1.2	132
461	5-Year Clinical Outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the Sirolimus-Eluting Stent in the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions. Journal of the American College of Cardiology, 2010, 55, 1093-1101.	1.2	218
462	Pathological Findings at Bifurcation Lesions. Journal of the American College of Cardiology, 2010, 55, 1679-1687.	1.2	228
463	Long-Term Outcomes After Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2010, 56, 1366-1375.	1.2	131
464	Long-Term Safety and Efficacy of Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2010, 56, 117-124.	1.2	272
465	Long-Term Outcome After Drug-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2010, 56, 641-645.	1.2	75
466	Coronary Stents. Journal of the American College of Cardiology, 2010, 56, S1-S42.	1.2	447
467	Stent Thrombosis. Journal of the American College of Cardiology, 2010, 56, 1357-1365.	1.2	363
468	Selection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up. Journal of the American College of Cardiology, 2010, 56, 1597-1604.	1.2	83
469	Thrombus aspiration for the treatment of definite stent thrombosis. Archives of Cardiovascular Diseases, 2010, 103, 33-38.	0.7	3
470	Drug-eluting stents in patients on long-term oral anticoagulation therapy: a mission impossible?. Interventional Cardiology, 2010, 2, 127-135.	0.0	4

#	ARTICLE	IF	CITATIONS
471	Effect of Stent Thrombosis on the Risk-Benefit Balance of Drug-Eluting Stents and Bare Metal Stents. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 528-535.	0.4	1
473	Guidelines for the Management of Antiplatelet Therapy in Patients With Coronary Stents Undergoing Non-Cardiac Surgery. <i>Heart Lung and Circulation</i> , 2010, 19, 2-10.	0.2	38
474	Death caused by simultaneous subacute stent thrombosis of sirolimus-eluting stents in left anterior descending artery and left circumflex artery. <i>International Journal of Cardiology</i> , 2010, 140, e8-e11.	0.8	11
475	Late lumen loss and follow-up percent diameter stenosis at different doses of oral valsartan six months after bare-metal stent implantation in type B2/C coronary lesions. <i>International Journal of Cardiology</i> , 2010, 142, 29-32.	0.8	5
476	Clinical outcomes of drug-eluting stent use in patients with ST elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2010, 143, 283-288.	0.8	6
477	Long-term clinical outcome with titanium-nitride-oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population. <i>International Journal of Cardiology</i> , 2010, 144, 42-46.	0.8	21
479	The incidence and clinical predictors of early stent thrombosis in patients with acute coronary syndrome. <i>American Heart Journal</i> , 2010, 159, 118-124.	1.2	23
480	Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). <i>American Heart Journal</i> , 2010, 159, 284-291.e1.	1.2	63
481	Long-term outcome of percutaneous catheter intervention for de novo coronary bifurcation lesions with drug-eluting stents or bare-metal stents. <i>American Heart Journal</i> , 2010, 159, 454-461.	1.2	22
482	Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents. <i>American Heart Journal</i> , 2010, 159, 684-690.e1.	1.2	26
483	Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. <i>American Heart Journal</i> , 2010, 159, 891-898.e1.	1.2	36
484	Vulnerable disease may induce neointimal coverage after sirolimus-eluting stent implantation. <i>American Heart Journal</i> , 2010, 160, 564-569.	1.2	8
485	Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. <i>American Heart Journal</i> , 2010, 160, 1035-1041.e1.	1.2	158
486	Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery Bypass Graft Treatment in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial. <i>Circulation</i> , 2010, 121, 2645-2653.	1.6	561
487	REVIEW: Stent Thrombosis—Risk Assessment and Prevention. <i>Cardiovascular Therapeutics</i> , 2010, 28, e92-100.	1.1	18
488	Long-term outcomes following coronary drug-eluting- and bare-metal-stent implantation. <i>Atherosclerosis</i> , 2010, 210, 503-509.	0.4	22
489	Diabetes and the platelet: Toward new therapeutic paradigms for diabetic atherothrombosis. <i>Atherosclerosis</i> , 2010, 212, 367-376.	0.4	57
490	One-year clinical outcome after provisional T-stenting for bifurcation lesions with the endothelial progenitor cell capturing stent compared with the bare-metal stent. <i>Atherosclerosis</i> , 2010, 213, 525-531.	0.4	9

#	ARTICLE	IF	CITATIONS
491	Influencia de la trombosis del stent en la relación riesgo-beneficio de los stents farmacoactivos y los stents convencionales. Revista Espanola De Cardiología, 2010, 63, 528-535.	0.6	3
493	Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet, The, 2010, 375, 201-209.	6.3	641
494	Everolimus or paclitaxel stents in real life: go COMPARE. Lancet, The, 2010, 375, 174-176.	6.3	3
495	Post-partum haemorrhage: beyond the confrontation between misoprostol and oxytocin. Lancet, The, 2010, 375, 176-178.	6.3	7
496	Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet, The, 2010, 375, 1090-1099.	6.3	198
497	Everolimus-eluting versus paclitaxel-eluting stents – Authors' reply. Lancet, The, 2010, 375, 1161-1162.	6.3	4
498	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2010, 31, 2501-2555.	1.0	2,649
499	Controversies in the Use of Drug-Eluting Stents for Acute Myocardial Infarction: A Critical Appraisal of the Data. Annual Review of Medicine, 2010, 61, 215-231.	5.0	6
500	Vigorous exercise as a triggering mechanism for late stent thrombosis: A description of three cases. Platelets, 2010, 21, 72-76.	1.1	11
501	The comparative safety of bare-metal and drug-eluting intracoronary stents. Expert Review of Medical Devices, 2010, 7, 611-624.	1.4	4
502	Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 49-61.	0.7	5
503	Biolimus-eluting biodegradable polymer-coated stent versus bare metal stent in acute ST-elevation and non-ST elevation myocardial infarction: Justification for biodegradable polymer-coated stent in acute coronary syndrome (JANICE) registry. Acute Cardiac Care, 2011, 13, 43-47.	0.2	0
504	How safe and how good are drug-eluting stents?. Future Cardiology, 2011, 7, 251-270.	0.5	16
505	Enhanced Endothelialization on Surface Modified Poly(L-Lactic Acid) Substrates. Tissue Engineering - Part A, 2011, 17, 865-876.	1.6	33
506	Bioresorbable Scaffold. Circulation, 2011, 123, 779-797.	1.6	385
509	Coronary Responses and Differential Mechanisms of Late Stent Thrombosis Attributed to First-Generation Sirolimus- and Paclitaxel-Eluting Stents. Journal of the American College of Cardiology, 2011, 57, 390-398.	1.2	283
510	Multicenter Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications After Drug-Eluting Stent Implantation for Coronary Heart Disease. Journal of the American College of Cardiology, 2011, 57, 280-289.	1.2	177
511	Long-Term Comparison of Drug-Eluting Stents and Coronary Artery Bypass Grafting for Multivessel Coronary Revascularization. Journal of the American College of Cardiology, 2011, 57, 128-137.	1.2	60

#	ARTICLE	IF	CITATIONS
512	The Pathology of Neoatherosclerosis in Human Coronary Implants. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1314-1322.	1.2	834
513	Long-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2143-2151.	1.2	92
514	Complexity of Atherosclerotic Coronary Artery Disease and Long-Term Outcomes in Patients With Unprotected Left Main Disease Treated With Drug-Eluting Stents or Coronary Artery Bypass Grafting. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2152-2159.	1.2	45
515	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2011, 58, e44-e122.	1.2	2,027
516	1-Year Outcome of TRIAS HR (TRI-Stent Adjudication Studyâ€“High Risk of Restenosis). <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 896-904.	1.1	49
517	Current and future drug-eluting coronary stent technology. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 485-503.	0.6	20
518	Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: Rationale and design of the Assessment with a double Randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and Clopidogrel after DES implantation, and (2) Treatment Interruption versus Continuation, 1 year after stenting (ARCTIC) study. <i>American Heart Journal</i> , 2011, 161, 5-12.e5.	1.2	78
519	Impact of intravascular ultrasound guidance on long-term clinical outcomes in patients treated with drug-eluting stent for bifurcation lesions: Data from a Korean multicenter bifurcation registry. <i>American Heart Journal</i> , 2011, 161, 180-187.	1.2	96
520	The possibility of delayed arterial healing 5 years after implantation of sirolimus-eluting stents: Serial observations by coronary angiography. <i>American Heart Journal</i> , 2011, 161, 1200-1206.	1.2	14
521	Antiplatelet therapy in the perioperative period. <i>European Journal of Internal Medicine</i> , 2011, 22, 26-31.	1.0	25
522	Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 175-181.	0.3	53
523	Intracoronary Optical Coherence Tomography for the Assessment of In-Stent Restenosis. <i>Heart Lung and Circulation</i> , 2011, 20, 332-335.	0.2	0
524	High on Treatment Platelet Reactivity and Stent Thrombosis. <i>Heart Lung and Circulation</i> , 2011, 20, 525-531.	0.2	12
525	Stent thrombosis: Nightmare of the interventional cardiology era. <i>International Journal of Cardiology</i> , 2011, 148, e51-e52.	0.8	3
526	Different patterns of neointimal coverage between acute coronary syndrome and stable angina after various types of drug-eluting stents implantation; 9-month follow-up optical coherence tomography study. <i>International Journal of Cardiology</i> , 2011, 146, 341-346.	0.8	46
527	Long-term clinical outcomes after drug eluting stent implantation in women with de novo coronary lesions. <i>International Journal of Cardiology</i> , 2011, 149, 55-62.	0.8	3
528	The CID Chronoâ„¢ cobaltâ€“chromium alloy carbofilm-coated coronary stent system. <i>International Journal of Cardiology</i> , 2011, 149, 199-204.	0.8	9
529	Neointimal tissue rupture as a mechanism of myocardial infarction very late following implantation of bare metal stents. Insights from optical coherence tomography. <i>International Journal of Cardiology</i> , 2011, 148, 348-349.	0.8	3

#	ARTICLE	IF	CITATIONS
530	Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. <i>International Journal of Cardiology</i> , 2011, 148, 96-101.	0.8	61
531	Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials. <i>International Journal of Cardiology</i> , 2011, 150, 84-89.	0.8	33
532	Comparison of efficacy between paclitaxel-eluting stents with different polymers in terms of major adverse cardiac events and stent thrombosis up to 12 months of clinical follow-up. <i>International Journal of Cardiology</i> , 2011, 152, 392-395.	0.8	0
533	Current concepts on coronary revascularization in diabetic patients. <i>European Heart Journal</i> , 2011, 32, 2748-2757.	1.0	82
534	Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. <i>Thrombosis Research</i> , 2011, 128, e130-e136.	0.8	29
535	Local Drug Delivery for Treatment of Coronary and Peripheral Artery Disease. <i>Cardiovascular Therapeutics</i> , 2011, 29, e54-e66.	1.1	18
536	Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. <i>Lancet, The</i> , 2011, 377, 1241-1247.	6.3	216
537	Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. <i>Lancet, The</i> , 2011, 378, 1940-1948.	6.3	321
538	Are Paclitaxel-Eluting Stents Better in Unprotected Left Main Coronary Artery Disease? Three-Year Clinical and Intravascular Imaging Results From a Randomized Study. <i>Medicina (Lithuania)</i> , 2011, 47, 77.	0.8	2
539	Comparison of outcome in 1809 patients treated with drug-eluting stents or bare-metal stents in a real-world setting. <i>Vascular Health and Risk Management</i> , 2011, 7, 693.	1.0	3
540	Late Stent Thrombosis After Drug-Eluting Stent Implantation: A Rare Case of Accelerated Neo-Atherosclerosis and Early Manifestation of Neointimal Rupture. <i>Korean Circulation Journal</i> , 2011, 41, 409.	0.7	3
541	Very Late Stent Thrombosis in a Drug-Eluting Stent due to Interruption of Anti-Platelet Agents in Patients With Acute Myocardial Infarction and Thrombocytosis. <i>Korean Circulation Journal</i> , 2011, 41, 417.	0.7	8
542	Stents farmacol3gicos liberadores de Everolimus XienceTM V no tratamento de pacientes com les3es coron3rias complexas na pr3tica di3ria: resultados iniciais do registro brasileiro BRAVO. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2011, 19, 357-366.	0.1	3
543	Compara33o randomizada entre o stent eluidor de paclitaxel de nova gera33o sem pol3mero e o stent eluidor de paclitaxel com pol3mero dur3vel em pacientes com doen3a arterial coron3ria: resultados da an3lise angiogr3fica e ultrassonogr3fica seriada do estudo PAX-A. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2011, 19, 379-391.	0.1	4
544	Everolimus-eluting stents: update on current clinical studies. <i>Medical Devices: Evidence and Research</i> , 2011, 4, 91.	0.4	3
545	Development of a Coronary Aneurysm at a Sirolimus-Eluting Stent-Implanted Lesion in a Patient With Churg-Strauss Syndrome. <i>Korean Circulation Journal</i> , 2011, 41, 559.	0.7	2
546	Advantages and disadvantages of biodegradable platforms in drug eluting stents. <i>World Journal of Cardiology</i> , 2011, 3, 84.	0.5	32
547	Association on cardiovascular interventions of PCS Current status of drug-eluting stents and drug-eluting balloons in patients with stable coronary artery disease: An expert consensus document of the Association for Percutaneous Cardiovascular Interventions and Polish Cardiac Society. <i>Postepy W Kardiologii Interwencyjnei</i> , 2011, 1, 20-55.	0.1	0

#	ARTICLE	IF	CITATIONS
548	Drug-Eluting Stents. , 2011, , 427-448.		6
549	Differences in Drug-Eluting Stents Used in Coronary Artery Disease. American Journal of the Medical Sciences, 2011, 342, 402-408.	0.4	2
550	A retrospective analysis of consecutive patients undergoing nonurgent percutaneous coronary intervention comparing bare metal stents with drug-eluting stents using the National Institute for Clinical Excellence criteria. Coronary Artery Disease, 2011, 22, 32-39.	0.3	7
551	Complete resolution of very late stent thrombosis with systemic thrombolysis. Journal of Cardiovascular Medicine, 2011, 12, 765-767.	0.6	1
552	Vessel healing: checking in-vivo results for better treatment. Journal of Cardiovascular Medicine, 2011, 12, 311-313.	0.6	0
553	Predictors of stent fracture in patients treated with closed-cell design stents. Coronary Artery Disease, 2011, 22, 40-44.	0.3	7
554	Antiplatelet Drugs. Anesthesia and Analgesia, 2011, 112, 292-318.	1.1	179
555	Comparison of haemodialysis patients and non-haemodialysis patients with respect to clinical characteristics and 3-year clinical outcomes after sirolimus-eluting stent implantation: insights from the Japan multi-centre post-marketing surveillance registry. European Heart Journal, 2011, 32, 829-837.	1.0	50
556	Coronary stent thrombosis: incidence, predictors and triggering mechanisms. Interventional Cardiology, 2011, 3, 581-588.	0.0	2
557	Impact of Cytochrome P450 2C19*2 Polymorphism on Intra-Stent Thrombus After Drug-Eluting Stent Implantation in Japanese Patients Receiving Clopidogrel. Circulation Journal, 2011, 75, 99-105.	0.7	65
558	Angioscopic Assessment of Arterial Repair Following Biodegradable Polymer-Coated Biolimus A9-Eluting Stent Implantation - Comparison With Durable Polymer-Coated Sirolimus-Eluting Stent -. Circulation Journal, 2011, 75, 1113-1119.	0.7	19
559	Bioresorbable Scaffold Technologies. Circulation Journal, 2011, 75, 509-520.	0.7	102
560	Characteristics and Predictors of Drug-Eluting Stent Thrombosis - Results From the Multicenter Korea Stent Thrombosis (KoST)' Registry -. Circulation Journal, 2011, 75, 1626-1632.	0.7	31
561	Speculative Mechanisms for Very Late Stent Thrombosis After Drug-Eluting Stent Implantation. Circulation Journal, 2011, 75, 779-780.	0.7	5
562	Role of Bare-Metal Stents for Left Main Coronary Artery Disease in the Era of Drug-Eluting Stents - Which Coronary Stent Should Be Used for Left Main Trunk Disease? BMS or DES? (BMS-Side) -. Circulation Journal, 2011, 75, 1243-1249.	0.7	6
563	Percutaneous Coronary Intervention With Drug-Eluting Stent for Unprotected Left Main Trunk Disease: Safety and Efficacy Compared With Bare Metal Stent. Circulation Journal, 2011, 75, 1250-1254.	0.7	7
564	Drug-Eluting Stent - Importance of Clinico-Pathological Correlations -. Circulation Journal, 2011, 75, 1548-1558.	0.7	21
565	Very Late Sirolimus-Eluting Stent Thrombosis Due to Stent Fracture and Late-Acquired Incomplete Stent Apposition Detected on Multislice Computed Tomography. Circulation Journal, 2011, 75, 2716-2717.	0.7	6

#	ARTICLE	IF	CITATIONS
566	The Rapid Evaluation of Vessel Healing after Angioplasty (REVEAL) trial. <i>Interventional Cardiology</i> , 2011, 3, 451-460.	0.0	1
567	Drug-eluting balloons: where are we and what are the problems?. <i>Clinical Investigation</i> , 2011, 1, 763-765.	0.0	0
568	Revascularisation in patients with mental illness. <i>British Journal of Psychiatry</i> , 2011, 199, 252-253.	1.7	1
569	Low Mean Corpuscular Hemoglobin Level is a Predictor of Discontinuation of Antiplatelet Therapy in Patients with Acute Coronary Syndrome. <i>Internal Medicine</i> , 2011, 50, 2933-2939.	0.3	1
571	Morphological and Quantitative Analysis of Vascular Wall and Neointimal Hyperplasia After Coronary Stenting - Comparison of Bare-Metal and Sirolimus-Eluting Stents Using Optical Coherence Tomography -. <i>Circulation Journal</i> , 2011, 75, 1633-1640.	0.7	18
573	Five-Year Clinical Outcome of Titanium-Nitride-Oxide-Coated Bioactive Stent Implantation in a Real-World Population: A Comparison with Paclitaxel-eluting Stents: The PORI Registry. <i>Journal of Interventional Cardiology</i> , 2011, 24, 1-8.	0.5	28
574	Low Stent Thrombosis Risk with the XIENCE V <sup>®</sup> Everolimus-Eluting Coronary Stent: Evidence from Randomized and Single-Arm Clinical Trials. <i>Journal of Interventional Cardiology</i> , 2011, 24, 326-341.	0.5	10
575	Do Patients with Drug-Eluting Stent Thrombosis Have a Similar Prognosis to Patients Presenting with ST-Elevation Myocardial Infarction of de novo Lesions?. <i>Journal of Interventional Cardiology</i> , 2011, 24, 320-325.	0.5	5
576	Drug-Eluting Stents during ST-Segment Elevation Acute Myocardial Infarction: A Critical Analysis. <i>Journal of Interventional Cardiology</i> , 2011, 24, 416-423.	0.5	0
577	What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?. <i>Journal of Cardiology</i> , 2011, 57, 53-60.	0.8	8
578	Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. <i>Journal of Cardiology</i> , 2011, 57, 194-201.	0.8	90
579	Effect of coronary endothelial function on outcomes in patients undergoing percutaneous coronary intervention. <i>Journal of Cardiology</i> , 2011, 57, 231-238.	0.8	23
580	Stent thrombosis and drug-eluting stents. <i>Journal of Cardiology</i> , 2011, 58, 92-98.	0.8	28
581	Stent thrombosis of drug eluting stent: Pathological perspective. <i>Journal of Cardiology</i> , 2011, 58, 84-91.	0.8	70
582	Comparison of Dual Drug-Eluting Cilotax Stent and Paclitaxel-Eluting Taxus Liberte Stent in Native Coronary Artery Lesions. <i>American Journal of Cardiology</i> , 2011, 107, 990-994.	0.7	13
583	Comparison of Three-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation Among Insulin-Treated Diabetic, Non-Insulin-Treated Diabetic, and Non-Diabetic Patients from j-Cypher Registry. <i>American Journal of Cardiology</i> , 2011, 107, 1155-1162.	0.7	45
584	Role of Intravascular Ultrasound in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2011, 108, 8-14.	0.7	37
585	Impact of Body Mass Index on the Five-Year Outcome of Patients Having Percutaneous Coronary Interventions With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2011, 108, 195-201.	0.7	37

#	ARTICLE	IF	CITATIONS
586	Effect of Pioglitazone on Endothelial Dysfunction After Sirolimus-Eluting Stent Implantation. American Journal of Cardiology, 2011, 108, 214-219.	0.7	13
587	Efficacy and Safety of Intensive Antiplatelet Therapy With Prasugrel from TRITON-TIMI 38 in a Core Clinical Cohort Defined by Worldwide Regulatory Agencies. American Journal of Cardiology, 2011, 108, 905-911.	0.7	59
588	Stent-Related Cardiac Events Beyond Three Years After Implantation of the Sirolimus-Eluting Stent (from the EVASTENT Patients). American Journal of Cardiology, 2011, 108, 1401-1407.	0.7	11
590	Kissing inflation is feasible with all second-generation drug-eluting balloons. Cardiovascular Revascularization Medicine, 2011, 12, 280-285.	0.3	23
591	Safety and efficacy of drug-eluting stents and bare metal stents in acute coronary syndrome. Cardiovascular Revascularization Medicine, 2011, 12, 385-390.	0.3	5
592	Influence of Low-Dose Aspirin (81 mg) on the Incidence of Definite Stent Thrombosis in Patients Receiving Bare-Metal and Drug-Eluting Stents. Clinical Cardiology, 2011, 34, 567-571.	0.7	3
593	Intravascular Ultrasound-Guided Primary Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction. Clinical Cardiology, 2011, 34, 706-713.	0.7	27
594	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 82, E266-355.	0.7	97
595	CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events. JAMA - Journal of the American Medical Association, 2011, 306, 2704.	3.8	420
596	Long-term (2 years) follow-up optical coherence tomographic study after sirolimus- and paclitaxel-eluting stent implantation: comparison to 9-month follow-up results. International Journal of Cardiovascular Imaging, 2011, 27, 875-881.	0.7	25
597	Optical coherence tomography endpoints in stent clinical investigations: strut coverage. International Journal of Cardiovascular Imaging, 2011, 27, 271-287.	0.7	36
598	Drug-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: a mortality analysis from the EUROTRANSFER Registry. Clinical Research in Cardiology, 2011, 100, 139-145.	1.5	12
599	Percutaneous coronary intervention for unprotected left main disease in very high risk patients: safety of drug-eluting stents. Heart and Vessels, 2011, 26, 17-24.	0.5	18
600	Second- and third-generation drug-eluting coronary stents. Herz, 2011, 36, 190-197.	0.4	41
602	Four-Year Follow-Up of TYPHOON (Trial to Assess the Use of the CYPHer Sirolimus-Eluting Coronary) Interventions, 2011, 4, 14-23.	1.1	107
603	How Should Patients Requiring Dual Antiplatelet Therapy be Managed When Undergoing Elective Endoscopic Gastrointestinal Procedures?. Current Treatment Options in Cardiovascular Medicine, 2011, 13, 46-56.	0.4	1
604	Potential difficulty for accurate categorization of drug-eluting stent thrombosis without coronary angiography: unignorable involvement of the cases with new onset acute myocardial infarction occurred in target vessels. Cardiovascular Intervention and Therapeutics, 2011, 26, 109-116.	1.2	0
605	Long-term safety and efficacy of sirolimus-eluting stents versus bare-metal stents in real world clinical practice in Japan. Cardiovascular Intervention and Therapeutics, 2011, 26, 234-245.	1.2	106



#	ARTICLE	IF	CITATIONS
606	Efficacy of dual antiplatelet therapy combined with Naoxintong Capsules (è,,âfèçèfâš) following coronary microembolization induced by homologous microthrombi in rats. Chinese Journal of Integrative Medicine, 2011, 17, 917-924.	0.7	16
607	Management of patients with coronary stents in elective thoracic surgery. General Thoracic and Cardiovascular Surgery, 2011, 59, 477-482.	0.4	13
608	Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2011, 3, 620-646.	3.3	16
609	Triple therapy in hospitalized patients: Facts and controversies. Journal of Hospital Medicine, 2011, 6, 537-545.	0.7	1
610	Long-term risk of clinical events from stenting side branches of coronary bifurcation lesions with drug-eluting and bare-metal stents: An observational meta-analysis. Catheterization and Cardiovascular Interventions, 2011, 77, 202-212.	0.7	19
611	Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheterization and Cardiovascular Interventions, 2011, 78, 3-12.	0.7	134
612	Nevoâ stent: A successful stent makeover. Catheterization and Cardiovascular Interventions, 2011, 77, 52-53.	0.7	2
613	Genousâ endothelial progenitor cell capturing stent: Thrombusâresistant but vulnerable to restenosis. Catheterization and Cardiovascular Interventions, 2011, 78, 196-197.	0.7	5
614	The inhibition of platelet adhesion and activation on collagen during balloon angioplasty by collagen-binding peptidoglycans. Biomaterials, 2011, 32, 2516-2523.	5.7	37
615	Drug-eluting stents for coronary artery disease: A review. Medical Engineering and Physics, 2011, 33, 148-163.	0.8	104
616	Vasomotor Function After Paclitaxel-Coated Balloon Post-Dilation in Porcine Coronary Stent Model. JACC: Cardiovascular Interventions, 2011, 4, 247-255.	1.1	17
617	5-Year Follow-Up After Primary Percutaneous Coronary Intervention With a Paclitaxel-Eluting Stent Versus a Bare-Metal Stent in Acute ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2011, 4, 24-29.	1.1	116
618	Very Late Stent Thrombosis After Primary Percutaneous Coronary Intervention With Bare-Metal and Drug-Eluting Stents for ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2011, 4, 30-38.	1.1	70
619	Randomized Trial of Stents versus Bypass Surgery for Left Main Coronary Artery Disease. New England Journal of Medicine, 2011, 364, 1718-1727.	13.9	571
620	Bayesian Change Point Detection in Monitoring Cardiac Surgery Outcomes. Quality Management in Health Care, 2011, 20, 207-222.	0.4	9
621	Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circulation, 2011, 123, 1745-1756.	1.6	222
622	Incidence, Risk Factors, and Clinical Sequelae of Angiographic Peri-Stent Contrast Staining After Sirolimus-Eluting Stent Implantation. Circulation, 2011, 123, 2382-2391.	1.6	117
623	Delayed Coverage in Malapposed and Side-Branch Struts With Respect to Well-Apposed Struts in Drug-Eluting Stents. Circulation, 2011, 124, 612-623.	1.6	122

#	ARTICLE	IF	CITATIONS
624	Dual antiplatelet therapy duration. <i>Current Opinion in Cardiology</i> , 2011, 26, S4-S14.	0.8	5
625	Trends in Coronary Revascularization in the United States From 2001 to 2009. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 193-197.	0.9	167
626	Five-Year Outcomes of Sirolimus-Eluting and Paclitaxel-Eluting Stents in Routine Clinical Practice. <i>Circulation</i> , 2011, 123, 2779-2781.	1.6	3
627	Very late stent thrombosis of Sirolimus-eluting stent 59 months after implantation: A first report from the Middle-East and review of literature. <i>Heart Views</i> , 2011, 12, 22.	0.1	3
628	Evaluation of Polymer-Based Comparator Drug-Eluting Stents Using a Rabbit Model of Iliac Artery Atherosclerosis. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 38-46.	1.4	75
629	Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 130-138.	1.4	10
630	Coronary Revascularization Trends in the United States, 2001-2008. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1769.	3.8	454
631	Letter by Nunes Regarding Article, "Clinical Cardiology: Physician Update: Erectile Dysfunction and Cardiovascular Disease"; <i>Circulation</i> , 2011, 124, e252; author reply e253.	1.6	0
632	Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes. <i>European Heart Journal</i> , 2011, 32, 2358-2364.	1.0	17
633	Predictors and Implications of Stent Thrombosis in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 577-584.	1.4	38
634	Next-generation stents. <i>Science-Business EXchange</i> , 2011, 4, 1227-1227.	0.0	0
635	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, e574-651.	1.6	1,946
636	Neutrophil-Derived Cathelicidin Protects from Neointimal Hyperplasia. <i>Science Translational Medicine</i> , 2011, 3, 103ra98.	5.8	100
637	Fatal very late stent thrombosis in a paclitaxel-eluting stent after treatment of gastrointestinal bleeding: a case report. <i>Grand Rounds</i> , 2011, 11, 48-52.	0.2	0
638	Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents. <i>Circulation</i> , 2011, 123, 2819-2828.	1.6	169
639	Computational structural modelling of coronary stent deployment: a review. <i>Computer Methods in Biomechanics and Biomedical Engineering</i> , 2011, 14, 331-348.	0.9	67
640	Cannabinoid receptor CB2 protects against balloon-induced neointima formation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 302, H1064-H1074.	1.5	23
641	Drug eluting stents: Current status and new developments. <i>Anatolian Journal of Cardiology</i> , 2012, 12, 676-83.	0.4	4

#	ARTICLE	IF	CITATIONS
642	Serial Assessment of Coronary Artery Response to Paclitaxel-Eluting Stents Using Optical Coherence Tomography. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 30-38.	1.4	26
643	Neoatherosclerosis. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 6-9.	1.4	33
644	Effect of Biolimus-Eluting Stents With Biodegradable Polymer vs Bare-Metal Stents on Cardiovascular Events Among Patients With Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 777.	3.8	278
645	Stent Selection in Patients with Myocardial Infarction: Drug Eluting, Biodegradable Polymers or Bare Metal Stents?. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2012, 7, 105-120.	1.5	2
646	Comparison of 5-Year Clinical Outcomes Between Sirolimus-Versus Paclitaxel-Eluting Stent. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 174-184.	1.4	14
647	Very late stent thrombosis. <i>Current Opinion in Cardiology</i> , 2012, 27, 634-641.	0.8	22
648	The Long-Term Effect of Coronary Stenting on Epicardial and Microvascular Endothelial Function. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 523-529.	1.4	14
649	Impact of Diabetes Mellitus on Vessel Response in the Drug-Eluting Stent Era. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 763-771.	1.4	25
650	Long-Term (>10 Years) Clinical Outcomes of First-in-Human Biodegradable Poly-L-lactic Acid Coronary Stents. <i>Circulation</i> , 2012, 125, 2343-2353.	1.6	209
651	Drug-eluting stents at a crossroads: the good, the bad and the ugly. <i>Future Cardiology</i> , 2012, 8, 1-3.	0.5	1
652	No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-eluting stents. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 429-432.	0.6	12
653	Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 977-987.	1.0	134
654	Outcomes After Unrestricted Use of Everolimus-Eluting and Sirolimus-Eluting Stents in Routine Clinical Practice. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 365-371.	1.4	39
655	Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1273-1285.	0.6	6
656	Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention. <i>Circulation</i> , 2012, 125, 1246-1255.	1.6	149
657	Biodegradable polymer and permanent polymer drug-eluting stents: at the crossroads of evidence and expectation. <i>Interventional Cardiology</i> , 2012, 4, 147-150.	0.0	0
660	Accelerating endothelialization of coronary stents by capturing circulating endothelial progenitor cells. <i>Interventional Cardiology</i> , 2012, 4, 169-181.	0.0	7
661	Can the restenosis benefit of drug-eluting and bare-metal stents be predicted?. <i>Interventional Cardiology</i> , 2012, 4, 53-55.	0.0	0

#	ARTICLE	IF	CITATIONS
662	Mechanisms of late stent-related myocardial infarction: insights from optical coherence tomography. <i>Interventional Cardiology</i> , 2012, 4, 645-651.	0.0	0
663	Factors influencing the outcomes of percutaneous coronary intervention in the stent era. <i>Interventional Cardiology</i> , 2012, 4, 557-568.	0.0	0
664	Biolimus-eluting stent with biodegradable polymer: one step forward in the fight against stent thrombosis vulnerability?. <i>Interventional Cardiology</i> , 2012, 4, 11-25.	0.0	1
665	Nobori® drug-eluting stent system: current data on a novel stent. <i>Interventional Cardiology</i> , 2012, 4, 309-318.	0.0	0
666	Practical approach to blood compatibility assessments: general considerations and standards. , 2012, , 159-206e.		9
667	Three-Year Follow-up of Sirolimus-Eluting Stents vs. Bare Metal Stents for Acute Myocardial Infarction. <i>Circulation Journal</i> , 2012, 76, 65-70.	0.7	13
668	Impact of Platelet Reactivity to Adenosine Diphosphate Before Implantation of Drug-Eluting Stents on Subsequent Adverse Cardiac Events in Patients With Stable Angina. <i>Circulation Journal</i> , 2012, 76, 641-649.	0.7	8
669	Influence of Omeprazole and Famotidine on the Antiplatelet Effects of Clopidogrel in Addition to Aspirin in Patients With Acute Coronary Syndromes. <i>Circulation Journal</i> , 2012, 76, 2673-2680.	0.7	20
670	Bare Metal Stent Thrombosis in Patients With Acute Coronary Syndrome. <i>Circulation Journal</i> , 2012, 76, 634-640.	0.7	7
671	Stent thrombosis: has the firestorm been extinguished?. <i>Lancet, The</i> , 2012, 379, 1368-1369.	6.3	10
672	Sustained Low Clinical Event Rates in Real-World Patients Receiving Everolimus-Eluting Coronary Stent System from a Large, Prospective, Condition of Approval Study: 2-Year Clinical Outcomes from the XIENCE V <sup>®</sup> USA Study. <i>Journal of Interventional Cardiology</i> , 2012, 25, 565-575.	0.5	6
673	Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents. <i>Circulation</i> , 2012, 125, 505-513.	1.6	555
674	Drug-Eluting Stents Compared With Bilateral Internal Thoracic Artery Grafts for Diabetic Patients. <i>Annals of Thoracic Surgery</i> , 2012, 94, 1455-1462.	0.7	17
675	A Meta-Analysis of Randomized Controlled Trials Appraising the Efficacy and Safety of Cilostazol after Coronary Artery Stent Implantation. <i>Cardiology</i> , 2012, 122, 133-143.	0.6	43
676	Stent Thrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 332-335.	1.4	18
677	Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease. <i>Clinical Research in Cardiology</i> , 2012, 101, 573-584.	1.5	26
678	Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 1482-1490.	6.3	412
679	Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. <i>Lancet, The</i> , 2012, 380, 1396-1405.	6.3	143

#	ARTICLE	IF	CITATIONS
680	Correlation of angiographic late loss with neointimal coverage of drug-eluting stent struts on follow-up optical coherence tomography. <i>International Journal of Cardiovascular Imaging</i> , 2012, 28, 1289-1297.	0.7	3
681	Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality. <i>Annals of Thoracic Surgery</i> , 2012, 94, 1927-1933.	0.7	5
682	Pathogenesis of late in-stent thrombosis after treatment with drug-eluting stents. <i>Journal of Cardiology Cases</i> , 2012, 6, e158-e160.	0.2	0
683	Very Late Stent Thrombosis With Newer Drug-Eluting Stents: No Longer an Issue?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 595-598.	0.4	8
684	Stenting in Acute STEMI Intervention. <i>Interventional Cardiology Clinics</i> , 2012, 1, 507-520.	0.2	1
685	Early Noninvasive Evaluation of Coronary Flow Reserve after Angioplasty in the Left Anterior Descending Coronary Artery Identifies Patients at High Risk of Restenosis at Follow-Up. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 902-910.	1.2	10
686	Trombosis muy tardÃa con nuevos stents farmacoactivos: Â¿ha dejado de ser un asunto relevante?. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 595-598.	0.6	17
687	Evidence of Safety and Effectiveness for a Drug-Eluting Stent. <i>Circulation</i> , 2012, 125, 1078-1080.	1.6	0
688	Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents. <i>Circulation</i> , 2012, 125, 1110-1121.	1.6	341
689	Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents. <i>American Heart Journal</i> , 2012, 163, 876-886.e2.	1.2	26
690	Safety of â€œBridgingâ€•With Eptifibatide for Patients With Coronary Stents Before Cardiac and Non-Cardiac Surgery. <i>American Journal of Cardiology</i> , 2012, 110, 485-490.	0.7	32
691	Paclitaxel coated balloons for coronary artery interventions: A comprehensive review of preclinical and clinical data. <i>International Journal of Cardiology</i> , 2012, 161, 4-12.	0.8	90
692	Histological confirmation of hypersensitivity as a contributor to very-late coronary stent thrombosis. <i>International Journal of Cardiology</i> , 2012, 157, e29-e30.	0.8	7
693	Freeing the vessel from metallic cage: what can we achieve with bioresorbable vascular scaffolds?. <i>Cardiovascular Intervention and Therapeutics</i> , 2012, 27, 141-154.	1.2	28
694	Everolimus-eluting ABSORB bioresorbable vascular scaffold: present and future perspectives. <i>Expert Review of Medical Devices</i> , 2012, 9, 327-338.	1.4	19
695	Coronary stent thrombosis in patients with chronic kidney disease: Balancing antiâ€ischemic efficacy and hemorrhagic risk. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 368-369.	0.7	2
696	Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 84.	0.7	2
697	Value of a new post-procedural intravascular ultrasound score in predicting target vessel revascularization after coronary drug-eluting stents implantation. <i>Journal of Zhejiang University: Science B</i> , 2012, 13, 624-630.	1.3	1

#	ARTICLE	IF	CITATIONS
698	Stent thrombosis: an overview. Expert Review of Cardiovascular Therapy, 2012, 10, 599-615.	0.6	16
699	Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: A meta-analysis of randomized trials. Archives of Cardiovascular Diseases, 2012, 105, 544-556.	0.7	6
700	Optimized Duration of Clopidogrel Therapy Following Treatment with the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice (OPTIMIZE) Trial: Rationale and design of a large-scale, randomized, multicenter study. American Heart Journal, 2012, 164, 810-816.e3.	1.2	18
701	A first-in-man study of sirolimus-eluting, biodegradable polymer coated cobalt chromium stent in real life patients. Indian Heart Journal, 2012, 64, 547-552.	0.2	15
702	Drug-eluting stents perform better than bare metal stents in small coronary vessels: A meta-analysis of randomised and observational clinical studies with mid-term follow up. International Journal of Cardiology, 2012, 161, 73-82.	0.8	25
703	Heparanase Regulates Thrombosis in Vascular Injury and Stent-Induced Flow Disturbance. Journal of the American College of Cardiology, 2012, 59, 1551-1560.	1.2	58
704	A Multicenter Randomized Trial Comparing Amphilimus- With Paclitaxel-Eluting Stents in De Novo Native Coronary Artery Lesions. Journal of the American College of Cardiology, 2012, 59, 1371-1376.	1.2	105
705	Primary Endpoint Results of the EVOLVE Trial. Journal of the American College of Cardiology, 2012, 59, 1362-1370.	1.2	188
706	A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World Patients. Journal of the American College of Cardiology, 2012, 59, 1350-1361.	1.2	229
707	Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus-Eluting Stents in Acute Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 381-387.	1.2	124
708	Examination of the In Vivo Mechanisms of Late Drug-Eluting Stent Thrombosis. JACC: Cardiovascular Interventions, 2012, 5, 12-20.	1.1	305
709	Clinical Presentation, Management, and Outcomes of Angiographically Documented Early, Late, and Very Late Stent Thrombosis. JACC: Cardiovascular Interventions, 2012, 5, 131-140.	1.1	159
710	Long-Term Vascular Healing in Response to Sirolimus- and Paclitaxel-Eluting Stents. JACC: Cardiovascular Interventions, 2012, 5, 946-957.	1.1	55
711	Coronary Endothelial Dysfunction Distal to Stent of First-Generation Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2012, 5, 966-973.	1.1	46
712	Predictors of Early, Late, and Very Late Stent Thrombosis After Primary Percutaneous Coronary Intervention With Bare-Metal and Drug-Eluting Stents for ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2012, 5, 1043-1051.	1.1	59
713	Impact of Insulin Resistance on Post-Procedural Myocardial Injury and Clinical Outcomes in Patients Who Underwent Elective Coronary Interventions With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2012, 5, 1159-1167.	1.1	49
714	Quantitative and Qualitative Changes in DES-Related Neointimal Tissue Based on Serial OCT. JACC: Cardiovascular Imaging, 2012, 5, 1147-1155.	2.3	64
715	Extracellular Matrix Molecules Facilitating Vascular Biointegration. Journal of Functional Biomaterials, 2012, 3, 569-587.	1.8	18

#	ARTICLE	IF	CITATIONS
716	Current perspectives of biodegradable drug-eluting stents for improved safety. <i>Biotechnology and Bioprocess Engineering</i> , 2012, 17, 912-924.	1.4	7
717	Six-month clinical outcomes of the Tryton Side Branch Stent for the treatment of bifurcation lesions. <i>Netherlands Heart Journal</i> , 2012, 20, 439-446.	0.3	14
718	The Risk of Adverse Cardiac and Bleeding Events Following Noncardiac Surgery Relative to Antiplatelet Therapy in Patients With Prior Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2005-2016.	1.2	37
719	Restenosis after PCI. Part 2: prevention and therapy. <i>Nature Reviews Cardiology</i> , 2012, 9, 79-90.	6.1	69
720	Complete versus incomplete revascularization for treatment of multivessel coronary artery disease in the drug-eluting stent era. <i>Heart and Vessels</i> , 2012, 27, 433-442.	0.5	32
721	Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents. <i>Heart and Vessels</i> , 2012, 27, 480-485.	0.5	6
722	Site Specific Controlled Release for Cardiovascular Disease: Translational Directions. , 2012, , 445-492.		1
723	Bare Metal Stent Thrombosis and In-Stent Neoatherosclerosis. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 47-54.	1.4	68
724	Drug-eluting stent coatings. <i>Interventional Cardiology</i> , 2012, 4, 73-83.	0.0	25
725	Rapamycin Regulates the Expression and Activity of KrÄ¼ppel-Like Transcription Factor 2 in Human Umbilical Vein Endothelial Cells. <i>PLoS ONE</i> , 2012, 7, e43315.	1.1	5
726	Pathological Perspective of Drug-Eluting Stent Thrombosis. <i>Thrombosis</i> , 2012, 2012, 1-8.	1.4	11
727	Stent Thrombosis: Incidence, Predictors and New Technologies. <i>Thrombosis</i> , 2012, 2012, 1-12.	1.4	53
728	Towards Personalized Medicine Based on Platelet Function Testing for Stent Thrombosis Patients. <i>Thrombosis</i> , 2012, 2012, 1-11.	1.4	9
729	Anticoagulant and Antiplatelet Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. <i>Thrombosis</i> , 2012, 2012, 1-8.	1.4	6
730	DES Overview: A Historical and Current Review of Pivotal Clinical Trial Programs. , 0, , .		0
731	Everolimus-eluting stents in interventional cardiology. <i>Vascular Health and Risk Management</i> , 2012, 8, 393.	1.0	15
732	Perfil clÄnico e evoluÃ§Ã£o tardia de pacientes com trombose de stent nÃ£o-farmacolÃ³gico. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2012, 20, 379-385.	0.1	0
733	Comparison of Optical Coherence Tomographic Assessment between First- and Second-Generation Drug-Eluting Stents. <i>Yonsei Medical Journal</i> , 2012, 53, 524.	0.9	31

#	ARTICLE	IF	CITATIONS
734	Nanotechnology in interventional cardiology. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2012, 4, 82-95.	3.3	16
735	The Disappearing Stent. Circulation, 2012, 125, 2291-2294.	1.6	6
736	Predictors for Neoatherosclerosis. Circulation: Cardiovascular Imaging, 2012, 5, 660-666.	1.3	143
737	Endothelialization and in-stent restenosis on the surface of glycoprotein IIIa monoclonal antibody eluting stent. Journal of Biomedical Materials Research - Part A, 2012, 100A, 1398-1406.	2.1	10
738	Drug eluting stenting in bifurcation coronary lesions long-term results applying a systematic treatment strategy. Catheterization and Cardiovascular Interventions, 2012, 79, 615-622.	0.7	9
739	The union of Anti-CD34 antibody can improve the performance of drug-eluting stents. Catheterization and Cardiovascular Interventions, 2012, 79, 972-978.	0.7	3
740	Incidence of periprocedural myocardial infarction following stent implantation: Comparison between first- and second-generation drug-eluting stents. Catheterization and Cardiovascular Interventions, 2012, 80, 524-530.	0.7	10
741	Long-term effects on vascular healing of bare metal stents delivered via paclitaxel-coated balloons in the porcine model of restenosis. Catheterization and Cardiovascular Interventions, 2012, 80, 603-610.	0.7	23
742	Comparison of Vascular Remodeling in Patients Treated With Sirolimus Versus Zotarolimus-Eluting Stent Following Acute Myocardial Infarction. Clinical Cardiology, 2012, 35, 49-54.	0.7	4
743	Five-year outcomes of Cypher, coronary stent: report from J-PMS Study. Cardiovascular Intervention and Therapeutics, 2012, 27, 63-71.	1.2	14
746	Evaluation of in-stent restenosis in the APPROACH trial (assessment on the prevention of progression) Tj ETQq0 0 0 rgBT /Overlock 10 T Journal of Cardiovascular Imaging, 2012, 28, 455-465.	0.7	12
747	Major determinants for the uncovered stent struts on optical coherence tomography after drug-eluting stent implantation. International Journal of Cardiovascular Imaging, 2012, 28, 705-714.	0.7	14
748	Late Stent Thrombosis: The Last Remaining Obstacle in Coronary Interventional Therapy. Current Cardiology Reports, 2012, 14, 408-417.	1.3	15
749	Optical Coherence Tomography Imaging: Novel Insights into the Vascular Response After Coronary Stent Implantation. Current Cardiovascular Imaging Reports, 2012, 5, 231-238.	0.4	8
750	Synthesis of biomimetic segmented polyurethanes as antifouling biomaterials. Acta Biomaterialia, 2012, 8, 549-558.	4.1	41
751	One-Year Clinical Outcomes after Sirolimus-Eluting Coronary Stent Implantation for Acute Myocardial Infarction in the Worldwide e-SELECT Registry. Journal of Interventional Cardiology, 2012, 25, 253-261.	0.5	2
752	Relationship between Stent Malapposition and Incomplete Neointimal Coverage after Drug-Eluting Stent Implantation. Journal of Interventional Cardiology, 2012, 25, 270-277.	0.5	10
753	Bifurcation stenting: the current state of play. Cardiovascular Revascularization Medicine, 2012, 13, 51-57.	0.3	0



#	ARTICLE	IF	CITATIONS
754	Randomized trial of insulin versus usual care in reducing restenosis after coronary intervention in patients with diabetes. the STent Restenosis And Metabolism (STREAM) study. Cardiovascular Revascularization Medicine, 2012, 13, 95-100.	0.3	13
755	Renal Function Assessed Using Cystatin C and Antiplatelet Efficacy of Clopidogrel Assessed Using the Vasodilator-Stimulated Phosphoprotein Index in Patients Having Percutaneous Coronary Intervention. American Journal of Cardiology, 2012, 109, 620-623.	0.7	8
756	Influence of Diabetes Mellitus on Long-Term (Five-Year) Outcomes of Drug-Eluting Stents and Coronary Artery Bypass Grafting for Multivessel Coronary Revascularization. American Journal of Cardiology, 2012, 109, 1548-1557.	0.7	22
757	Effects of Thiazolidinediones on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After Drug-Eluting Stent Implantation: A Retrospective Cohort Study Using the National Health Insurance Database in Taiwan. Clinical Therapeutics, 2012, 34, 885-893.	1.1	6
758	Safety of Temporary and Permanent Suspension of Antiplatelet Therapy After Drug Eluting Stent Implantation in Contemporary "Real-World" Practice. Journal of Interventional Cardiology, 2012, 25, 482-492.	0.5	21
759	Low molecular weight heparin versus unfractionated heparin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stents. Journal of Cardiology, 2012, 59, 22-29.	0.8	6
760	Better stent expansion by two-time inflation of stent balloon and its responsible mechanism. Journal of Cardiology, 2012, 59, 160-166.	0.8	16
761	An analytical solution for the stress state at stent-coating interfaces. Journal of the Mechanical Behavior of Biomedical Materials, 2012, 10, 183-196.	1.5	10
762	Zotarolimus-eluting vs. sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy. European Journal of Clinical Investigation, 2012, 42, 1047-1054.	1.7	10
763	Sirolimus use and incidence of venous thromboembolism in cardiac transplant recipients. Clinical Transplantation, 2012, 26, 953-959.	0.8	24
764	Impact of intravascular ultrasound-guided percutaneous coronary intervention on long-term clinical outcomes in a real world population. Catheterization and Cardiovascular Interventions, 2013, 81, 407-416.	0.7	49
765	Evaluation of long-term follow-up with neointimal coverage and stent apposition after sirolimus-eluting stent implantation by optical coherence tomography. Catheterization and Cardiovascular Interventions, 2013, 81, 768-775.	0.7	7
766	Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet, The, 2013, 381, 836-844.	6.3	343
767	Long-Term Outcome After Drug-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2013, 6, 548-553.	1.1	41
768	Medical Management After Coronary Stent Implantation. JAMA - Journal of the American Medical Association, 2013, 310, 189.	3.8	84
769	Influence of initial acute myocardial infarction presentation on the outcome of surgical procedures after coronary stent implantation: a report from the CREDO-Kyoto PCI/CABG Registry Cohort-2. Cardiovascular Intervention and Therapeutics, 2013, 28, 45-55.	1.2	7
770	ADP-Receptor Inhibitors in the Perioperative Period: The Good, the Bad, and the Ugly. Journal of Cardiothoracic and Vascular Anesthesia, 2013, 27, 779-795.	0.6	12
771	Optimizing the design of a bioabsorbable metal stent using computer simulation methods. Biomaterials, 2013, 34, 8049-8060.	5.7	77

#	ARTICLE	IF	CITATIONS
772	St. Johnâ€™s Wort in Patients Non-responders to Clopidogrel Undergoing Percutaneous Coronary Intervention: a Single-Center Randomized Open-Label Trial (St. Johnâ€™s Trial). Journal of Cardiovascular Translational Research, 2013, 6, 411-414.	1.1	7
773	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, The, 2013, 382, 1714-1722.	6.3	537
774	Progress in Treatment by Percutaneous Coronary Intervention: The Stent of the Future. Revista Espanola De Cardiologia (English Ed ), 2013, 66, 483-496.	0.4	34
775	Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial. Heart and Vessels, 2013, 28, 424-433.	0.5	12
776	Outcome of percutaneous coronary intervention with drug-eluting stents in unprotected left main versus non-left main native coronary artery disease: results from the prospective multicenter German DES.DE registry. Clinical Research in Cardiology, 2013, 102, 679-686.	1.5	6
777	Clinical outcomes of different first- and second-generation drug-eluting stents in routine clinical practice: results from the prospective multicenter German DES.DE registry. Clinical Research in Cardiology, 2013, 102, 371-381.	1.5	12
778	The risk of stent thrombosis is multifactorial and may remain for long. Journal of Cardiology Cases, 2013, 8, e64-e65.	0.2	0
779	Modelos animales de reparaci3n vascular y reendotelizaci3n. Revista Espanola De Cardiologia Suplementos, 2013, 13, 20-28.	0.2	0
780	Clinical outcomes with Biolimus (A9)â„¢ eluting stent, â€BioMatrixâ€™™ in diabetic patients â€¢ interim results from multicenter post market surveillance registry in India. Indian Heart Journal, 2013, 65, 586-592.	0.2	6
781	Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents. Journal of the American College of Cardiology, 2013, 61, 2406-2416.	1.2	68
782	MicroRNAâ€21 mediates the rapamycinâ€induced suppression of endothelial proliferation and migration. FEBS Letters, 2013, 587, 378-385.	1.3	43
784	Evaluation of neointimal coverage and apposition with various drug-eluting stents over 12 months after implantation by optical coherence tomography. International Journal of Cardiology, 2013, 162, 166-171.	0.8	15
785	Public health science: a call for abstracts. Lancet, The, 2013, 381, 789.	6.3	0
786	Fabrication of a Novel Polymer-Free Nanostructured Drug-Eluting Coating for Cardiovascular Stents. ACS Applied Materials & Interfaces, 2013, 5, 10337-10345.	4.0	58
787	OCT Analysis in Patients With Very Late Stent Thrombosis. JACC: Cardiovascular Imaging, 2013, 6, 695-703.	2.3	80
788	Engineering the Abio-Bio Interface to Enable More than Moore in Functional Bioelectronics. Journal of the Electrochemical Society, 2013, 160, B60-B65.	1.3	15
789	Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents. JAMA - Journal of the American Medical Association, 2013, 310, 2510-22.	3.8	513
790	Incidence and predictors of the late catch-up phenomenon after drug-eluting stent implantation. International Journal of Cardiology, 2013, 168, 2588-2592.	0.8	26

#	ARTICLE	IF	CITATIONS
791	Coronary stent restenosis and occlusion: messages from the dead for the living. <i>European Heart Journal</i> , 2013, 34, 3248-3250.	1.0	1
792	Very late stent thrombosis after paclitaxel-eluting stent implantation with full neointimal tissue coverage visualized by optical coherence tomography. <i>Journal of Cardiology Cases</i> , 2013, 7, e168-e170.	0.2	1
793	Use of IVUS guided coronary stenting with drug eluting stent. <i>International Journal of Cardiology</i> , 2013, 170, 54-63.	0.8	59
794	Serial Assessment of Vessel Interactions After Drug-Eluting Stent Implantation in Unprotected Distal Left Main Coronary Artery Disease Using Frequency-Domain Optical Coherence Tomography. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1035-1045.	1.1	18
795	Advanced stent coating for drug delivery and in vivo biocompatibility. <i>Journal of Nanoparticle Research</i> , 2013, 15, 1.	0.8	14
796	Surface modification of a polyhedral oligomeric silsesquioxane poly(carbonate-urea) urethane (POSS-PCU) nanocomposite polymer as a stent coating for enhanced capture of endothelial progenitor cells. <i>Biointerphases</i> , 2013, 8, 23.	0.6	39
797	Neointimal coverage and vasodilator response to titanium-nitride-oxide-coated bioactive stents and everolimus-eluting stents in patients with acute coronary syndrome: insights from the BASE-ACS trial. <i>International Journal of Cardiovascular Imaging</i> , 2013, 29, 1693-1703.	0.7	19
798	Avoiding stent thrombosis: advances in technique, antiplatelet pharmacotherapy and stent design. <i>Interventional Cardiology</i> , 2013, 5, 179-201.	0.0	0
799	Optimal revascularization for complex coronary artery disease. <i>Nature Reviews Cardiology</i> , 2013, 10, 635-647.	6.1	38
800	Comparison of 3-year Clinical Outcomes Between Resolute <sup>®</sup> , Zotarolimus <sup>®</sup> and Sirolimus <sup>®</sup> -eluting Stents for Long Coronary Artery Stenosis. <i>Journal of Interventional Cardiology</i> , 2013, 26, 378-383.	0.5	3
801	Ambulatory transradial percutaneous coronary intervention: A safe, effective, and cost-saving strategy. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 15-23.	0.7	39
802	Clopidogrel <sup>®</sup> Resistance: Where are We Now?. <i>Cardiovascular Therapeutics</i> , 2013, 31, 3-11.	1.1	28
803	Do Statins have a Role in Reduction/Prevention of Post-PCI Restenosis?. <i>Cardiovascular Therapeutics</i> , 2013, 31, 12-26.	1.1	25
804	Stent thrombosis is a major concern in clinical practice: A single Saudi center experience. <i>Journal of the Saudi Heart Association</i> , 2013, 25, 233-238.	0.2	3
805	Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: The Bern <sup>®</sup> Rotterdam diabetes cohort study. <i>International Journal of Cardiology</i> , 2013, 170, 36-42.	0.8	25
806	Long-term outcomes of patients receiving zotarolimus-eluting stents in ST elevation myocardial infarction, non-ST elevation acute coronary syndrome, and stable angina: Data from the Resolute program. <i>International Journal of Cardiology</i> , 2013, 168, 3522-3526.	0.8	9
807	Time Dependency of Outcomes for Drug-Eluting vs Bare-Metal Stents. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1616-1622.	0.8	5
808	Risk of Stent Thrombosis Among Bare-Metal Stents, First-Generation Drug-Eluting Stents, and Second-Generation Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1267-1274.	1.1	286

#	ARTICLE	IF	CITATIONS
809	Coronary angioscopic findings 9 months after everolimus-eluting stent implantation compared with sirolimus-eluting stents. <i>Journal of Cardiology</i> , 2013, 61, 22-30.	0.8	16
810	Metformin Impairs Vascular Endothelial Recovery After Stent Placement in the Setting of Locally Eluted Mammalian Target of Rapamycin Inhibitors Via S6 Kinase-Dependent Inhibition of Cell Proliferation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 971-980.	1.2	35
811	Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high-sensitivity C-reactive protein. <i>International Journal of Cardiology</i> , 2013, 167, 1848-1853.	0.8	13
812	Disappearing stents—DREAMS of a sorcerer's apprentice?. <i>Lancet, The</i> , 2013, 381, 787-789.	6.3	1
813	Long-term outcome of sirolimus-eluting vs bare-metal stent in the setting of acute myocardial infarction: 5-year results of the SESAMI trial. <i>International Journal of Cardiology</i> , 2013, 166, 399-403.	0.8	17
814	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. <i>Lancet, The</i> , 2013, 382, 1879-1888.	6.3	127
815	Safety and efficacy of biodegradable polymer-coated biolimus-eluting stents. <i>Egyptian Heart Journal</i> , 2013, 65, 207-212.	0.4	4
816	Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. <i>International Journal of Cardiology</i> , 2013, 168, 5162-5166.	0.8	29
817	A clinical evaluation of the ProNOVA XR polymer-free sirolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions (EURONOVA XR I study). <i>Indian Heart Journal</i> , 2013, 65, 388-394.	0.2	6
818	Clinical, angiographic, and intravascular ultrasound predictors of early stent thrombosis in patients with acute myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 168, 1674-1675.	0.8	6
820	Iron homeostasis and cardiovascular events after acute infections. <i>International Journal of Cardiology</i> , 2013, 168, 1675-1676.	0.8	1
821	Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 168, 2632-2636.	0.8	11
822	The evidence that evidence-based medicine omits. <i>Preventive Medicine</i> , 2013, 57, 745-747.	1.6	76
823	Drug-eluting Stents: Will the transformation to bioabsorption make durable polymers obsolete?. <i>Cardiovascular Revascularization Medicine</i> , 2013, 14, 69-70.	0.3	2
824	Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. <i>Lancet, The</i> , 2013, 381, 661-669.	6.3	173
825	Six-month follow-up evaluation for everolimus-eluting stents by intracoronary optical coherence tomography: Comparison with paclitaxel-eluting stents. <i>International Journal of Cardiology</i> , 2013, 166, 181-186.	0.8	31
826	Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 777-789.	1.1	296
827	Impact of diabetes on long-term mortality following multivessel percutaneous interventions: An insight into optimal statistical analysis. <i>International Journal of Cardiology</i> , 2013, 167, 2120-2125.	0.8	0

#	ARTICLE	IF	CITATIONS
828	Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. <i>International Journal of Cardiology</i> , 2013, 167, 575-584.	0.8	160
829	Intravascular ultrasound assessed incomplete stent apposition and stent fracture in stent thrombosis after bare metal versus drug-eluting stent treatment the Nordic Intravascular Ultrasound Study (NIVUS). <i>International Journal of Cardiology</i> , 2013, 168, 1010-1016.	0.8	27
830	Comparison between zotarolimus-eluting stents and first generation drug-eluting stents in the treatment of patients with acute ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 166, 118-125.	0.8	8
831	Contemporary Analysis of Incidence and Outcomes of Stent Thrombosis Presenting as ST Elevation Myocardial Infarction in a Primary Percutaneous Coronary Intervention Cohort. <i>American Journal of Cardiology</i> , 2013, 112, 1347-1354.	0.7	5
832	Frequency, Mechanisms, and Implications of Late Peri-Stent Contrast Staining: Analysis (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.7	8
833	Current applications of optical coherence tomography for coronary intervention. <i>International Journal of Cardiology</i> , 2013, 165, 7-16.	0.8	47
834	Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes. <i>Journal of Cardiology</i> , 2013, 62, 158-164.	0.8	28
835	SORT OUT V: a new episode in the DES wars. <i>Lancet</i> , The, 2013, 381, 609-611.	6.3	4
836	Cutting balloon combined with paclitaxel-eluting balloon for treatment of in-stent restenosis. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 79-85.	0.7	8
837	Antiplatelet Therapy After Coronary Stenting. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 1-10.	0.4	15
838	Association of neointimal morphology by optical coherence tomography with rupture of neoatherosclerotic plaque very late after coronary stent implantation.. <i>Proceedings of SPIE</i> , 2013, , .	0.8	4
839	Pharmacotherapy for the reduction of stent thrombosis. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 567-576.	0.6	1
840	Drug-Eluting Coronary-Artery Stents. <i>New England Journal of Medicine</i> , 2013, 368, 254-265.	13.9	618
841	Newly available and recent advances in drug-eluting stents. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 555-566.	0.6	4
842	Study Design and Rationale of a Multicenter, Open-Labeled, Randomized Controlled Trial Comparing Three 2nd-Generation Drug-Eluting Stents in Real-World Practice (CHOICE trial). <i>American Heart Journal</i> , 2013, 166, 224-229.	1.2	4
843	Oxidative Stress and Pathological Changes After Coronary Artery Interventions. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1471-1481.	1.2	95
844	Placement of tryton side branch stent only; A new treatment strategy for Medina 0,0,1 coronary bifurcation lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E395-402.	0.7	10
845	Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial. <i>Heart</i> , 2013, 99, 1267-1274.	1.2	36

#	ARTICLE	IF	CITATIONS
846	The invasive assessment of coronary atherosclerosis and stents using optical coherence tomography: a clinical update. <i>Heart Asia</i> , 2013, 5, 154-161.	1.1	6
847	Long-term safety of drug-eluting stents. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1359-1378.	0.6	5
848	Biolimus-eluting stent with biodegradable polymer (Nobori®): an overview of recent clinical results, SORT OUT V and COMPARE II trials. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1293-1296.	0.6	4
849	Percutaneous coronary intervention in diabetic patients: should choice of stents be influenced?. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 541-553.	0.6	8
850	When is evidence sufficient for decision-making? A framework for understanding the pace of evidence adoption. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 383-391.	0.6	14
851	Randomized study to assess the effect of thrombus aspiration on flow area in patients with ST-elevation myocardial infarction: an optical frequency domain imaging studyâ€”TROFI trial. <i>European Heart Journal</i> , 2013, 34, 1050-1060.	1.0	103
852	Coronary artery stents and surgery; the basis of sound perioperative management. <i>Health</i> , 2013, 05, 1730-1736.	0.1	2
853	FIB Patterning of Stainless Steel for the Development of Nano-structured Stent Surfaces for Cardiovascular Applications. <i>Lecture Notes in Nanoscale Science and Technology</i> , 2013, , 391-416.	0.4	0
854	Experience with Biodegradable Polymer Coated Sirolimus-Eluting Coronary Stent System in â€œReal-Lifeâ€• Percutaneous Coronary Intervention: 24-Month Data from the Manipal-S Registry. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2013, 7, 1959-63.	0.8	4
855	Risk Factors for Coronary Drug-Eluting Stent Thrombosis: Influence of Procedural, Patient, Lesion, and Stent Related Factors and Dual Antiplatelet Therapy. <i>ISRN Cardiology</i> , 2013, 2013, 1-8.	1.6	18
856	Ten Years of Percutaneous Coronary Intervention in a Low-Volume Military Treatment Facility: A Quality Improvement Project. <i>Military Medicine</i> , 2013, 178, 1029-1035.	0.4	1
857	Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: Two-year subgroup analysis of the ZEST randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 1106-1114.	0.7	19
858	Developments in procedural and disease registries. <i>Current Opinion in Cardiology</i> , 2013, 28, 405-410.	0.8	7
859	Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2013, 24, 690-697.	0.3	7
860	Advances in Coronary Revascularization. , 2013, , 214-239.		0
861	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. <i>BMJ, The</i> , 2013, 347, f6530-f6530.	3.0	194
862	A higher colour grade yellow plaque was detected at one year after implantation of an everolimus-eluting stent than after a zotarolimus-eluting stent. <i>Heart Asia</i> , 2013, 5, 192-196.	1.1	3
863	Pharmacogenomics Study of Clopidogrel by RFLP based Genotyping of CYP2C19 in Cardiovascular Disease Patients in North-East Population of India. <i>Journal of Pharmacogenomics &amp; Pharmacoproteomics</i> , 2013, 05, .	0.2	2

#	ARTICLE	IF	CITATIONS
864	Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease. <i>ISRN Cardiology</i> , 2013, 2013, 1-7.	1.6	4
865	Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reduces the Risk of Cardiac Events and Restenosis After Drug-Eluting Stent Implantation: A Meta-Analysis. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 532-539.	1.0	9
866	<b>Real-World Safety and Effectiveness Outcomes of a Zotarolimus-Eluting Stent: Final 3-Year Report of the RESOLUTE International Study.</b> <i>Journal of Interventional Cardiology</i> , 2013, 26, 515-523.	0.5	11
867	Angiographic and Clinical Outcomes of Everolimus-Eluting Stent in the Treatment of Extra Long Stenoses (AETES). <i>Journal of Interventional Cardiology</i> , 2013, 26, 22-28.	0.5	10
868	Impact of advanced age on the safety and effectiveness of paclitaxel-eluting stent implantation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 869-877.	0.7	12
869	Coronary Arterial Remodeling and Out-Stent Plaque Change After Drug-Eluting Stent Implantation. <i>Circulation Journal</i> , 2013, 77, 363-371.	0.7	9
870	Difference in Clinical and Angiographic Characteristics of Very Late Stent Thrombosis Between Drug-Eluting and Bare-Metal Stent Implantations. <i>Circulation Journal</i> , 2013, 77, 1453-1460.	0.7	11
871	Long-Term Outcome of Drug-Eluting vs. Bare-Metal Stents in Patients With Acute Myocardial Infarction. <i>Circulation Journal</i> , 2013, 77, 2024-2031.	0.7	10
872	Guidelines for Elective Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease (JCS 2011) Published in 2012. <i>Circulation Journal</i> , 2013, 77, 1590-1607.	0.7	67
873	Consideration of Dual Anti-platelet Therapy Duration after Drug-eluting Stent Implantation in a Japanese Population: A Five-year Follow-up after Sirolimus-Eluting Stent Implantation. <i>Internal Medicine</i> , 2013, 52, 703-711.	0.3	3
874	Stent Thrombosis after Coronary Stent Implantation: A Protective Effect of High-Dose Statin Therapy?. <i>Cardiology</i> , 2013, 126, 115-121.	0.6	5
875	Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform. <i>Clinical Medicine Insights: Cardiology</i> , 2013, 7, CMC.S11516.	0.6	16
876	Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 1127-1133.	0.7	6
877	Management of severe perioperative bleeding. <i>European Journal of Anaesthesiology</i> , 2013, 30, 270-382.	0.7	740
878	One-year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E428-36.	0.7	6
879	Use of Antiplatelet Therapy after Percutaneous Coronary Intervention with Bare-Metal Stents and Different Types of Drug-Eluting Stents. <i>Current Clinical Pharmacology</i> , 2013, 8, 59-66.	0.2	0
880	Comparison of Two Different Strategies of Intravascular Ultrasound Guidance during Percutaneous Coronary Intervention; Routine versus Selective. <i>Korean Circulation Journal</i> , 2013, 43, 303.	0.7	1
881	Relationship between Angiographic Late Loss and 5-Year Clinical Outcome after Drug-Eluting Stent Implantation. <i>Yonsei Medical Journal</i> , 2013, 54, 41.	0.9	0

#	ARTICLE	IF	CITATIONS
882	The use of drug-eluting stents in acute myocardial infarction “ is the battle coming to an end? From despair to acceptance. <i>Postepy W Kardiologii Interwencyjnej</i> , 2013, 1, 50-60.	0.1	5
883	Successful Prasugrel Rescue Therapy in Clopidogrel Resistant Patients Who Had Recurrent Stent Thrombosis of Drug-Eluting-Stent: The Role of Prasugrel in Clopidogrel Nonresponders. <i>Korean Circulation Journal</i> , 2013, 43, 343.	0.7	2
884	Efficacy and Safety of Biodegradable Polymer Biolimus-Eluting Stents versus Durable Polymer Drug-Eluting Stents: A Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e78667.	1.1	10
885	An Anti-CD34 Antibody-Functionalized Clinical-Grade POSS-PCU Nanocomposite Polymer for Cardiovascular Stent Coating Applications: A Preliminary Assessment of Endothelial Progenitor Cell Capture and Hemocompatibility. <i>PLoS ONE</i> , 2013, 8, e77112.	1.1	41
886	A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease. <i>Biologics: Targets and Therapy</i> , 2013, 7, 149.	3.0	29
887	Stent Evaluation with Optical Coherence Tomography. <i>Yonsei Medical Journal</i> , 2013, 54, 1075.	0.9	28
888	Hemostatic Aspects of Cardiovascular Medicine. , 2013, , 342-394.		0
889	ANTIPLATELET THERAPY CONTROL: CREDIBILITY GAP OR SEARCH FOR NEW DECISIONS?. <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 682-689.	0.3	2
890	Impact of CYP2C19 Polymorphism on Platelet Function Tests and Coagulation and Inflammatory Biomarkers in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21, 64-76.	0.9	17
891	Stent Thrombosis is the Primary Cause of ST-Segment Elevation Myocardial Infarction following Coronary Stent Implantation: A Five Year Follow-Up of the SORT OUT II Study. <i>PLoS ONE</i> , 2014, 9, e113399.	1.1	8
892	Quality of life (QOL) evaluation after acute coronary syndrome with simultaneous clopidogrel treatment. <i>Archives of Medical Science</i> , 2014, 1, 33-38.	0.4	9
893	Impact of rivaroxaban on stent thrombosis and secondary prevention of cardiovascular events in acute coronary syndrome. <i>Research Reports in Clinical Cardiology</i> , 0, , 103.	0.2	1
894	Acute Stent Thrombosis after Coronary Stenting in Patients with Acute Coronary Syndrome. <i>Journal of Lipid and Atherosclerosis</i> , 2014, 3, 43.	1.1	0
895	Bioabsorbable Vascular Scaffold: A Revolution in Coronary Intervention. <i>Cardiovascular Journal</i> , 2014, 6, 149-163.	0.0	3
896	Systematic review/Meta-analysis Clinical outcomes of second- versus first-generation drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. <i>Archives of Medical Science</i> , 2014, 4, 643-650.	0.4	12
897	Are We There Yet? Deciding When It Is Safe (and Wise) to Stop Clopidogrel after Stent Implantation. <i>Journal of Interventional Cardiology</i> , 2014, 27, 127-130.	0.5	0
898	Everolimus-Eluting Stents Improve Vascular Response in a Diabetic Animal Model. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 526-532.	1.4	11
899	Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial. <i>European Heart Journal</i> , 2014, 35, 2812-2820.	1.0	54



#	ARTICLE	IF	CITATIONS
900	Biocompatibility of Coronary Stents. <i>Materials</i> , 2014, 7, 769-786.	1.3	40
901	CardioPulse ArticlesThe Russian National Congress of Cardiology 2014Moving from academia to industryEACPR country of the month initiative: NetherlandsHow hearts are formed in embryosDifferential clinical outcomes after 1 year vs. 5 years in the SORT OUT III randomized comparison of zotarolimus- and sirolimus-eluting coronary stents:. <i>European Heart Journal</i> , 2014, 35, 2335-2341.	1.0	0
902	Optimal stent design: past, present and future. <i>Interventional Cardiology</i> , 2014, 6, 29-44.	0.0	9
903	A clinical update on the use of resolute stents with dual anti-platelet therapy interruption. <i>Interventional Cardiology</i> , 2014, 6, 453-462.	0.0	0
904	Coronary Stent Thrombosis With Vorapaxar Versus Placebo. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2309-2317.	1.2	41
905	Endothelial progenitor cell (EPC)-seeded intravascular stents. , 2014, , 110-124.		2
906	Cangrelor for treatment during percutaneous coronary intervention. <i>Future Cardiology</i> , 2014, 10, 201-213.	0.5	3
907	The relationship between reâ€endothelialization and endothelial function after DES implantation: Comparison between paclitaxel eluting stent and zotarolims eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 412-417.	0.7	10
908	World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. <i>Nature Reviews Cardiology</i> , 2014, 11, 597-606.	6.1	267
909	First report of a novel polymerâ€free dualâ€drug eluting stent in <i>de novo</i> coronary artery disease: Results of the first in human BICARE trial. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 405-411.	0.7	15
910	Patterns of Longâ€Term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the <sc>TIMI</sc>â€38 Coronary Stent Registry. <i>Clinical Cardiology</i> , 2014, 37, 293-299.	0.7	5
911	Comparison of Biodegradable Polymer Versus Durable Polymer Sirolimusâ€Eluting Stenting in Patients with Acute STâ€Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of the RESOLVE Study. <i>Journal of Interventional Cardiology</i> , 2014, 27, 131-141.	0.5	9
912	New generation drugâ€eluting stents for STâ€elevation myocardial infarction: A new paradigm for safety. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 955-962.	0.7	10
913	Ibuprofen inhibits migration and proliferation of human coronary artery smooth muscle cells by inducing a differentiated phenotype: role of peroxisome proliferator-activated receptor Î³. <i>Journal of Pharmacy and Pharmacology</i> , 2014, 66, 779-792.	1.2	5
914	Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Shorter or Longer?. <i>Cardiology and Therapy</i> , 2014, 3, 1-12.	1.1	5
915	RAPSTROMâ„¸ Firstâ€inâ€Man Study Longâ€Term Results of a Biodegradable Polymer Sustainedâ€Release Sirolimusâ€Eluting Stent in De Novo Coronary Stenoses. <i>Journal of Interventional Cardiology</i> , 2014, 27, 373-380.	0.5	2
916	Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?. <i>Current Opinion in Cardiology</i> , 2014, 29, 301-306.	0.8	1
917	Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 64, 41-46.	0.8	8

#	ARTICLE	IF	CITATIONS
918	Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centre. <i>BMJ Open</i> , 2014, 4, e004892-e004892.	0.8	23
919	Biodegradable versus durable polymer drug eluting stents in coronary artery disease: Insights from a meta-analysis of 5834 patients. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 411-424.	0.8	21
921	Biodegradable polymer Biolimus-eluting stent (Nobori&reg;) for the treatment of coronary artery lesions: review of concept and clinical results. <i>Medical Devices: Evidence and Research</i> , 2014, 7, 35.	0.4	9
922	Stent performance: never too late to sort it out. <i>Lancet, The</i> , 2014, 383, 2024-2026.	6.3	2
923	Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY). <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 225-235.	0.7	12
924	Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. <i>Lancet, The</i> , 2014, 383, 2047-2056.	6.3	96
925	Serial three-dimensional optical coherence tomography assessment of strut coverage and intraluminal structures after drug-eluting stent implantation. <i>Cardiovascular Intervention and Therapeutics</i> , 2014, 29, 31-39.	1.2	4
926	Impact of angiographic peri-stent contrast staining (PSS) on late adverse events after sirolimus-eluting stent implantation: an observation from the multicenter j-Cypher registry PSS substudy. <i>Cardiovascular Intervention and Therapeutics</i> , 2014, 29, 226-236.	1.2	14
927	Optimizing Antithrombotic Therapy After Coronary Stent Implantation in Patients on Chronic Oral Anticoagulation. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 64-71.	1.1	2
929	Impact of the Stent Length on Long-Term Clinical Outcomes Following Newer-Generation Drug-Eluting Stent Implantation. <i>American Journal of Cardiology</i> , 2014, 113, 457-464.	0.7	42
930	New stent surface materials: The impact of polymer-dependent interactions of human endothelial cells, smooth muscle cells, and platelets. <i>Acta Biomaterialia</i> , 2014, 10, 688-700.	4.1	68
931	Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. <i>Circulation</i> , 2014, 129, 304-312.	1.6	263
932	Clinical Outcomes With Bioabsorbable Polymer- Versus Durable Polymer-Based Drug-Eluting and Bare-Metal Stents. <i>Journal of the American College of Cardiology</i> , 2014, 63, 299-307.	1.2	269
933	Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis. <i>Clinical Research in Cardiology</i> , 2014, 103, 21-27.	1.5	10
934	First report of a subacute stent thrombosis in a prasugrel resistant patient successfully managed with ticagrelor. <i>Platelets</i> , 2014, 25, 636-638.	1.1	12
935	Construction of a Coronary Artery Atlas from CT Angiography. <i>Lecture Notes in Computer Science</i> , 2014, 17, 513-520.	1.0	11
936	Dual Antiplatelet Therapy in the Anticoagulated Patient Undergoing Percutaneous Coronary Intervention Risks, Benefits, and Unanswered Questions. <i>Current Cardiology Reports</i> , 2014, 16, 548.	1.3	2
937	Stent Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1081-1092.	1.1	159

#	ARTICLE	IF	CITATIONS
938	Polymer-free drug-eluting stent in unselected patient population: A single center experience. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 350-353.	0.3	6
939	Correlates and Outcomes of Late and Very Late Drug-Eluting Stent Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1093-1102.	1.1	55
940	Late Stent Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1103-1104.	1.1	1
941	Bioresorbable scaffolds for the treatment of coronary artery disease: current status and future perspective. <i>Expert Review of Medical Devices</i> , 2014, 11, 467-480.	1.4	9
942	First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. <i>Open Heart</i> , 2014, 1, e000064.	0.9	88
943	Late and very late drug-eluting stent thrombosis in the immediate postoperative period after antiplatelet withdrawal: a retrospective study. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2014, 8, 185-192.	1.0	3
944	Targeting PI3K $\beta$ activity decreases vascular trauma-induced intimal hyperplasia through modulation of the Th1 response. <i>Journal of Experimental Medicine</i> , 2014, 211, 1779-1792.	4.2	28
945	Percutaneous coronary intervention. <i>Medicine</i> , 2014, 42, 520-526.	0.2	2
946	One-year outcome of biolimus eluting stent with biodegradable polymer in all comers: The Italian Nobori Stent Prospective Registry. <i>International Journal of Cardiology</i> , 2014, 177, 11-16.	0.8	8
947	Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2086-2097.	1.2	388
948	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.	1.0	4,141
949	Quantitative assessment of tissue prolapse on optical coherence tomography and its relation to underlying plaque morphologies and clinical outcome in patients with elective stent implantation. <i>International Journal of Cardiology</i> , 2014, 176, 182-190.	0.8	35
950	Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. <i>Lancet, The</i> , 2014, 384, 1577-1585.	6.3	269
951	Clinical outcomes after final kissing balloon inflation compared with no final kissing balloon inflation in bifurcation lesions treated with a dedicated coronary bifurcation stent. <i>Heart</i> , 2014, 100, 479-486.	1.2	14
952	Curcumin- and natural extract-loaded nanofibres for potential treatment of lung and breast cancer: <i>in vitro</i> efficacy evaluation. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2014, 25, 985-998.	1.9	72
953	Nitinol-Based Nanotubular Coatings for the Modulation of Human Vascular Cell Function. <i>Nano Letters</i> , 2014, 14, 5021-5028.	4.5	46
954	The EXAMINATION Trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tt</i>	1.1	80
955	Recent advances in micro/nanoscale biomedical implants. <i>Journal of Controlled Release</i> , 2014, 189, 25-45.	4.8	65

#	ARTICLE	IF	CITATIONS
956	Choosing the Right Coronary Stent in the Modern Era. <i>Current Cardiology Reports</i> , 2014, 16, 469.	1.3	1
957	Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: The DEMONSTRATE study. <i>International Journal of Cardiology</i> , 2014, 176, 904-909.	0.8	31
958	Three-Year Patient-Related and Stent-Related Outcomes of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World Practice (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 662 2014, 114, 1329-1338.	0.7	20
959	Three-Year Outcomes After Revascularization With Everolimus- and Sirolimus-Eluting Stents From the SORT OUT IV Trial. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 840-848.	1.1	28
960	Long-term (8 year) outcomes and predictors of major adverse cardiac events after full metal jacket drug-eluting stent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 361-365.	0.7	13
961	A prospective study evaluating efficacy of polymer free Pronova XR stent in treatment of de novo coronary artery stenosis. <i>Indian Heart Journal</i> , 2014, 66, 11-15.	0.2	1
963	Comparison of Outcomes After Percutaneous Coronary Intervention Among Different Coronary Subsets (Stable and Unstable Angina Pectoris and ST-Segment and Non-ST-Segment Myocardial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 662	0.7	20
964	Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease. <i>American Heart Journal</i> , 2014, 167, 241-248.e1.	1.2	20
965	Neo-atherosclerosis in very late stent thrombosis of drug eluting stent. <i>Journal of the Saudi Heart Association</i> , 2014, 26, 226-230.	0.2	0
966	Stent malapposition, as a potential mechanism of very late stent thrombosis after bare-metal stent implantation: A case report. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 178-181.	0.3	1
967	“East Asian Paradox” Challenge for the Current Antiplatelet Strategy of “One-Guideline-Fits-All Races” in Acute Coronary Syndrome. <i>Current Cardiology Reports</i> , 2014, 16, 485.	1.3	136
968	Pooled Analysis of Two Randomized Trials Comparing Titanium-nitride-oxide-coated Stent Versus Drug-eluting Stent in STEMI. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2014, 67, 531-537.	0.4	4
969	Comparación de stents de paclitaxel y stents de everolimus en el infarto agudo de miocardio con elevación del segmento ST e influencia de la trombectomía en los resultados. <i>Estudio ESTROFA-IM. Revista Espanola De Cardiologia</i> , 2014, 67, 999-1006.	0.6	11
971	Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: Rationale and design of the BIOSCIENCE trial. <i>American Heart Journal</i> , 2014, 168, 256-261.	1.2	16
972	Comparison of Paclitaxel and Everolimus-eluting Stents in ST-segment Elevation Myocardial Infarction and Influence of Thrombectomy on Outcomes. <i>ESTROFA-IM Study. Revista Espanola De Cardiologia (English Ed )</i> , 2014, 67, 999-1006.	0.4	2
973	Causes of Very Late Stent Thrombosis Investigated Using Optical Coherence Tomography. <i>Internal Medicine</i> , 2014, 53, 2031-2039.	0.3	11
974	Comparison of Long-Term Outcome After Percutaneous Coronary Intervention for Stent Thrombosis Between Early, Late, and Very Late Stent Thrombosis. <i>Circulation Journal</i> , 2014, 78, 101-109.	0.7	26
975	Comprehensive Treatment of Diabetic Patients With Second-Generation Drug-Eluting Stent Implantation. <i>Circulation Journal</i> , 2014, 78, 2149-2150.	0.7	1

#	ARTICLE	IF	CITATIONS
976	Favorable Vessel Healing After Nobori Biolimus A9-Eluting Stent Implantation. <i>Circulation Journal</i> , 2014, 78, 1882-1890.	0.7	17
977	Atherosclerotic Change at One Year After Implantation of Endeavor Zotarolimus-Eluting Stent vs. Everolimus-Eluting Stent. <i>Circulation Journal</i> , 2014, 78, 1428-1436.	0.7	20
978	Clinical, angiographic, and intravascular ultrasound results of the VestSaync II trial. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 1073-1079.	0.7	11
979	Resultados iniciais e tardios de pacientes tratados com stent híbrido eluidor de sirolimus ou stent eluidor de everolimus. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2015, 23, 114-118.	0.1	0
982	Second-generation drug-eluting stent treatment for isolated proximal left anterior descending artery stenoses. The SAFIRA Registry data. <i>Revista Brasileira De Cardiologia Invasiva (English Edition)</i> , 2015, 23, 256-260.	0.1	0
983	Dual Antiplatelet Therapy for Coronary Artery Disease. <i>Circulation Journal</i> , 2015, 79, 255-262.	0.7	16
984	Vascular response after implantation of biolimus A9-eluting stent with bioabsorbable polymer and everolimus-eluting stents with durable polymer. Results of the optical coherence tomography analysis of the BIOACTIVE randomized trial. <i>Revista Brasileira De Cardiologia Invasiva (English Edition)</i> Tj ETQq0 0 0 rgBT / Overlock 10 Tf 50 492	0.1	0
985	Early and late outcomes of patients treated with hybrid sirolimus-eluting stent or everolimus-eluting stent. <i>Revista Brasileira De Cardiologia Invasiva (English Edition)</i> , 2015, 23, 114-118.	0.1	0
987	Clinical outcome of patients with implantation of second-generation drug-eluting stents in the right coronary ostium: Insights from 2-year follow-up of the TWENTE trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 524-531.	0.7	14
988	Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the TWENTE trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, E76-82.	0.7	8
989	Long-Term Effects of Novel Combination Coating Anti-CD34 Antibody Applied on Sirolimus-Eluting Stents. <i>Journal of Interventional Cardiology</i> , 2015, 28, 257-263.	0.5	6
990	Stent length as a potential indicator to select patients who may benefit from long-term dual antiplatelet therapy. <i>Interventional Cardiology</i> , 2015, 7, 419-426.	0.0	0
991	Serial intravascular ultrasound analysis of complex bifurcation coronary lesions treated with the tryton bifurcation stent in conjunction with an everolimus-eluting stent: IUVANT (Intravascular) Tj ETQq0 0 0 rgBT / Overlock 10 Tf 50 2	0.7	3
992	New-generation drug-eluting stents reduce stent thrombosis and myocardial infarction: A propensity-score-adjusted analysis from the multicenter REAL registry (REgistro Regionale) Tj ETQq1 1 0.784314 rgBT / Overlock 10 Tf 50 797-806.	0.7	5
993	Identification of Intrastent Pathology Associated With Late Stent Thrombosis Using Optical Coherence Tomography. <i>Journal of Interventional Cardiology</i> , 2015, 28, 439-448.	0.5	5
994	Ischaemic heart disease – a selected review of recent developments. <i>Current Opinion in Cardiology</i> , 2015, 30, 657-662.	0.8	5
995	Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials. <i>Cardiovascular Therapeutics</i> , 2015, 33, 253-263.	1.1	11
996	First-in-man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary lesions: Clinical, Angiographic, and OCT outcomes of CREDIT-1. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 744-751.	0.7	10

#	ARTICLE	IF	CITATIONS
997	Microwave spectrometry for the evaluation of in-stent neoatherosclerosis. Biomedical Physics and Engineering Express, 2015, 1, 035202.	0.6	1
998	STENTING STRATEGY AND FOLLOW-UP RESULTS OF MULTI-CENTER REGISTRY IN FUKUSHIMA CITY FOR LEFT MAIN CORONARY ARTERY DISEASE: BARE METAL STENT VERSUS DRUG-ELUTING STENT. Fukushima Journal of Medical Sciences, 2015, 61, 79-85.	0.1	1
999	Neoatherosclerosis: Coronary stents seal atherosclerotic lesions but result in making a new problem of atherosclerosis. World Journal of Cardiology, 2015, 7, 776.	0.5	32
1000	Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes. Medical Devices: Evidence and Research, 2015, 8, 317.	0.4	5
1001	Roles of Intravascular Ultrasound in Patients with Acute Myocardial Infarction. Korean Circulation Journal, 2015, 45, 259.	0.7	10
1002	Prevention of stent thrombosis: challenges and solutions. Vascular Health and Risk Management, 2015, 11, 93.	1.0	41
1003	Clinical Outcomes in Low Risk Coronary Artery Disease Patients Treated with Different Limus-Based Drug-Eluting Stents - A Nationwide Retrospective Cohort Study Using Insurance Claims Database. PLoS ONE, 2015, 10, e0122860.	1.1	5
1004	Optimization of Drug Delivery by Drug-Eluting Stents. PLoS ONE, 2015, 10, e0130182.	1.1	53
1005	Evaluation of an Integrated Telemonitoring Surveillance System in Patients with Coronary Heart Disease. Methods of Information in Medicine, 2015, 54, 388-397.	0.7	32
1006	Multifaceted prospects of nanocomposites for cardiovascular grafts and stents. International Journal of Nanomedicine, 2015, 10, 2785.	3.3	19
1007	Safety and efficacy of a novel iopromide-based paclitaxel-eluting balloon following bare metal stent implantation in rabbit aorta abdominalis. Bio-Medical Materials and Engineering, 2015, 26, 79-88.	0.4	4
1008	A Case Report of Recurrent Subacute Stent Thrombosis After Drug Eluting Stent Implantation: What Is the Real Reason?. Cardiology Research, 2015, 6, 367-371.	0.5	2
1009	Favorable Outcomes after Implantation of Biodegradable Polymer Coated Sirolimus-Eluting Stents in Diabetic Population: Results from INDOLIMUS-G Diabetic Registry. International Journal of Vascular Medicine, 2015, 2015, 1-5.	0.4	1
1010	Changes in the Practice of Coronary Revascularization between 2006 and 2010 in the Republic of Korea. Yonsei Medical Journal, 2015, 56, 895.	0.9	18
1011	Acute two-vessel occlusion due to simultaneous very late stent thrombosis following sirolimus-eluting stent implantation: a case report and review of the literature. Postepy W Kardiologii Interwencyjnej, 2015, 3, 252-255.	0.1	1
1012	Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. European Heart Journal, 2015, 36, 2147-2159.	1.0	362
1013	Percutaneous Coronary Intervention and the Various Coronary Artery Disease Syndromes. Cardiovascular Medicine, 2015, , 597-620.	0.0	0
1014	Drug-eluting stents vs. bare metal stents in patients with cardiogenic shock. Journal of Cardiovascular Medicine, 2015, 16, 220-229.	0.6	12

#	ARTICLE	IF	CITATIONS
1015	Acute ischemic events are frequent after primary coronary stenting. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 178-188.	0.6	2
1016	Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement. <i>Annals of Internal Medicine</i> , 2015, 163, 118-126.	2.0	51
1017	Editorial: Remaining issue after drug-eluting stent implantation: Histopathological mechanisms of early-phase in-stent restenosis. <i>Journal of Cardiology Cases</i> , 2015, 12, 150-151.	0.2	0
1018	Comparison of Zotarolimus- and Everolimus-Eluting Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002230.	1.4	122
1019	Current strategies for bridging dual antiplatelet therapy in patients requiring surgery. <i>Interventional Cardiology</i> , 2015, 7, 137-148.	0.0	2
1020	Seguridad y eficacia de nuevos modelos de stents liberadores de sirolimus en el modelo preclínico. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 1118-1124.	0.6	5
1021	An update on drug-eluting stents versus bare-metal stents in PCI treatment: are there any remaining indications for BMS use?. <i>Interventional Cardiology</i> , 2015, 7, 497-505.	0.0	1
1022	Solving the Issue of Restenosis After Stenting of Intracranial Stenoses: Experience with Two Thin-Strut Drug-Eluting Stents (DES)â€”Taxus Elementâ„¢ and Resolute Integrityâ„¢. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 583-591.	0.9	16
1023	Titania nanotube arrays for local drug delivery: recent advances and perspectives. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 103-127.	2.4	146
1024	Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. <i>International Journal of Cardiology</i> , 2015, 183, 190-197.	0.8	4
1025	Stent thrombosis in early-generation drug-eluting stents versus newer-generation everolimus-eluting stent assorted by LVEF. <i>Heart</i> , 2015, 101, 50-57.	1.2	8
1027	Antiplatelet therapy after drug-eluting stent implantation. <i>Journal of Cardiology</i> , 2015, 65, 98-104.	0.8	7
1028	Drug-Eluting Stents: the Past, Present, and Future. <i>Current Atherosclerosis Reports</i> , 2015, 17, 485.	2.0	39
1029	Trend in percutaneous coronary intervention volume following the COURAGE and BARI-2D trials. <i>International Journal of Cardiology</i> , 2015, 183, 6-10.	0.8	28
1030	Meta-Analysis Appraising High Maintenance Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention With and Without High On-Clopidogrel Platelet Reactivity. <i>American Journal of Cardiology</i> , 2015, 115, 592-601.	0.7	8
1031	Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration. <i>Pharmacological Research</i> , 2015, 93, 22-27.	3.1	45
1032	Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. <i>Lancet, The</i> , 2015, 385, 1527-1535.	6.3	107
1033	Stent Thrombosis: Current Management and Outcomes. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2015, 17, 365.	0.4	5

#	ARTICLE	IF	CITATIONS
1034	Ultra-thin strut cobalt chromium bare metal stent usage in a complex real-world setting. (SOLSTICE) Tj ETQq0 0 0 rgBT /Overlck 10 Tf 5	0.3	10
1035	Local delivery of paclitaxel in the treatment of peripheral arterial disease. <i>European Journal of Clinical Investigation</i> , 2015, 45, 333-345.	1.7	54
1036	Thrombotic Complications Associated With Early and Late Nonadherence to Dual Antiplatelet Therapy. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 404-410.	1.1	41
1038	Study design of the influence of serotonin inhibition on patients with RENAL impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study. <i>Contemporary Clinical Trials</i> , 2015, 43, 20-24.	0.8	3
1039	Safety and Efficacy of New Sirolimus-eluting Stent Models in a Preclinical Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 1118-1124.	0.4	3
1040	Prevention of Collagen-Induced Platelet Binding and Activation by Thermosensitive Nanoparticles. <i>AAPS Journal</i> , 2015, 17, 1117-1125.	2.2	4
1041	Coronary Angioscopy. , 2015, , .		4
1042	Glucagon-Like Peptide-1 Receptor Activation Does Not Affect Re-Endothelialization but Reduces Intimal Hyperplasia via Direct Effects on Smooth Muscle Cells in a Nondiabetic Model of Arterial Injury. <i>Journal of Vascular Research</i> , 2015, 52, 41-52.	0.6	26
1043	Two-year vessel healing after everolimus-eluting stent implantation: Serial assessment by optical coherence tomography. <i>Journal of Cardiology</i> , 2015, 65, 298-304.	0.8	15
1044	Comparison of Strut Coverage at 6 Months by Optical Coherence Tomography With Everolimus-Eluting Stenting of Bare-Metal Stent Restenosis Versus Stenosis of Nonstented Atherosclerotic Narrowing (from the DESERT Study). <i>American Journal of Cardiology</i> , 2015, 115, 1351-1356.	0.7	6
1045	Duration of dual antiplatelet therapy after coronary artery stenting: where is the sweet spot between ischaemia and bleeding?. <i>European Heart Journal</i> , 2015, 36, 1207-1211.	1.0	44
1046	Primary percutaneous coronary intervention and bleeding risk in the era of drug-eluting stent: a long-term cohort study. <i>Cardiovascular Intervention and Therapeutics</i> , 2015, 30, 216-226.	1.2	5
1047	Prolonged antiplatelet therapy after drug-eluting stents. <i>Lancet, The</i> , 2015, 385, 2332-2333.	6.3	2
1048	Efficacy and safety of limus-eluting versus paclitaxel-eluting coronary artery stents in patients with diabetes mellitus: A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 184, 680-691.	0.8	11
1049	Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. <i>Lancet, The</i> , 2015, 385, 2371-2382.	6.3	345
1050	Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease. <i>New England Journal of Medicine</i> , 2015, 372, 1204-1212.	13.9	397
1051	Comparison of Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Intervention in Patients with Diabetes. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2015, 17, 377.	0.4	3
1052	Short- Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1092-1102.	1.2	163



#	ARTICLE	IF	CITATIONS
1053	The Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1311-1313.	1.2	4
1054	Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1127-1145.	0.6	11
1055	Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gräntzig Lecture ESC 2014. <i>European Heart Journal</i> , 2015, 36, 3320-3331.	1.0	441
1056	Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	13
1057	Usefulness of the Left Anterior Descending Coronary Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute) <i>Tj ETQq0 0 0 rgBT /Overföck 10 Tf</i>	0.7	13
1058	Fabrication and Characterization of Nonwoven Auxetic Polymer Stent. <i>Polymer-Plastics Technology and Engineering</i> , 2015, 54, 1553-1559.	1.9	27
1059	Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation. <i>Current Cardiology Reports</i> , 2015, 17, 64.	1.3	1
1060	Comparison of clinical outcomes in patients presenting with an acute coronary syndrome due to stent thrombosis or saphenous vein graft occlusion and undergoing percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 441-446.	0.3	2
1061	Very Late Scaffold Thrombosis. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1901-1914.	1.2	186
1062	Dual antiplatelet therapy: optimal timing, management, and duration. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 198-204.	1.4	32
1063	OCT demonstrating neoatherosclerosis as part of the continuous process of coronary artery disease. <i>Herz</i> , 2015, 40, 845-854.	0.4	15
1064	Absorb bioresorbable stents for the treatment of coronary artery disease. <i>Expert Review of Medical Devices</i> , 2015, 12, 545-557.	1.4	6
1065	Dual Antiplatelet Therapy with Clopidogrel and Aspirin for Secondary Stroke Prevention. <i>Current Cardiology Reports</i> , 2015, 17, 89.	1.3	1
1066	Relation between stent thrombosis and calcium channel blocker after drug-eluting stent implantation. <i>Journal of Cardiology</i> , 2015, 66, 333-340.	0.8	5
1067	In-Stent Yellow Plaque at 1 Year After Implantation Is Associated With Future Event of Very Late Stent Failure. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 814-821.	1.1	76
1068	Experimental assessment of effects of antiproliferative drugs of drug-eluting stents on endothelial cells. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 344-347.	0.3	3
1069	Effect of Intravascular Ultrasound-Guided vs Angiography-Guided Everolimus-Eluting Stent Implantation. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2155.	3.8	418
1070	Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: A meta-analysis of randomized clinical trials. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 34-40.	0.7	30

#	ARTICLE	IF	CITATIONS
1071	SYNTAX score and the risk of stent thrombosis after percutaneous coronary intervention in patients with non- $\sigma$ T $\sigma$ segment elevation acute coronary syndromes: An ACUTY trial substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 1-10.	0.7	32
1072	Rationale and design: Impact of intravascular ultrasound guidance on long-term clinical outcomes of everolimus-eluting stents in long coronary lesions. <i>Contemporary Clinical Trials</i> , 2015, 40, 90-94.	0.8	7
1073	<i>Cardiovascular OCT Imaging.</i> , 2015, , .		5
1074	6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin. <i>Journal of the American College of Cardiology</i> , 2015, 65, 777-786.	1.2	322
1075	Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 23-34.	1.0	25
1076	A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. <i>Lancet, The</i> , 2015, 385, 43-54.	6.3	514
1077	Lack of association between peri-procedural myocardial damage and CYP2C19 gene variant in elective percutaneous coronary intervention. <i>Heart and Vessels</i> , 2015, 30, 572-579.	0.5	1
1078	Black hole restenosis after drug-eluting stent implantation for in-stent restenosis: potential mechanism and optimal strategy. <i>Heart and Vessels</i> , 2015, 30, 682-686.	0.5	2
1079	Comparison of Long-Term Clinical Outcomes of Lesions Exhibiting Focal and Segmental Peri-Stent Contrast Staining. <i>Journal of the American Heart Association</i> , 2016, 5, e002878.	1.6	3
1080	The clinical outcomes of triple antiplatelet therapy versus dual antiplatelet therapy for high-risk patients after coronary stent implantation: a meta-analysis of 11 clinical trials and 9,553 patients. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3435-3448.	2.0	14
1081	Preliminary Evaluation of Clinical and Angiographic Outcomes with Biodegradable Polymer Coated Sirolimus-Eluting Stent in De Novo Coronary Artery Disease: Results of the MANIPAL-FLEX Study. <i>Scientifica</i> , 2016, 2016, 1-8.	0.6	10
1082	Meta-analysis of randomized controlled trials on efficacy and safety of extended thienopyridine therapy after drug-eluting stent implantation. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 409-416.	0.7	1
1083	Long-term performance of the second-generation cobalt-chromium sirolimus-eluting stents in real-world clinical practice: 3-year clinical outcomes from the prospective multicenter FOCUS registry. <i>Journal of Thoracic Disease</i> , 2016, 8, 1601-1610.	0.6	5
1084	Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , 2016, 115, 979-992.	1.8	14
1085	Extreme late-phase observation using coronary angioscopy until 7 years after sirolimus-eluting stent implantation. <i>Coronary Artery Disease</i> , 2016, 27, 29-33.	0.3	2
1086	Importance and usage of the CHA2DS2-VASc score in predicting acute stent thrombosis. <i>Coronary Artery Disease</i> , 2016, 27, 478-482.	0.3	26
1087	Clinical outcome of titanium-nitride-coated cobalt-chromium stents in patients with de novo coronary lesions: 12-month results of the OPTIMAX first-man study. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, E122-7.	0.7	5
1088	Solely abluminal drug release from coronary stents could possibly improve reendothelialization. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, E59-66.	0.7	11

#	ARTICLE	IF	CITATIONS
1090	Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2016, 134, e156-78.	1.6	105
1091	Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1116-1139.	1.2	154
1092	Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents. <i>American Heart Journal</i> , 2016, 175, 121-129.	1.2	39
1093	Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial. <i>American Heart Journal</i> , 2016, 178, 37-44.	1.2	20
1094	Biodegradable Polymer-Based Sirolimus-Eluting Stents With Differing Elution and Absorption Kinetics. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2249-2258.	1.2	40
1095	Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). <i>Cardiology</i> , 2016, 134, 11-18.	0.6	8
1096	Comparison of long-term clinical outcomes after the second-generation cobalt-chromium sirolimus-eluting stents implantation in diabetic versus non-diabetic patients: a subgroup analysis from the prospective FOCUS registry. <i>Annals of Medicine</i> , 2016, 48, 202-210.	1.5	0
1097	Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From the DUTCH PEERS (TWENTE II) Randomized Trial. <i>Revista Espanola De Cardiologia (English)</i> Tj ETQq1d.4.784334 rgBT /O		
1098	Aspirin, Plavix, and Other Antiplatelet Medications. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2016, 28, 497-506.	0.4	11
1099	Frequency of Stent Thrombosis Risk at 5 Years in Women Versus Men With Zotarolimus-Eluting Compared With Sirolimus-Eluting Stent. <i>American Journal of Cardiology</i> , 2016, 118, 1178-1186.	0.7	4
1100	Pathology of Endovascular Stents. <i>Interventional Cardiology Clinics</i> , 2016, 5, 391-403.	0.2	15
1102	Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	9
1103	Antiproliferative Drugs for Restenosis Prevention. <i>Interventional Cardiology Clinics</i> , 2016, 5, 321-329.	0.2	24
1104	One-year clinical outcomes after sirolimus-eluting coronary stent implantation in diabetics enrolled in the worldwide SELECT registry. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 52-62.	0.7	3
1105	Safety and efficacy profile of bioresorbable polylactide polymer biolimus-eluting stents versus durable polymer everolimus and zotarolimus-eluting stents in patients with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, E173-E182.	0.7	5
1106	Angioscopic Comparison of Resolute and Endeavor Zotarolimus-Eluting Stents. <i>Circulation Journal</i> , 2016, 80, 650-656.	0.7	6
1107	Three-Year Clinical Outcomes of Everolimus-Eluting Stents From the Post-Marketing Surveillance Study of Cobalt-Chromium Everolimus-Eluting Stent (XIENCE V/PROMUS) in Japan. <i>Circulation Journal</i> , 2016, 80, 906-912.	0.7	31
1108	Comparison of Chronic Angioscopic Findings of Bare Metal Stents, 1st-Generation Drug-Eluting Stents and 2nd-Generation Drug-Eluting Stents—Multicenter Study of Intra-Coronary Angioscopy After Stent (MICASA). <i>Circulation Journal</i> , 2016, 80, 1916-1921.	0.7	18

#	ARTICLE	IF	CITATIONS
1109	Evaluation of Early Healing Profile and Neointimal Transformation Over 24 Months Using Longitudinal Sequential Optical Coherence Tomography Assessments and 3-Year Clinical Results of the New Dual-Therapy Endothelial Progenitor Cell Capturing Sirolimus-Eluting Combo Stent. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	28
1110	Influence of catheter insertion on the hemodynamic environment in coronary arteries. <i>Medical Engineering and Physics</i> , 2016, 38, 946-951.	0.8	10
1111	Impact of optical coherence tomography- and coronary angiography-assessed neointimal tissue characteristics on occurrence of periprocedural myonecrosis in patients with in-stent restenosis. <i>International Journal of Cardiovascular Imaging</i> , 2016, 32, 1483-1494.	0.7	6
1112	Evaluation of the efficacy of paclitaxel with curcumin combination in ovarian cancer cells. <i>Oncology Letters</i> , 2016, 12, 3944-3948.	0.8	46
1113	Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis. <i>Scientific Reports</i> , 2016, 6, 33054.	1.6	14
1114	Patterned Carbon Nanotube Growth on Convex Cylindrical Stainless Steel Substrates for the Production of Coronary Stents. , 2016, , .		1
1115	Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 104.	0.7	11
1116	CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents. <i>Medicine (United States)</i> , 2016, 95, e4049.	0.4	3
1117	Safety and efficacy of a second-generation coronary sirolimus-eluting stent with biodegradable polymers in daily clinical practice. <i>Coronary Artery Disease</i> , 2016, 27, 89-94.	0.3	6
1118	Bioresorbable Stents in PCI. <i>Current Cardiology Reports</i> , 2016, 18, 74.	1.3	9
1119	Dual antiplatelet therapy after coronary stenting. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1775-1787.	0.9	11
1120	Safety and effectiveness of the new P2Y12r inhibitor agents vs clopidogrel in ACS patients according to the geographic area: East Asia vs Europe. <i>International Journal of Cardiology</i> , 2016, 220, 488-495.	0.8	8
1121	Intracoronary Brachytherapy for Recurrent Drug-Eluting Stent Failure. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1259-1265.	1.1	56
1122	Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 38.	0.7	57
1123	Comparison Between Non-invasive (Coronary Computed Tomography Angiography Derived) and Invasive-Fractional Flow Reserve in Patients with Serial Stenoses Within One Coronary Artery: A NXT Trial substudy. <i>Annals of Biomedical Engineering</i> , 2016, 44, 580-589.	1.3	19
1124	Impact of stent length on clinical outcomes of first-generation and new-generation drug-eluting stents. <i>Cardiovascular Intervention and Therapeutics</i> , 2016, 31, 114-121.	1.2	11
1125	Are BVS suitable for ACS patients? Support from a large single center real live registry. <i>International Journal of Cardiology</i> , 2016, 218, 89-97.	0.8	14
1126	Long-term clinical outcomes of everolimus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary interventions: a meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 34.	0.7	8

#	ARTICLE	IF	CITATIONS
1127	Fabrication of endothelial progenitor cell capture surface via DNA aptamer modifying dopamine/polyethyleneimine copolymer film. <i>Applied Surface Science</i> , 2016, 386, 138-150.	3.1	21
1128	Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation. <i>Heart and Vessels</i> , 2016, 31, 1247-1256.	0.5	9
1129	Coating Techniques and Release Kinetics of Drug-Eluting Stents. <i>Journal of Medical Devices, Transactions of the ASME</i> , 2016, 10, .	0.4	29
1130	Current characteristics and management of ST elevation and non-ST elevation myocardial infarction in the Tokyo metropolitan area: from the Tokyo CCU network registered cohort. <i>Heart and Vessels</i> , 2016, 31, 1740-1751.	0.5	69
1131	Prolonged Clopidogrel Use is Associated with Improved Clinical Outcomes Following Drug-Eluting But Not Bare Metal Stent Implantation. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 111-118.	1.0	2
1132	The Tradeoff Between Shorter and Longer Courses of Dual Antiplatelet Therapy After Implantation of Newer Generation Drug-Eluting Stents. <i>Current Cardiology Reports</i> , 2016, 18, 8.	1.3	4
1133	Embedding clinical interventions into observational studies. <i>Contemporary Clinical Trials</i> , 2016, 46, 100-105.	0.8	14
1134	Moving Toward Eradication of Stent-Associated Thrombosis. <i>Journal of the American College of Cardiology</i> , 2016, 67, 763-765.	1.2	1
1135	Clinical characteristics, angiographic findings, and one-year outcome of 101 consecutive stent thrombosis cases in British Columbia. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 74-80.	0.3	3
1136	The management of antithrombotic agents for patients undergoing GI endoscopy. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 3-16.	0.5	538
1137	Comparison of outcomes after everolimus-eluting stent implantation in diabetic versus non-diabetic patients in the Tokyo-MD PCI study. <i>Journal of Cardiology</i> , 2016, 67, 241-247.	0.8	15
1138	Coronary Stents: The Impact of Technological Advances on Clinical Outcomes. <i>Annals of Biomedical Engineering</i> , 2016, 44, 488-496.	1.3	36
1139	Short- and long-term benefits of drug-eluting stents compared to bare metal stents even in treatment for large coronary arteries. <i>Heart and Vessels</i> , 2016, 31, 635-642.	0.5	9
1140	Angiographic predictors of 2-year stent thrombosis in patients receiving drug-eluting stents: Insights from the ADAPT-DES study. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 26-35.	0.7	16
1141	Peripheral Vascular Restenosis: A Retrospective Study on the Use of Drug-Eluting Balloons in Native Arteries, Vein Grafts and Dialysis Accesses. <i>Scandinavian Journal of Surgery</i> , 2017, 106, 158-164.	1.3	8
1142	Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 255-264.	1.1	38
1143	Bioresorbable Scaffolds for Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2017, 19, 5.	1.3	4
1144	Development of a platelet adhesion transport equation for a computational thrombosis model. <i>Journal of Biomechanics</i> , 2017, 50, 114-120.	0.9	12

#	ARTICLE	IF	CITATIONS
1145	Comparison of angioscopic findings among second-generation drug-eluting stents. <i>Journal of Cardiology</i> , 2017, 70, 297-302.	0.8	14
1146	Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2017, 230, 310-318.	0.8	28
1147	Treatment of coronary artery in-stent restenosis. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 191-202.	0.6	42
1148	Tracking delivery of a drug surrogate in the porcine heart using photoacoustic imaging and spectroscopy. <i>Journal of Biomedical Optics</i> , 2017, 22, 041016.	1.4	6
1149	Process development for high-resolution 3D-printing of bioresorbable vascular stents. <i>Proceedings of SPIE</i> , 2017, , .	0.8	7
1150	The REMEDEE-OCT Study. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 489-499.	1.1	35
1151	Stents: Biomechanics, Biomaterials, and Insights from Computational Modeling. <i>Annals of Biomedical Engineering</i> , 2017, 45, 853-872.	1.3	53
1152	Single or dual antiplatelet therapy after PCI. <i>Nature Reviews Cardiology</i> , 2017, 14, 294-303.	6.1	35
1153	Evaluation of the MiStent sustained sirolimus eluting biodegradable polymer coated stent for the treatment of coronary artery disease: does uniform sustained abluminal drug release result in earlier strut coverage and better safety profile?. <i>Expert Review of Medical Devices</i> , 2017, 14, 325-334.	1.4	8
1154	Incident Myocardial Infarction and Very Late Stent Thrombosis in Outpatients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2149-2156.	1.2	35
1155	Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	6
1156	6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1202-1210.	1.1	52
1157	Does the new generation of drug-eluting stents render bare metal stents obsolete?. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 456-461.	0.3	11
1158	Drug-Eluting Stents Versus Bare Metal Stents for Percutaneous Coronary Intervention in Kidney Transplant Recipients. <i>Transplantation</i> , 2017, 101, 851-857.	0.5	3
1159	Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017, 22, 347-355.	1.0	13
1160	The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2017, 235, 73-86.	0.8	6
1161	Plaque erosion delays vascular healing after drug eluting stent implantation in patients with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 592-600.	0.7	26
1162	Revisiting the role of durable polymers in cardiovascular devices. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 835-846.	0.6	15

#	ARTICLE	IF	CITATIONS
1164	Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. <i>Lancet, The</i> , 2017, 390, 1843-1852.	6.3	214
1165	From Nonclinical Research to Clinical Trials and Patient-registries: Challenges and Opportunities in Biomedical Research. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2017, 70, 1121-1133.	0.4	10
1166	Evaluation of ion implantation for anti-thrombogenic coronary stent in vitro and in vivo. <i>Journal of Industrial and Engineering Chemistry</i> , 2017, 54, 290-297.	2.9	9
1167	Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome. <i>Clinical Cardiology</i> , 2017, 40, 789-796.	0.7	5
1168	Effects of Linagliptin on Vessel Wall Healing in the Rat Model of Arterial Injury Under Normal and Diabetic Conditions. <i>Journal of Cardiovascular Pharmacology</i> , 2017, 69, 101-109.	0.8	6
1169	Fabrication Speed Optimization for High-resolution 3D-printing of Bioresorbable Vascular Scaffolds. <i>Procedia CIRP</i> , 2017, 65, 131-138.	1.0	14
1170	Drug-eluting stents in clinical routine: a 1-year follow-up analysis based on German health insurance administrative data from 2008 to 2014. <i>BMJ Open</i> , 2017, 7, e017460.	0.8	3
1171	Clinical implications of blood-material interaction and drug eluting stent polymers in review. <i>Expert Review of Medical Devices</i> , 2017, 14, 707-716.	1.4	14
1172	Duration of dual anti-platelet therapy – State of the art after the DAPT and PEGASUS-TIMI 54 trials. <i>Acta Cardiologica</i> , 2017, 72, 256-264.	0.3	5
1175	Three-month evaluation of strut healing using a novel optical coherence tomography analytical method following bioresorbable polymer everolimus-eluting stent implantation in humans. <i>Coronary Artery Disease</i> , 2017, 28, 126-134.	0.3	14
1176	Time course of the antiplatelet effect after switching to clopidogrel from initial prasugrel therapy in patients with acute coronary syndrome. <i>Heart and Vessels</i> , 2017, 32, 1432-1438.	0.5	2
1177	Drug-Eluting Balloon Technology for Native Non-Small Coronary Artery Disease: Another Crusade against Skepticism!. <i>Cardiology</i> , 2017, 137, 22-24.	0.6	0
1178	Collagen-binding nanoparticles for extracellular anti-inflammatory peptide delivery decrease platelet activation, promote endothelial migration, and suppress inflammation. <i>Acta Biomaterialia</i> , 2017, 49, 78-88.	4.1	16
1179	Titanium-nitride-oxide-coated coronary stents: insights from the available evidence. <i>Annals of Medicine</i> , 2017, 49, 299-309.	1.5	17
1180	Evaluation of bioresorbable polymers as potential stent material – In vivo degradation behavior and histocompatibility. <i>Journal of Applied Polymer Science</i> , 2017, 134, .	1.3	11
1181	Efficacy and Safety of Percutaneous Coronary Intervention for Elderly Patients in the Second-Generation Drug-Eluting Stent Era: The SHINANO Registry. <i>Angiology</i> , 2017, 68, 688-697.	0.8	8
1182	Very early tissue coverage after drug-eluting stent implantation: an optical coherence tomography study. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 25-30.	0.7	8
1183	Characteristics of Highly Cited Articles in Interventional Cardiology. <i>American Journal of Cardiology</i> , 2017, 120, 2100-2109.	0.7	23

#	ARTICLE	IF	CITATIONS
1185	The dawn of neurosurgery in pre-conquest Mesoamerican territories. <i>Child's Nervous System</i> , 2017, 33, 1621-1629.	0.6	3
1186	Elevated Levels of Very Low-density Lipoprotein Cholesterol Independently Associated with In-stent Restenosis in Diabetic Patients after Drug-eluting Stent Implantation. <i>Chinese Medical Journal</i> , 2017, 130, 2326-2332.	0.9	12
1187	Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring. <i>Frontiers in Pharmacology</i> , 2017, 8, 738.	1.6	2
1188	Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 769-779.	0.7	6
1189	7.28 Drug Eluting Stents â†. , 2017, , 548-590.		0
1190	The drug delivery system used in interventional radiology. <i>Drug Delivery System</i> , 2017, 32, 17-28.	0.0	0
1191	Drug-Eluting vs. Bare-Metal Stents: Is it a Matter of Vessel Size?. <i>Journal of Clinical Trials</i> , 2017, 07, .	0.1	0
1192	Nobori-Biolimus-Eluting Stents versus Resolute Zotarolimus-Eluting Stents in Patients Undergoing Coronary Intervention: A Propensity Score Matching. <i>Yonsei Medical Journal</i> , 2017, 58, 290.	0.9	3
1193	INNOVATIONS IN CARE. <i>Innovation in Aging</i> , 2017, 1, 975-975.	0.0	0
1194	The optimal duration of dual antiplatelet therapy after implantation of drug-eluting coronary stents: an unanswered question. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, S91-S94.	0.7	2
1195	Impact of Coronary Stent Fracture on Restenotic Neointimal Tissue Characterization After Drug-Eluting Stent Implantation. <i>International Heart Journal</i> , 2017, 58, 861-867.	0.5	5
1196	A clinical risk score to identify patients at high risk of very late stent thrombosis. <i>Journal of Interventional Cardiology</i> , 2018, 31, 159-169.	0.5	6
1197	Hypersensitivity to Cardiovascular Implants: Stents. , 2018, , 263-271.		2
1198	Stent thrombosis rates the first year and beyond with new- and old-generation drug-eluting stents compared to bare metal stents. <i>Clinical Research in Cardiology</i> , 2018, 107, 816-823.	1.5	21
1199	Rapamycin activates TGF receptor independently of its ligand: implications for endothelial dysfunction. <i>Clinical Science</i> , 2018, 132, 437-447.	1.8	15
1200	Anticoagulants and Antiplatelet Agents in Patients Undergoing Polypectomy. , 2018, , 121-134.		1
1202	Upregulation of miR-221 and -222 in response to increased extracellular signal-regulated kinases 1/2 activity exacerbates neointimal hyperplasia in diabetes mellitus. <i>Atherosclerosis</i> , 2018, 269, 71-78.	0.4	30
1203	Drug-Eluting Stents Versus Bare-Metal Stents in Patients With End-Stage Renal Disease. <i>American Journal of the Medical Sciences</i> , 2018, 355, 331-341.	0.4	0



#	ARTICLE	IF	CITATIONS
1204	Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 478-490.	1.6	61
1205	Outcomes of microvascular flap reconstruction of the head and neck in patients receiving systemic immunosuppressive therapy for organ transplantation. <i>Journal of Surgical Oncology</i> , 2018, 117, 1575-1583.	0.8	3
1206	Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 369-377.	0.6	15
1207	Participation of transient receptor potential vanilloid 1 in paclitaxel-induced acute visceral and peripheral nociception in rodents. <i>European Journal of Pharmacology</i> , 2018, 828, 42-51.	1.7	25
1208	Comparison of the endothelial coverage in everolimus and zotarolimus-eluting stents in normal, atherosclerotic, and bifurcation rabbit iliac arteries. <i>Cardiovascular Intervention and Therapeutics</i> , 2018, 33, 55-61.	1.2	11
1209	Rationale and design of amphimus sirolimus-eluting stents versus zotarolimus-eluting stents in all-comers requiring percutaneous coronary intervention (ReCre8): A multicenter randomized clinical trial. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 410-416.	0.7	9
1210	Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug-eluting stent: The ANCHOR study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 435-443.	0.7	7
1211	Late Stent Evaluation (Neoatherosclerosis). , 2018, , 165-175.		0
1213	The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 205-212.	2.8	20
1214	High-speed on-demand 3D printed bioresorbable vascular scaffolds. <i>Materials Today Chemistry</i> , 2018, 7, 25-34.	1.7	50
1215	Impact of everolimus-eluting stent length on long-term clinical outcomes of percutaneous coronary intervention. <i>Journal of Cardiology</i> , 2018, 71, 444-451.	0.8	12
1216	Platelet function monitoring for stent thrombosis in critically ill patients with an acute Coronary syndrome. <i>Journal of Interventional Cardiology</i> , 2018, 31, 277-283.	0.5	6
1217	Recommendations for perioperative management of lung cancer patients with comorbidities. <i>General Thoracic and Cardiovascular Surgery</i> , 2018, 66, 71-80.	0.4	3
1218	Palliative treatment of coronary atherosclerotic cancer by drug-eluting or bare-metal stents: From oculo-stenotic reflex period to age of precision medicine. <i>Indian Heart Journal</i> , 2018, 70, 191-193.	0.2	1
1219	Long-Term Use of Antiplatelet Therapy in Real-World Patients with Acute Myocardial Infarction: Insights from the PIPER Study. <i>TH Open</i> , 2018, 02, e437-e444.	0.7	5
1220	Local suture ligation-assisted percutaneous sclerotherapy for Kasabach-Merritt phenomenon-associated kaposiform haemangioendothelioma. <i>Oncology Letters</i> , 2018, 17, 981-989.	0.8	1
1221	Comparison of Efficacy and Safety between First- and Second-Generation Drug-Eluting Stents in Patients with Acute Coronary Syndrome. <i>Chinese Medical Journal</i> , 2018, 131, 1397-1405.	0.9	0
1222	Validation of Predictive Value of Patterns of Nonadherence to Antiplatelet Regimen in Stented Patients Thrombotic Risk Score in Chinese Population Undergoing Percutaneous Coronary Intervention. <i>Chinese Medical Journal</i> , 2018, 131, 2699-2704.	0.9	8

#	ARTICLE	IF	CITATIONS
1223	A rapamycin derivative, biolimus, preferentially activates autophagy in vascular smooth muscle cells. <i>Scientific Reports</i> , 2018, 8, 16551.	1.6	18
1224	Nitric oxide donor delivery. , 2018, , 291-304.		2
1225	Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006741.	1.4	13
1226	Procedural advantages of a novel coronary stent design with ultra-thin struts and bioabsorbable abluminal polymer coating in an all-comers registry. <i>Postepy W Kardiologii Interwencyjnej</i> , 2018, 14, 240-246.	0.1	2
1227	Molecular, Cellular, and Tissue Engineering of the Vascular System. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	0.8	6
1228	Vascular Intervention: From Angioplasty to Bioresorbable Vascular Scaffold. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1097, 181-189.	0.8	3
1229	Statin Therapy and Diabetes Do Not Affect Aneurysm Occlusion or Clinical Outcomes After Pipeline Embolization Device Treatment: A Preliminary Study. <i>World Neurosurgery</i> , 2018, 120, e525-e532.	0.7	6
1230	Early-Phase Vascular Healing of Bioabsorbable vs. Durable Polymer-Coated Everolimus-Eluting Stents in Patients With ST-Elevation Myocardial Infarctionâ€” 2-Week and 4-Month Analyses With Optical Coherence Tomography â€”. <i>Circulation Journal</i> , 2018, 82, 2594-2601.	0.7	11
1231	Building a cloud-based data sharing model for the Saudi national registry for implantable medical devices: Results of a readiness assessment. <i>International Journal of Medical Informatics</i> , 2018, 118, 113-119.	1.6	10
1232	Stent Thrombosis. , 2018, , 217-224.		1
1233	Bioresorbable scaffold technology: The yet unfulfilled promise of becoming the workhorse stent in the cardiac catheterization laboratory. <i>Egyptian Heart Journal</i> , 2018, 70, 409-414.	0.4	0
1234	Clinical Characteristics, Procedural Factors, and Outcomes of Percutaneous Coronary Intervention in Patients With Mechanical and Bioprosthetic Heart Valves. <i>American Journal of Cardiology</i> , 2018, 122, 1536-1540.	0.7	0
1235	Differences between first-generation and second-generation drug-eluting stent regarding in-stent neoatherosclerosis characteristics: an optical coherence tomography analysis. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 1521-1528.	0.7	8
1236	Evolution of the SYNERGY bioresorbable polymer metallic coronary stent. <i>Future Cardiology</i> , 2018, 14, 307-317.	0.5	11
1237	Rhombic-Shaped Channel Stent with Enhanced Drug Capacity and Fatigue Life. <i>Micromachines</i> , 2018, 9, 3.	1.4	8
1238	Polymer coatings for biocompatibility and reduced nonspecific adsorption. , 2018, , 155-198.		7
1239	Biomimetic Tissue Engineering: Tuning the Immune and Inflammatory Response to Implantable Biomaterials. <i>Advanced Healthcare Materials</i> , 2018, 7, e1800490.	3.9	84
1240	Novel Polymer-Free Everolimus-Eluting Stent Fabricated using Femtosecond Laser Improves Re-endothelialization and Anti-inflammation. <i>Scientific Reports</i> , 2018, 8, 7383.	1.6	15

#	ARTICLE	IF	CITATIONS
1241	In vitro and in vivo Assessment of Keratose as a Novel Excipient of Paclitaxel Coated Balloons. <i>Frontiers in Pharmacology</i> , 2018, 9, 808.	1.6	18
1242	9-year clinical follow-up of patients with ST-segment elevation myocardial infarction with Genous or TAXUS Libert <sup>®</sup> stents. <i>PLoS ONE</i> , 2018, 13, e0201416.	1.1	6
1243	The comparison of early healing 1-month after PCI among CoCr-everolimus-eluting stent (EES), biodegradable polymer (BP)-EES and BP-sirolimus-eluting stent: Insights from OFDI and coronary angiography. <i>IJC Heart and Vasculature</i> , 2018, 20, 40-45.	0.6	3
1244	Bioresorbable Vascular Scaffold technology, the rise and fall in clinical practice. <i>Journal of Indian College of Cardiology</i> , 2018, 8, 143-147.	0.1	0
1245	Individualized antithrombotic therapy in high-risk cardiovascular patients. <i>Personalized Medicine</i> , 2018, 15, 223-236.	0.8	1
1246	Clinical outcomes and complications of treatment with supraflex stent in patients with coronary artery disease: One-year follow-up. <i>European Journal of Translational Myology</i> , 2019, 29, 8231.	0.8	5
1247	Wirelessly Heating Stents via Radiofrequency Resonance toward Enabling Endovascular Hyperthermia. <i>Advanced Healthcare Materials</i> , 2019, 8, e1900708.	3.9	8
1249	Reply. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2228.	1.1	0
1250	Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention?. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007705.	1.4	6
1251	Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-centre observational cohort study. <i>Cardiovascular Diabetology</i> , 2019, 18, 11.	2.7	32
1252	Rapamycin: A Bacteria-Derived Immunosuppressant That Has Anti-atherosclerotic Effects and Its Clinical Application. <i>Frontiers in Pharmacology</i> , 2018, 9, 1520.	1.6	41
1253	Causes of Mortality After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005355.	0.9	29
1254	The blood compatibility challenge. Part 2: Protein adsorption phenomena governing blood reactivity. <i>Acta Biomaterialia</i> , 2019, 94, 11-24.	4.1	155
1255	Pharmacokinetics and bioequivalence of low-dose clopidogrel in healthy Chinese volunteers under fasted and fed conditions. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 300-307.	1.1	5
1256	A prospective, multicenter, randomized OCT study of early neointimal condition at first and second months after BuMA Supreme stent versus XIENCE stent implantation in high-bleeding-risk coronary artery disease patients: study protocol for a randomized controlled trial. <i>Trials</i> , 2019, 20, 335.	0.7	0
1257	An electrospun fiber-covered stent with programmable dual drug release for endothelialization acceleration and lumen stenosis prevention. <i>Acta Biomaterialia</i> , 2019, 94, 295-305.	4.1	50
1258	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019, 40, 2632-2653.	1.0	335
1259	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 240-261.	1.6	428

#	ARTICLE	IF	CITATIONS
1260	Are drug-eluting stents safer than bare-metal stents?. <i>Lancet, The</i> , 2019, 393, 2472-2474.	6.3	9
1261	Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 577-582.	0.3	7
1262	Hyaluronic Acid Nanoparticle Composite Films Confer Favorable Time-Dependent Biofunctions for Vascular Wound Healing. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 1833-1848.	2.6	21
1263	Incidence, angiographic and clinical predictors, and impact of stent thrombosis: a 6-year survey of 6,545 consecutive patients. <i>Netherlands Heart Journal</i> , 2019, 27, 321-329.	0.3	13
1264	Antiplatelet Drugs in the Management of Coronary Artery Disease. , 2019, , 1017-1029.		0
1265	Bioabsorbable stents: only bad news?. <i>European Heart Journal Supplements</i> , 2019, 21, B28-B30.	0.0	13
1266	Unconfirmed Very Long-Term Clinical Benefit of Xience Over Cypher. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 648-650.	1.1	2
1267	Five-year outcomes after first- and second-generation drug-eluting stent implantation in all patients undergoing percutaneous coronary intervention. <i>Journal of Cardiology</i> , 2019, 74, 169-174.	0.8	7
1268	Assessment of strut coverage of everolimus-eluting platinum chromium stent 2 weeks after implantation by optical coherence tomography. <i>Heart and Vessels</i> , 2019, 34, 1258-1265.	0.5	5
1269	ORAI channels in cellular remodeling of cardiorespiratory disease. <i>Cell Calcium</i> , 2019, 79, 1-10.	1.1	27
1270	Comparison of neointimal coverage between durable polymer everolimus-eluting stents and bioresorbable polymer everolimus-eluting stents 1 year after implantation using high-resolution coronary angiography. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 204-209.	0.7	6
1271	Risk of Postpolypectomy Bleeding With Uninterrupted Clopidogrel Therapy in an Industry-Independent, Double-Blind, Randomized Trial. <i>Gastroenterology</i> , 2019, 156, 918-925.e1.	0.6	35
1272	Prospective evaluation of an ultrathin strut biodegradable polymer-coated sirolimus-eluting stent: 12 months results from the S-FLEX UK registry. <i>BMJ Open</i> , 2019, 9, e026578.	0.8	7
1273	Drug-coated balloons for coronary artery disease: current concepts and controversies. <i>Future Cardiology</i> , 2019, 15, 437-454.	0.5	14
1274	An abluminal biodegradable polymer sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients undergoing coronary revascularization: 3-year clinical outcomes of a randomized non-inferiority trial. <i>Scientific Reports</i> , 2019, 9, 18549.	1.6	0
1275	&lt;p&gt;Anti-Adhesive And Antiproliferative Synergistic Surface Modification Of Intraocular Lens For Reduced Posterior Capsular Opacification&lt;/p&gt;. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 9047-9061.	3.3	48
1276	Very Late Stent Thrombosis in Drug-Eluting Stents New Observations and Clinical Implications. <i>Cardiology in Review</i> , 2019, 27, 279-285.	0.6	12
1277	MAGnesium-based bioresorbable scaffold and vasomotor function in patients with acute ST segment elevation myocardial infarction: The MAGSTEMI trial: Rationale and design. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 64-70.	0.7	10

#	ARTICLE	IF	CITATIONS
1278	A serial 3- and 9-year optical coherence tomography assessment of vascular healing response to sirolimus- and paclitaxel-eluting stents. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 9-21.	0.7	2
1279	2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. <i>Science Bulletin</i> , 2019, 64, 166-179.	4.3	34
1280	The EluNIR <sup>TM</sup> Ridaforolimus Eluting Coronary Stent System. <i>Expert Review of Medical Devices</i> , 2019, 16, 71-76.	1.4	7
1281	1.6 Anticoagulation in the perioperative setting. , 2019, , .		0
1282	DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 75-86.	1.0	10
1283	Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety. <i>Annals of Pharmacotherapy</i> , 2019, 53, 726-737.	0.9	17
1284	Immune-inflammatory response after bioresorbable vascular scaffold implantation in patients with acute myocardial infarction with ST elevation in a long-term perspective. <i>Heart and Vessels</i> , 2019, 34, 557-563.	0.5	8
1285	Association of the CHA <sub>2</sub> DS <sub>2</sub> -VASc Score with Acute Stent Thrombosis in Patients with an ST Elevation Myocardial Infarction Who Underwent a Primary Percutaneous Coronary Intervention. <i>Medical Principles and Practice</i> , 2019, 28, 115-123.	1.1	11
1286	Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent. <i>Circulation</i> , 2019, 139, 67-77.	1.6	33
1287	Effects of Cilostazol-Based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation: An Updated Meta-Analysis of the Randomized Controlled Trials. <i>Clinical Drug Investigation</i> , 2019, 39, 1-13.	1.1	8
1288	Long-term outcome of brachytherapy treatment for coronary in-stent restenosis: Ten-year follow-up. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E211-E216.	0.7	1
1289	Patient and lesion characteristics in late/very late stent thrombosis with everolimus-eluting stents from real-world adverse event reporting. <i>Journal of Cardiology</i> , 2020, 75, 255-260.	0.8	9
1290	Long-term outcome in patients treated with first- versus second-generation drug-eluting stents for the treatment of unprotected left main coronary artery stenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 1085-1091.	0.7	4
1291	Acute and sub-acute stent thrombosis: Frequency, predictors and features in patients undergoing primary percutaneous intervention at a tertiary care cardiac centre. <i>IJC Heart and Vasculature</i> , 2020, 26, 100427.	0.6	10
1292	Association Between Plasma Trimethylamine N-oxide and Neoatherosclerosis in Patients With Very Late Stent Thrombosis. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1252-1260.	0.8	13
1293	Practical approach to blood compatibility assessments: General considerations and standards. , 2020, , 167-205.		0
1294	Long-Term Performance of the COMBO Dual-Therapy Stent: Results from the REMEDEE Registry. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 567-570.	0.3	3
1295	Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2251-2262.	1.1	70

#	ARTICLE	IF	CITATIONS
1296	Magmaris resorbable magnesium scaffolds: Are they here to stay?. <i>Revista Portuguesa De Cardiologia</i> , 2020, 39, 427-429.	0.2	0
1297	Endothelial progenitor cells as the target for cardiovascular disease prediction, personalized prevention, and treatments: progressing beyond the state-of-the-art. <i>EPMA Journal</i> , 2020, 11, 629-643.	3.3	17
1298	Impact of previous percutaneous coronary intervention on cardiovascular outcomes and mortality after lung cancer surgery: A nationwide study in Korea. <i>Thoracic Cancer</i> , 2020, 11, 2517-2528.	0.8	1
1301	The new era for research on polyphenols and food factors. <i>Archives of Biochemistry and Biophysics</i> , 2020, 696, 108678.	1.4	1
1302	Prodrugs for nitroreductase based cancer therapy-4: Towards prostate cancer targeting: Synthesis of N-heterocyclic nitro prodrugs, Ssap-NtrB enzymatic activation and anticancer evaluation. <i>Bioorganic Chemistry</i> , 2020, 105, 104450.	2.0	7
1304	P.603 Aggression, hostility and stress in relation to quality of life in breast cancer patients. <i>European Neuropsychopharmacology</i> , 2020, 40, S344-S345.	0.3	0
1305	P.659 Anxiolytic activity of risperidone co-treated with a selective 5-HT6 agonist, but not antagonist, in the rat conflict drinking Vogel test. <i>European Neuropsychopharmacology</i> , 2020, 40, S373.	0.3	0
1306	PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 431.e9-431.e13.	0.8	19
1307	Nystagmus induit par vibration: un test vestibulaire de d�pistage utile chez l'enfant malentendant. <i>Annales Francaises D'Oto-Rhino-Laryngologie Et De Pathologie Cervico-Faciale</i> , 2020, 137, 415-421.	0.0	0
1308	Experiences Aging With a Physical Disability During The COVID-19 Pandemic. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, e140.	0.5	0
1309	The Relationship Between Self-Identity, Self-Awareness, and Occupational Engagement in People with Traumatic Brain Injury: A Study Protocol. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, e152-e153.	0.5	0
1310	Assessing alcohol consumption through wastewater-based epidemiology: Spain as a case study. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108241.	1.6	30
1311	Adult patient living 32 years with postduodenal remnant small bowel of only 35 cm in jejunoileocolic anastomosis type II weaned off parenteral nutrition. A case report. <i>International Journal of Surgery Case Reports</i> , 2020, 74, 148-151.	0.2	0
1312	The contextual taphonomy of middens at Neolithic Kfar HaHoresh. <i>Journal of Archaeological Science: Reports</i> , 2020, 33, 102531.	0.2	2
1313	Myosins: Driving us towards novel targets and biomarkers in cancer. <i>International Review of Cell and Molecular Biology</i> , 2020, 356, 291-322.	1.6	0
1314	Assessing autophagic flux in yeast. <i>Methods in Cell Biology</i> , 2021, 164, 73-94.	0.5	1
1315	Hierarchical model form uncertainty quantification for turbulent combustion modeling. <i>Combustion and Flame</i> , 2020, 221, 288-295.	2.8	2
1316	Pan-european landscape of research into neurodevelopmental copy number variants: A survey by the MINDDS consortium. <i>European Journal of Medical Genetics</i> , 2020, 63, 104093.	0.7	2

#	ARTICLE	IF	CITATIONS
1317	Evaluation of comprehensive annual care plans by pharmacists in Alberta for patients with complex conditions. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 1029-1036.e1.	0.7	3
1318	A rare condition: Spontaneous subarachnoid haemorrhage due to spinal hemangioblastoma: Report of 2 cases and review of the literature. <i>Neurochirurgie</i> , 2020, 66, 359-364.	0.6	6
1319	Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease. <i>Annals of Medicine and Surgery</i> , 2020, 60, 413-416.	0.5	43
1320	Pore structure and plutonium retention in fractal-like (Ce Al)-oxide Laponite clusters. <i>Applied Clay Science</i> , 2020, 198, 105799.	2.6	6
1321	Parasites of an Arctic scavenger; the wolverine ( <i>Gulo gulo</i> ). <i>International Journal for Parasitology: Parasites and Wildlife</i> , 2020, 13, 178-185.	0.6	2
1323	Is there inter-observer variation in the interpretation of SSEPs in comatose cardiac arrest survivors? Further considerations following the Italian multicenter ProNeCa study. <i>Resuscitation</i> , 2020, 155, 207-210.	1.3	4
1324	Sorting an array using the topological sort of a corresponding comparison graph. <i>Theoretical Computer Science</i> , 2020, 845, 76-97.	0.5	2
1325	Study on temperature characteristics and correction of strain gauge balance in actual airflow environment. <i>Aerospace Science and Technology</i> , 2020, 106, 106201.	2.5	5
1326	Triple RNA-Seq Reveals Synergy in a Human Virus-Fungus Co-infection Model. <i>Cell Reports</i> , 2020, 33, 108389.	2.9	25
1327	Resistance to type A insulin: A new mutation of the receptor gene of the insulin described. <i>EndocrinologÃa Diabetes Y NutriciÃn (English Ed )</i> , 2020, 67, 611-612.	0.1	0
1329	The attitude and psychological status of medical staff in China during the COVID-19 outbreak: a cross-sectional survey. <i>Lancet, The</i> , 2020, 396, S2.	6.3	3
1333	Diagnostic and prognostic significance of carotid doppler ultrasonography in diabetic atherosclerosis. <i>Atherosclerosis</i> , 2020, 315, e52.	0.4	0
1334	The next step in the clinical use of microRNAs: The elimination of heparin interference. <i>Atherosclerosis</i> , 2020, 315, e191.	0.4	0
1335	Molecular characterization of patients with and without coronary artery disease with â€œextreme LDL-C phenotypesâ€•. <i>Atherosclerosis</i> , 2020, 315, e222.	0.4	0
1336	Audit of the excision of non-melanoma skin cancers (NMSCs) of the head and neck. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2020, 58, e147.	0.4	0
1337	Mortality Due to Mitral Regurgitation Among Adults in the United States: 1999-2018. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2633-2643.	1.4	10
1340	Submissions to Space Research Today. <i>Space Research Today</i> , 2020, 209, 47-48.	1.0	0
1341	Demographics and Outcomes of Interhospital Neurosurgical Transfer Patients Undergoing Spine Surgery. <i>World Neurosurgery</i> , 2020, 144, e221-e226.	0.7	9

#	ARTICLE	IF	CITATIONS
1342	Minimally invasive plate osteosynthesis (MIPO) for mid-shaft fracture of the tibia (AO/OTA) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 742 Td	0.5	5
1346	Differential response to PCSK-9 inhibitor therapy is related to the type of low density lipoprotein receptor gene mutation in patients with homozygous familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2020, 315, e42.	0.4	0
1347	Effects of L-carnitine supplementation on oxidative and metabolic status in patients with type 2 diabetes mellitus: A randomized, double-blind, clinical trial. <i>European Journal of Integrative Medicine</i> , 2020, 40, 101243.	0.8	1
1349	Severe acute respiratory syndrome coronavirus 2 infection prevention in orthodontic practice. <i>American Journal of Orthodontics and Dentofacial Orthopedics</i> , 2020, 158, 777-779.	0.8	1
1351	Unspoken dialogues between educational and family language policies: Language policy beyond legislations. <i>Linguistics and Education</i> , 2020, 60, 100876.	0.5	11
1352	Positioning global pharmacy research partnerships to advance health equity. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1619-1621.	1.5	1
1353	13568 Efficacy of ALA-PDT in the treatment of actinic keratoses on the upper extremities: A post hoc analysis of a phase 3, randomized, vehicle-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB8.	0.6	0
1354	15059 Baricitinib, an oral reversible Janus kinase 1 and 2 inhibitor, for atopic dermatitis: Head and neck response across two phase 3 studies. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB28.	0.6	0
1355	15302 Psoriasis area and severity index component improvements at week 48 in patients treated with guselkumab compared with secukinumab: Findings from the ECLIPSE study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB34.	0.6	2
1356	15340 Long-term treatment with secukinumab led to sustained clinical improvement and normalization of inflammatory markers in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB37.	0.6	3
1357	Confidence toward vaccination as reported by parents of children admitted to a tertiary care hospital in Riyadh, Saudi Arabia: A cross sectional study. <i>Vacunas (English Edition)</i> , 2020, 21, 95-104.	0.3	1
1358	Insights on the molecular structure evolution for tricalcium silicate and slag composite: From <sup>29</sup> Si and <sup>27</sup> Al NMR to molecular dynamics. <i>Composites Part B: Engineering</i> , 2020, 202, 108401.	5.9	45
1359	Pore-throat structure characteristics and its effect on flow behavior in Gaotaizi tight siltstone reservoir, northern Songliao Basin. <i>Marine and Petroleum Geology</i> , 2020, 122, 104651.	1.5	25
1360	Blood oxytocin levels are not associated with ADHD tendencies and emotionality in healthy adults. <i>Neuroscience Letters</i> , 2020, 738, 135312.	1.0	1
1361	Mitofusion Underlines the Ability of Mitochondrial Peptide MOTS-c to Prompt GLUT4 Translocation. <i>Free Radical Biology and Medicine</i> , 2020, 159, S65.	1.3	0
1363	Estado actual y perspectivas futuras en el manejo de la hipertensi3n intracraneal posterior a traumatismo craneoencefalico: craniectom4a descompresiva, hipotermia terap4utica y barbit4ricos. <i>Neurolog4a</i> , 2023, 38, 357-363.	0.3	5
1364	Evaluation of thoracic kyphosis and lumbar lordosis in adolescents. <i>Gait and Posture</i> , 2020, 81, 186.	0.6	0
1366	Propranolol Off-Target: A New Therapeutic Option in Neutrophil-Dependent Dermatoses?. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2326-2329.	0.3	0



#	ARTICLE	IF	CITATIONS
1367	Early Outcomes in the ROADSTER 2 Study of Transcarotid Artery Revascularization in Patients With Significant Carotid Artery Disease. <i>Journal of Vascular Surgery</i> , 2020, 72, 2208.	0.6	1
1368	An experimental investigation into performance characteristics of H-shaped and Savonius-type VAWT rotors. <i>Scientific African</i> , 2020, 10, e00603.	0.7	6
1369	Erythrocytosis induced by sodium-glucose cotransporter-2 inhibitors. <i>Cmaj</i> , 2020, 192, E1271-E1271.	0.9	6
1370	Business intelligence and analytics as a driver of dynamic and operational capabilities in times of intense macroeconomic turbulence. <i>Journal of High Technology Management Research</i> , 2020, 31, 100389.	2.7	7
1371	Hierarchical Bayesian parameter estimation for cumulative prospect theory. <i>Journal of Mathematical Psychology</i> , 2020, 98, 102429.	1.0	4
1372	The safety and efficacy of prolonged use of one-way speaking valves. <i>Australian Critical Care</i> , 2021, 34, 319-326.	0.6	4
1373	Featuring the radiative transmission of energy in viscoelastic nanofluid with swimming microorganisms. <i>International Communications in Heat and Mass Transfer</i> , 2020, 117, 104788.	2.9	5
1374	Enhancing oxygen reduction activity and CO <sub>2</sub> -tolerance of A-site-deficient BaCo <sub>0.7</sub> Fe <sub>0.3</sub> O <sub>3-<math>\delta</math></sub> cathode by surface-decoration with Pr <sub>6</sub> O <sub>11</sub> particles. <i>International Journal of Hydrogen Energy</i> , 2020, 45, 31070-31079.	3.8	8
1375	Recent developments in model-based fault detection and diagnostics of gas pipelines under transient conditions. <i>Journal of Natural Gas Science and Engineering</i> , 2020, 83, 103550.	2.1	19
1376	Simulation of multi-annual time series of solar photovoltaic power: Is the ERA5-land reanalysis the next big step?. <i>Sustainable Energy Technologies and Assessments</i> , 2020, 42, 100829.	1.7	19
1377	Associations of myeloperoxidase, interleukin-17A and heparin-binding EGF-like growth factor levels with in-stent restenosis after percutaneous coronary intervention: a single-centre caseâ€“control study in China. <i>BMJ Open</i> , 2020, 10, e039405.	0.8	7
1378	Quantum-light shaping and quantum spectroscopy in semiconductors. <i>Semiconductors and Semimetals</i> , 2020, , 417-460.	0.4	4
1379	Multi-constraints adaptive finite-time integrated guidance and control design. <i>Aerospace Science and Technology</i> , 2020, 107, 106334.	2.5	19
1380	High performance of ceramic current collector fabricated at 550Â°C through in-situ joining of reduced Mn <sub>1.5</sub> Co <sub>1.5</sub> O <sub>4</sub> for metal-supported solid oxide fuel cells. <i>International Journal of Hydrogen Energy</i> , 2020, 45, 29123-29130.	3.8	7
1381	Toxic metals in top selling cigarettes sold in China: Pulmonary bioaccessibility using simulated lung fluids and fuzzy health risk assessment. <i>Journal of Cleaner Production</i> , 2020, 275, 124131.	4.6	11
1383	Individual and environmental dimensions influencing the middle managersâ€™ contribution to safety: the emergence of a â€“safety-related universeâ€™. <i>Safety Science</i> , 2020, 132, 104946.	2.6	2
1386	Asthma and emphysema overlap in nonsmokers. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 711-713.	0.5	0
1387	Modeled economic potential for Eucalyptus spp. production for jet fuel additives in the United States. <i>Biomass and Bioenergy</i> , 2020, 143, 105807.	2.9	2

#	ARTICLE	IF	CITATIONS
1388	Formation mechanisms of surface passivating phases and their impact on the kinetics of galena leaching in ferric chloride, ferric perchlorate, and ferric nitrate solutions. <i>Hydrometallurgy</i> , 2020, 197, 105468.	1.8	8
1389	Selective electrocatalytic reduction of carbon dioxide to formate by a trimetallic Sn-Co/Cu foam electrode. <i>Journal of Electroanalytical Chemistry</i> , 2020, 877, 114623.	1.9	7
1391	Titanium-Nitride-Oxide-Coated Versus Everolimus-Eluting Stents in Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1697-1705.	1.1	27
1394	Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953). <i>European Journal of Cancer</i> , 2020, 138, S7.	1.3	3
1395	Tinagl1 gene therapy for tumor-wide remodeling of triple negative breast cancer. <i>European Journal of Cancer</i> , 2020, 138, S37-S38.	1.3	0
1396	Linking Functional Independence Measure Scores and Spinal Cord Injury Functional Index Assistive Technology Scores: Looking Backward and Moving Forward. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, e29.	0.5	0
1397	Pharmacological Interventions for Reducing Intracranial Pressure After Traumatic Brain Injury: An Overview of Systematic Reviews with Randomized Controlled Trials. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, e112-e113.	0.5	0
1398	Heterostructural Co/CeO <sub>2</sub> /Co <sub>2</sub> P/CoP@NC dodecahedrons derived from CeO <sub>2</sub> -inserted zeolitic imidazolate framework-67 as efficient bifunctional electrocatalysts for overall water splitting. <i>International Journal of Hydrogen Energy</i> , 2020, 45, 30559-30570.	3.8	28
1399	Workflow Applications of Artificial Intelligence in Radiology and an Overview of Available Tools. <i>Journal of the American College of Radiology</i> , 2020, 17, 1363-1370.	0.9	25
1400	Multiparametric Cardiac Magnetic Resonance for Chronic Kidney Disease. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2368-2370.	2.3	0
1401	Protocolo diagnóstico de la disfagia. <i>Medicine</i> , 2020, 13, 405-408.	0.0	0
1402	Long-Term Survival After Surgical or Percutaneous Revascularization in Patients With Diabetes and Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1153-1164.	1.2	48
1403	In vivo biological safety evaluation of an iron-based bioresorbable drug-eluting stent. <i>BioMetals</i> , 2020, 33, 217-228.	1.8	9
1404	Final five-year results of the REMEDEE Registry: Real-world experience with the dual-therapy COMBO stent. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 98, 503-510.	0.7	6
1406	The Accuracy of Trade Classification Systems on the Foreign Exchange Market: Evidence from the RUB/USD Market. <i>Finance Research Letters</i> , 2020, , 101892.	3.4	1
1407	Critical analysis of the quality of internet resources for patients with varicose veins. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021, 9, 1017-1024.e7.	0.9	8
1408	Teaching How to Practice Ethics During Simulation: Exploring Clinical Nurse Educators'™ Experiences. <i>Clinical Simulation in Nursing</i> , 2020, 47, 57-59.	1.5	0
1409	Birth weight, Apgar score, and fetal complications in mothers with severe preeclampsia. <i>Enfermería Clínica</i> , 2020, 30, 533-536.	0.1	3

#	ARTICLE	IF	CITATIONS
1410	The Impact of Surface Structure Transformations on the Performance of Li-Excess Cation-Disordered Rocksalt Cathodes. <i>Cell Reports Physical Science</i> , 2020, 1, 100187.	2.8	20
1411	m6A Regulates Liver Metabolic Disorders and Hepatogenous Diabetes. <i>Genomics, Proteomics and Bioinformatics</i> , 2020, 18, 371-383.	3.0	49
1413	Reply to the letter to the editor: DPD testing in radical chemoradiation for anal squamous cell carcinoma? by R. Muirhead, H. Jones, D. Gilbert, A. Gilbert & C. Jacobs. <i>Annals of Oncology</i> , 2020, 31, 1587-1588.	0.6	1
1414	The pharmacokinetic and pharmacodynamic relationship between apraglutide and citrulline: a randomized, placebo-controlled, double-blind study in healthy volunteers. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 413-414.	0.5	2
1415	Determinants of Anorexia at admission to the geriatric hospital. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 528.	0.5	0
1416	Relationship between adjusted skeletal muscle index and the proportion of macronutrients intake in breast cancer patients in indonesia. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 551.	0.5	0
1417	Performance of the healthy lifestyle index (HLI) and predimed in comparison with the 2018 WCRF/AICR score™. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 562.	0.5	0
1418	The self evaluation of food intake (SEFI®) as a screening test for hospital malnutrition in children over 10 years. preliminary results.. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 573.	0.5	1
1419	Early weight gain trajectories and body composition in infancy in very preterm infants. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 576-577.	0.5	0
1420	Pyro processing cement kiln bypass dust: Enhancing clinker phase formation. <i>Construction and Building Materials</i> , 2020, 259, 120420.	3.2	11
1421	Severe anemia in a patient with vulvar melanoma. <i>Surgery</i> , 2020, 168, e21-e22.	1.0	2
1422	Antibiotic Stewardship for Nursing: Can E-Learning Be a First Step?. <i>American Journal of Infection Control</i> , 2020, 48, S15.	1.1	0
1423	Impact of COVID-19 pandemic on patients with rare disease in Hong Kong. <i>European Journal of Medical Genetics</i> , 2020, 63, 104062.	0.7	42
1425	Testosterone regulates the intracellular bacterial community formation of uropathogenic <i>Escherichia coli</i> in prostate cells via STAT3. <i>International Journal of Medical Microbiology</i> , 2020, 310, 151450.	1.5	11
1426	Glycerol-assisted one-step instant catapult steam explosion enhances enzymatic digestibility of corn stover. <i>Industrial Crops and Products</i> , 2020, 157, 112907.	2.5	5
1427	An Augmented Reality Framework for Robotic Tool-path Teaching. <i>Procedia CIRP</i> , 2020, 93, 1218-1223.	1.0	13
1429	Psychological distress among young adults exposed to armed conflict in Kashmir. <i>Children and Youth Services Review</i> , 2020, 118, 105460.	1.0	7
1430	CNN Inference acceleration using low-power devices for human monitoring and security scenarios. <i>Computers and Electrical Engineering</i> , 2020, 88, 106859.	3.0	9

#	ARTICLE	IF	CITATIONS
1431	Towards interoperable research site documentation – Recommendations for information models and data provision. <i>Ecological Informatics</i> , 2020, 60, 101158.	2.3	4
1432	Oxygen isotope study of the Asuka-881020 CH chondrite I: Non-porphyrinic chondrules. <i>Geochimica Et Cosmochimica Acta</i> , 2020, 290, 180-200.	1.6	4
1433	Enterocytozoon bienewsi in raw milk of cattle, sheep and water buffalo in Turkey: Genotype distributions and zoonotic concerns. <i>International Journal of Food Microbiology</i> , 2020, 334, 108828.	2.1	15
1434	Utilization of waste heat from commercial kitchen exhaust for water heating and dish drying. <i>Journal of Building Engineering</i> , 2020, 32, 101788.	1.6	5
1437	Same-sex sexual behaviour. <i>Current Biology</i> , 2020, 30, R1345-R1346.	1.8	2
1438	Plant Biology: BASL Gives the Plant Nucleus a Sense of Direction. <i>Current Biology</i> , 2020, 30, R1375-R1377.	1.8	4
1439	Determinants of Nutritional Status in School-Aged Children in Mecha, Northwest Ethiopia. <i>Current Therapeutic Research</i> , 2020, 93, 100598.	0.5	5
1442	Nouveau traitement pour l'arthropathie chronique pédiatrique. <i>Revue Francophone Des Laboratoires</i> , 2020, 2020, 11.	0.0	0
1444	An RCT of Rapid Genomic Sequencing among Seriously Ill Infants Results in High Clinical Utility, Changes in Management, and Low Perceived Harm. <i>American Journal of Human Genetics</i> , 2020, 107, 942-952.	2.6	110
1445	155 Using Point-of-Care Ultrasound to Predict Clinical Outcomes in Patients With COVID-19. <i>Annals of Emergency Medicine</i> , 2020, 76, S60-S61.	0.3	0
1446	291 Firearm Presence and Storage in Rural Youth Homes. <i>Annals of Emergency Medicine</i> , 2020, 76, S112-S113.	0.3	0
1447	A look into the link between centrosome amplification and breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2020, 132, 110924.	2.5	10
1448	Dynamics of cytokines, immune cell counts and disease severity in patients with community-acquired pneumonia – Unravelling potential causal relationships. <i>Cytokine</i> , 2020, 136, 155263.	1.4	6
1449	Between-session reliability of subject-specific musculoskeletal models of the spine derived from optoelectronic motion capture data. <i>Journal of Biomechanics</i> , 2020, 112, 110044.	0.9	18
1455	Hippocampal and parahippocampal volumes vary by sex and traumatic life events in children. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, 288-297.	1.4	7
1456	Lockdowns across Europe. <i>New Scientist</i> , 2020, 248, 7-9.	0.0	0
1457	Otite externe fongique aspergillaire avec atteinte temporo-mandibulo-zygomatique. <i>Annales Francaises D'Oto-Rhino-Laryngologie Et De Pathologie Cervico-Faciale</i> , 2020, 137, 126-128.	0.0	0
1458	Ghrelin uses the GHS-R1a/Gi/cAMP pathway and induces differentiation only in mature osteoblasts. This ghrelin pathway is impaired in AIS patients. <i>Biochemistry and Biophysics Reports</i> , 2020, 24, 100782.	0.7	2

#	ARTICLE	IF	CITATIONS
1459	Assessment of the potential of combining wave and solar energy resources to power supply worldwide offshore oil and gas platforms. <i>Energy Conversion and Management</i> , 2020, 223, 113299.	4.4	40
1460	Accurate quantum-corrected cubic equations of state for helium, neon, hydrogen, deuterium and their mixtures. <i>Fluid Phase Equilibria</i> , 2020, 524, 112790.	1.4	14
1461	Compression and rebound characteristics of agricultural sandy pasture soils from South Greenland. <i>Geoderma</i> , 2020, 380, 114608.	2.3	11
1462	Very late-phase vascular response after everolimus-eluting stent implantation assessed by optical coherence tomography. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 1627-1635.	0.7	0
1463	Sirolimus-Eluting Electrospun-Produced Matrices as Coatings for Vascular Stents: Dependence of Drug Release on Matrix Structure and Composition of the External Environment. <i>Materials</i> , 2020, 13, 2692.	1.3	7
1464	Efficacy and safety of standard and low dose ticagrelor versus clopidogrel in east Asian Patients with chronic total occlusion undergoing percutaneous coronary intervention: a single center retrospective study. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 109.	0.7	7
1465	Percutaneous coronary intervention for left main stem disease: Impact of diabetes mellitus on mortality. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E416-E422.	0.7	3
1466	Stability and bioactivity of pepCD47 attachment on stainless steel surfaces. <i>Acta Biomaterialia</i> , 2020, 104, 231-240.	4.1	7
1467	A scoring system to predict the occurrence of very late stent thrombosis following percutaneous coronary intervention for acute coronary syndrome. <i>Scientific Reports</i> , 2020, 10, 6378.	1.6	4
1468	Duration of dual antiplatelet therapy in patients with acute coronary syndrome undergoing drug-eluting stent implantation: A meta-analysis. <i>Journal of International Medical Research</i> , 2020, 48, 030006052091505.	0.4	0
1469	World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI. <i>Global Heart</i> , 2020, 9, 457.	0.9	34
1471	New soliton wave structures of nonlinear (4+1)-dimensional Fokas dynamical model by using different methods. <i>AEJ - Alexandria Engineering Journal</i> , 2021, 60, 795-803.	3.4	26
1472	Hourly performance forecast of a dew point cooler using explainable Artificial Intelligence and evolutionary optimisations by 2050. <i>Applied Energy</i> , 2021, 281, 116062.	5.1	26
1473	Galvanic oxidation of bimetallic Zn-Fe nanoparticles for oxygen scavenging. <i>Applied Surface Science</i> , 2021, 537, 147896.	3.1	7
1474	To the self and beyond: Arousal and functional connectivity of the temporo-parietal junction contributes to spontaneous sensations perception. <i>Behavioural Brain Research</i> , 2021, 396, 112880.	1.2	13
1475	Analysis of bile acid profile in plasma to differentiate cholangiocarcinoma from benign biliary diseases and healthy controls. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 205, 105775.	1.2	22
1476	Comparación de las características demográficas y comorbilidad de los pacientes con COVID-19 fallecidos en hospitales españoles, en función de si ingresaron o no en Cuidados Intensivos. <i>Medicina Intensiva</i> , 2021, 45, 14-26.	0.4	7
1477	Agent-based modeling of supply disruptions in the global rare earths market. <i>Resources, Conservation and Recycling</i> , 2021, 164, 105193.	5.3	16

#	ARTICLE	IF	CITATIONS
1478	Influence of pH, ionic strength and isoascorbic acid on the gel-forming ability of Jumbo squid muscle ( <i>Dosidicus gigas</i> ). <i>Food Chemistry</i> , 2021, 337, 127993.	4.2	2
1479	Changes in heterotrophic microbial communities induced by biocidal treatments in the Monastery of San Marti�o Pinario (Santiago de Compostela, NW Spain). <i>International Biodeterioration and Biodegradation</i> , 2021, 156, 105130.	1.9	15
1480	Multiple ionisation and Coulomb explosion in terawatt photoexcitation of Xenon clusters: An experimental and theoretical study. <i>Journal of Photochemistry and Photobiology A: Chemistry</i> , 2021, 404, 112884.	2.0	3
1481	Mode displaying mouse cursors for reducing input language mode confusion: Utility and user attitude evaluation. <i>Applied Ergonomics</i> , 2021, 90, 103170.	1.7	0
1482	Childhood obesity may accelerate timing of human facial growth. <i>Archives of Oral Biology</i> , 2021, 121, 104964.	0.8	6
1483	Highly specific, quantitative polymerase chain reaction probe for the quantification of human cells in cynomolgus monkeys. <i>Drug Metabolism and Pharmacokinetics</i> , 2021, 36, 100359.	1.1	3
1484	Late-Gadolinium Enhancement Interface Area and Electrophysiological Simulations Predict Arrhythmic Events in Patients With Nonischemic Dilated Cardiomyopathy. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 238-249.	1.3	13
1486	Stressor, coping mechanism, and motivation among health care workers in dealing with stress due to the COVID-19 pandemic in Indonesia. <i>Asian Journal of Psychiatry</i> , 2021, 56, 102470.	0.9	32
1487	Diagenetic evolution and densification mechanism of the Upper Paleozoic tight sandstones in the Ordos Basin, Northern China. <i>Journal of Asian Earth Sciences</i> , 2021, 205, 104613.	1.0	22
1488	Obesity alters <i>Ace2</i> and <i>Tmprss2</i> expression in lung, trachea, and esophagus in a sex-dependent manner: Implications for COVID-19. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 92-96.	1.0	30
1489	Clinical outcomes after percutaneous coronary intervention for early versus late and very late stent thrombosis: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 682-692.	1.0	6
1490	Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management. <i>Nature Reviews Cardiology</i> , 2021, 18, 37-57.	6.1	42
1491	Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent. <i>American Heart Journal</i> , 2021, 231, 147-156.	1.2	21
1492	Stabilization of inertial Cohen-Grossberg neural networks with generalized delays: A direct analysis approach. <i>Chaos, Solitons and Fractals</i> , 2021, 142, 110432.	2.5	25
1493	Experimental and finite element study of high-strength steel framed-tube structures with replaceable shear links under cyclic loading. <i>Structures</i> , 2021, 29, 48-64.	1.7	10
1494	Role of multimodality imaging in evaluation of cardiovascular involvement in COVID-19. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 8-16.	2.3	32
1496	Utilization and assessment of recycled polyethylene terephthalate strapping bands as lightweight aggregates in Eco-efficient composite mortars. <i>Construction and Building Materials</i> , 2021, 270, 121427.	3.2	16
1497	A multimodal fake news detection model based on crossmodal attention residual and multichannel convolutional neural networks. <i>Information Processing and Management</i> , 2021, 58, 102437.	5.4	97

#	ARTICLE	IF	CITATIONS
1498	Impact of coronavirus pandemic crisis on technologies and cloud computing applications. Journal of Electronic Science and Technology, 2021, 19, 100059.	2.0	67
1499	Distance decay of benthic macroinvertebrate communities in a mountain river network: Do dispersal routes and dispersal ability matter?. Science of the Total Environment, 2021, 758, 143630.	3.9	12
1500	Optimizing Surgical Techniques in Robot-Assisted Radical Prostatectomy. Urologic Clinics of North America, 2021, 48, 1-9.	0.8	3
1501	Investigation on a gas-atomized spray cooling upon flat and micro-structured surfaces. International Journal of Thermal Sciences, 2021, 161, 106751.	2.6	50
1503	Climatology and trends of downward shortwave radiation over Brazil. Atmospheric Research, 2021, 250, 105347.	1.8	18
1504	Statehood experience and income inequality: A historical perspective. Economic Modelling, 2021, 94, 415-429.	1.8	24
1505	High-dimensional brain-wide functional connectivity mapping in magnetoencephalography. Journal of Neuroscience Methods, 2021, 348, 108991.	1.3	4
1506	Mapping functional diversity using individual tree-based morphological and physiological traits in a subtropical forest. Remote Sensing of Environment, 2021, 252, 112170.	4.6	46
1507	Environmental Protection Requires Accurate Application of Scientific Evidence. Trends in Ecology and Evolution, 2021, 36, 14-15.	4.2	4
1508	Polyelectrolyte complex templated synthesis of monodisperse, sub-100Ånm porous silica nanoparticles for cancer targeted and stimuli-responsive drug delivery. Journal of Colloid and Interface Science, 2021, 584, 669-683.	5.0	11
1509	Evaluation of subsurface damage layer of BK7 glass via cross-sectional surface nanoindentation. Precision Engineering, 2021, 67, 293-300.	1.8	4
1510	Glyphosate targets fish monoaminergic systems leading to oxidative stress and anxiety. Environment International, 2021, 146, 106253.	4.8	47
1511	Radiomics nomogram: A noninvasive tool for preoperative evaluation of the invasiveness of pulmonary adenocarcinomas manifesting as ground-glass nodules. Translational Oncology, 2021, 14, 100936.	1.7	12
1513	Comparison of surface modification and deuterium retention in W and W-Cr alloy film under high energy deuterium ion implantation. Fusion Engineering and Design, 2021, 162, 112082.	1.0	9
1514	From rock eating to vegetarian ecosystems â€” Disentangling processes of phosphorus acquisition across biomes. Geoderma, 2021, 388, 114827.	2.3	22
1515	Domain wall motion induced magnetophoresis in unpatterned perpendicular magnetic anisotropy Co layers with Dzyaloshinskii-Moriya interactions. Journal of Magnetism and Magnetic Materials, 2021, 519, 167454.	1.0	1
1516	Are there urban-rural gaps in Spaniards financial knowledge?. Journal of Rural Studies, 2021, 81, 363-373.	2.1	4
1517	Short communication: Chemical structure, concentration, and pH are key factors influencing antimicrobial activity of conjugated bile acids against lactobacilli. Journal of Dairy Science, 2021, 104, 1524-1530.	1.4	4





#	ARTICLE	IF	CITATIONS
1538	Defect-deferred correction method based on a subgrid artificial viscosity model for fluid-fluid interaction. <i>Applied Numerical Mathematics</i> , 2021, 160, 178-191.	1.2	9
1539	Treatment of iron ore beneficiation plant process water by electrocoagulation. <i>Arabian Journal of Chemistry</i> , 2021, 14, 102902.	2.3	16
1540	Machine learning based quantitative texture analysis of CT images for diagnosis of renal lesions. <i>Biomedical Signal Processing and Control</i> , 2021, 64, 102311.	3.5	2
1541	Legality requirements for wood import in the EU: Who wins, who loses?. <i>Forest Policy and Economics</i> , 2021, 123, 102338.	1.5	6
1542	A parametric study of dehydrogenation of various Liquid Organic Hydrogen Carrier (LOHC) materials and its application to methanation process. <i>International Journal of Hydrogen Energy</i> , 2021, 46, 4100-4115.	3.8	21
1543	Inkjet-printing-derived lead-zirconate-titanate-based thick films for printed electronics. <i>Materials and Design</i> , 2021, 198, 109324.	3.3	10
1544	Role of Resection in Glioblastoma Management. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 9-22.	0.8	14
1545	The water, energy, and land footprint of tilapia aquaculture in Mexico, a comparison of the footprints of fish and meat. <i>Resources, Conservation and Recycling</i> , 2021, 165, 105224.	5.3	20
1547	Evaluating skin cancer chemopreventive potential of water extract of <i>Syzygium samarangense</i> leaves through activation of the Nrf2-mediated cellular defense system. <i>South African Journal of Botany</i> , 2021, 137, 303-310.	1.2	6
1548	Delayed postoperative radiotherapy might improve the long-term prognosis of locally advanced esophageal squamous cell carcinoma. <i>Translational Oncology</i> , 2021, 14, 100956.	1.7	0
1549	Ocular manifestations of SARS-CoV-2: Literature review. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2021, 96, 32-40.	0.1	8
1550	Seropositivity of Visceral leishmaniasis on people of VL endemic three districts of Nepal. <i>Parasitology International</i> , 2021, 80, 102236.	0.6	2
1551	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , 2021, 121, 422-432.	1.8	149
1552	The Burden of Fingertip Trauma on the US Military. <i>Hand Clinics</i> , 2021, 37, 155-165.	0.4	6
1553	Thermal-fluid-structure analysis of fast pressure relief valve under severe nuclear accident. <i>Nuclear Engineering and Design</i> , 2021, 371, 110937.	0.8	13
1554	The Impact of Author Financial Conflicts on Robotic-Assisted Joint Arthroplasty Research. <i>Journal of Arthroplasty</i> , 2021, 36, 1462-1469.	1.5	29
1556	Imported intermediates, technological capabilities and exports: Evidence from Brazilian firm-level data. <i>Research Policy</i> , 2021, 50, 104141.	3.3	8
1557	Induced bioresistance via BNP detection for machine learning-based risk assessment. <i>Biosensors and Bioelectronics</i> , 2021, 175, 112903.	5.3	5

#	ARTICLE	IF	CITATIONS
1558	Development of optimal energy management for a residential fuel cell hybrid power system with heat recovery. <i>Energy</i> , 2021, 219, 119499.	4.5	24
1559	Dark, singular, bright, rational and periodic solutions of the space-time fractional Fokas-Lenells equation by the $\hat{I}_t^\alpha$ -model expansion method. <i>Optik</i> , 2021, 228, 165843.	1.4	18
1560	The Case   A man with acute bilateral urolithiasis. <i>Kidney International</i> , 2021, 99, 1029-1030.	2.6	0
1561	Producing crispy chickpea snacks by air, freeze, and microwave multi-flash drying. <i>LWT - Food Science and Technology</i> , 2021, 140, 110781.	2.5	8
1563	On $\hat{I}_t^\alpha$ -bounded and M-compact reflections of topological spaces. <i>Topology and Its Applications</i> , 2021, 289, 107547.	0.2	2
1564	sBCB (standardized Burn-Crack-Burn): A standardized modification of burning method for otolith age estimation. <i>Fisheries Research</i> , 2021, 233, 105767.	0.9	3
1565	Formulated protein-polysaccharide-surfactant ternary complexes for co-encapsulation of curcumin and resveratrol: Characterization, stability and in vitro digestibility. <i>Food Hydrocolloids</i> , 2021, 111, 106265.	5.6	39
1566	Cross-resistance of cisplatin selected cells to anti-microtubule agents: Role of general survival mechanisms. <i>Translational Oncology</i> , 2021, 14, 100917.	1.7	8
1567	A system of quantities from software metrology. <i>Measurement: Journal of the International Measurement Confederation</i> , 2021, 168, 108435.	2.5	3
1568	Durable fluorinated-SiO <sub>2</sub> /epoxy superhydrophobic coatings on polycarbonate with strong interfacial adhesion enhanced by solvent-induced crystallization. <i>Progress in Organic Coatings</i> , 2021, 150, 106002.	1.9	13
1569	Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 454-465.	1.0	14
1570	Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences. <i>Korean Circulation Journal</i> , 2021, 51, 202.	0.7	27
1571	Is This a Good Time to Revisit the Tropics?. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 428-430.	1.1	1
1572	The advantage of surgical revascularization in diabetic patients with multivessel disease: More arterial conduits, more benefit. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 119-122.	0.4	4
1573	Primer Per $\frac{1}{4}$ tan Koroner Girişim Yapılan Hastalarda Akut Stent Trombozunu Önlemek İçin R2CHA2DS2-VASc Skoru ile CHA2DS2-VASc Skorları Arasındaki Karşılaştırmalı İnceleme. <i>Acta Medica Alanya</i> , 0, , .	0.2	0
1574	Construction of biological factor-coated stent and its effect on promoting endothelialization. <i>Materials Science and Engineering C</i> , 2021, 122, 111943.	3.8	7
1575	Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E188-E196.	0.7	6
1576	Biosafety and efficacy evaluation of a biodegradable magnesium-based drug-eluting stent in porcine coronary artery. <i>Scientific Reports</i> , 2021, 11, 7330.	1.6	12

#	ARTICLE	IF	CITATIONS
1577	Prediction of Coronary Stent Underexpansion by Pre-Procedural Intravascular Ultrasound-Based Deep Learning. JACC: Cardiovascular Interventions, 2021, 14, 1021-1029.	1.1	26
1578	The Development of an ex vivo Flow System to Assess Acute Arterial Drug Retention of Cardiovascular Intravascular Devices. Frontiers in Medical Technology, 2021, 3, 675188.	1.3	4
1579	Coronary Stent Healing in Cancer Patients—An Optical Coherence Tomography Perspective. Frontiers in Cardiovascular Medicine, 2021, 8, 665303.	1.1	3
1580	Vascular remodeling after everolimus-eluting stent implantation in non-ST segment elevation acute coronary syndrome: optical coherence tomography. Complex Issues of Cardiovascular Diseases, 2021, 10, 60-71.	0.3	0
1581	Provisional drug-coated balloon treatment guided by physiology on de novo coronary lesion. Cardiology Journal, 2021, 28, 615-622.	0.5	6
1582	A mechanistic analysis of delamination of elastic coatings from the surface of plastically deformed stents. International Journal of Solids and Structures, 2021, 224, 111051.	1.3	4
1583	The importance of proximal optimization technique with intravascular imaging guided for stenting unprotected left main distal bifurcation lesions: The Milan and New Tokyo registry. Catheterization and Cardiovascular Interventions, 2021, 98, E814-E822.	0.7	4
1584	Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention. BMC Cardiovascular Disorders, 2021, 21, 435.	0.7	7
1585	Evaluation of cellular response and drug delivery efficacy of nanoporous stainless steel material. Biomaterials Research, 2021, 25, 30.	3.2	8
1586	Exploring the best monochromatic energy level in dual energy spectral imaging for coronary stents after percutaneous coronary intervention. Scientific Reports, 2021, 11, 17576.	1.6	3
1587	Antiplatelet Therapy After Percutaneous Coronary Intervention—Past, Current and Future Perspectives. Circulation Journal, 2021, , .	0.7	1
1588	Impact of intravascular ultrasound and final kissing balloon dilatation on long-term clinical outcome in percutaneous revascularization with 1-stent strategy for left main coronary artery stenosis in drug-eluting stent era. Coronary Artery Disease, 2022, 33, 9-17.	0.3	2
1589	Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. International Journal of Cardiology, 2013, 167, 575-584.	0.8	87
1590	Coronary Stents. , 2019, , 1-13.		1
1591	Coating homogeneity in the manufacture of Drug-Eluting Stents. IFMBE Proceedings, 2009, , 2240-2243.	0.2	1
1592	Biomechanical Aspects of Potential Stent Malapposition at Coronary Stent Implantation. IFMBE Proceedings, 2009, , 136-139.	0.2	7
1593	Advanced hybrid nanomaterials for biomedical applications. Progress in Materials Science, 2020, 114, 100686.	16.0	140
1594	Case Scenario: A Patient on Dual Antiplatelet Therapy with an Intracranial Hemorrhage after Percutaneous Coronary Intervention. Anesthesiology, 2014, 121, 644-653.	1.3	4

#	ARTICLE	IF	CITATIONS
1595	A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. <i>Journal of Clinical Investigation</i> , 2014, 124, 4102-4114.	3.9	157
1596	In-stent restenosis of drug-eluting stents: clinical presentation and outcomes in a real-world scenario. <i>Egyptian Heart Journal</i> , 2019, 71, 28.	0.4	13
1597	New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent. <i>Journal of Geriatric Cardiology</i> , 2018, 15, 137-145.	0.2	18
1598	Independent Factors for In-Hospital Death Following Drug-Eluting Stent Thrombosis From the Japanese Adverse Event Report System. <i>Circulation Journal</i> , 2020, 84, 1568-1574.	0.7	3
1599	Clinical Outcomes from Unselected Real-World Patients with Acute Myocardial Infarction Receiving Biodegradable Polymer Coated Sirolimus-Eluting Stents. <i>Journal of Cardiology and Therapeutics</i> , 0, .	0.1	1
1600	Short-Term Consequences of Angiographically-Confirmed Coronary Stent Thrombosis. <i>PLoS ONE</i> , 2013, 8, e77330.	1.1	7
1601	Association of Localized Hypersensitivity and In-Stent Neoatherosclerosis with the Very Late Drug-Eluting Stent Thrombosis. <i>PLoS ONE</i> , 2014, 9, e113870.	1.1	14
1602	Everolimus-Eluting Stents Reduce Monocyte Expression of Toll-Like Receptor 4. <i>Advanced Pharmaceutical Bulletin</i> , 2015, 5, 643-647.	0.6	7
1603	Early Phase Arterial Reaction Following Drug-Eluting and Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction. <i>International Heart Journal</i> , 2015, 56, 389-394.	0.5	9
1604	Initial Impact of Drug-Eluting Stents on Coronary Artery Bypass Grafting. <i>International Heart Journal</i> , 2007, 48, 455-461.	0.5	2
1605	Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy. <i>European Cardiology Review</i> , 2020, 15, 1-8.	0.7	9
1606	Stent Passivation with Silicon Carbide as a Possible Alternative to Drug-eluting Stents – A Comprehensive Review of Pre-clinical and Clinical Results. <i>Interventional Cardiology Review</i> , 2009, 4, 60.	0.7	16
1608	Trombose de stent farmacológico no "mundo-real": análise crítica do Registro DESIRE (Drug-Eluting) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.1	5
1609	Stent com liberação de everolimus vs. stent com liberação de zotarolimus na prática clínica do mundo real. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2010, 18, 400-406.	0.1	3
1610	Seguimento angiográfico e clínico tardio do novo stent farmacológico não-polimérico liberador de paclitaxel para o tratamento de lesões coronárias de novo: resultados do estudo PAX-B. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2012, 20, 146-154.	0.1	1
1611	Ideal coronary stent: development, characteristics, and vessel size impact. <i>Annales Academiae Medicae Silesiensis</i> , 2020, 74, 191-197.	0.1	1
1612	Major adverse cardiovascular event (MACE) after percutaneous coronary intervention in one-year follow-up study. <i>Electronic Physician</i> , 2018, 10, 6383-6389.	0.2	7
1613	The Adverse Events Rate of Endothelial Progenitor Cell Capturing Stent in the Treatment of CAD Patients. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2019, 21, 725-733.	0.6	2

#	ARTICLE	IF	CITATIONS
1614	Novel Strategies in Anti-Platelet Treatment for Coronary Artery Disease. <i>Vascular Disease Prevention</i> , 2009, 6, 75-84.	0.2	5
1615	A Case Report of a DES-Implanted Patient : Continuation of Antiplatelet Therapy Would Prevent Stent Thrombosis after Surgery. <i>The Journal of Japan Society for Clinical Anesthesia</i> , 2011, 31, 986-989.	0.0	1
1616	Very late stent thrombosis of bare-metal coronary stent nine years after primary percutaneous coronary intervention. <i>Vojnosanitetski Pregled</i> , 2016, 73, 774-778.	0.1	1
1617	A new rapamycin-abluminally coated chitosan/heparin stent system accelerates early re-endothelialisation and improves anti-coagulant properties in porcine coronary artery models. <i>Clinical and Investigative Medicine</i> , 2014, 37, 395.	0.3	4
1618	CONSTRUCTION OF BIOMIMETIC POLYMER SURFACE FOR ENDOTHELIAL CELL SELECTIVITY. <i>Acta Polymerica Sinica</i> , 2010, 00, 1474-1478.	0.0	2
1619	Comparison of Drug-Eluting Stents in Acute Myocardial Infarction Patients with Chronic Kidney Disease. <i>Korean Journal of Internal Medicine</i> , 2012, 27, 397.	0.7	4
1620	Bioresorbable Scaffolds: The Revolution in Coronary Stenting?. <i>AIMS Medical Science</i> , 2016, 3, 126-146.	0.2	3
1621	Clinical Performance of the Cobalt-Chromium Biodegradable Polymer Coated Sirolimus-Eluting Stent in an Unselected Real-World Population. <i>International Journal of Clinical Medicine</i> , 2014, 05, 206-215.	0.1	4
1622	An insight into the current use of drug eluting stents in acute and elective percutaneous coronary interventions in Europe. A report on the EuroPCI Survey. <i>EuroIntervention</i> , 2008, 3, 429-441.	1.4	17
1623	Angiographic outcomes of Orsiro biodegradable polymer sirolimus-eluting stents and Resolute Integrity durable polymer zotarolimus-eluting stents: results of the ORIENT trial. <i>EuroIntervention</i> , 2017, 12, 1623-1631.	1.4	25
1624	Final five-year outcomes after implantation of biodegradable polymer-coated biolimus-eluting stents versus durable polymer-coated sirolimus-eluting stents. <i>EuroIntervention</i> , 2017, 13, 1336-1344.	1.4	11
1625	State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation – past, present and future perspectives. <i>EuroIntervention</i> , 2017, 13, 717-733.	1.4	37
1626	Final five-year clinical outcomes in the EVOLVE trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. <i>EuroIntervention</i> , 2018, 13, 2047-2050.	1.4	42
1627	State of the art: coronary artery stents – past, present and future. <i>EuroIntervention</i> , 2017, 13, 706-716.	1.4	63
1628	Incidence and predictors of outcomes after a first definite coronary stent thrombosis. <i>EuroIntervention</i> , 2020, 16, e344-e350.	1.4	7
1629	Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. <i>EuroIntervention</i> , 2010, 6, 447-453.	1.4	116
1630	Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis. <i>EuroIntervention</i> , 2010, 6, 527-536.	1.4	29
1631	Outcomes after revascularisation with everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes and stable angina pectoris: a substudy of the SORT OUT IV trial. <i>EuroIntervention</i> , 2014, 10, 212-223.	1.4	8

#	ARTICLE	IF	CITATIONS
1632	Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial. <i>EuroIntervention</i> , 2014, 10, 449-457.	1.4	41
1633	Coronary stents seeded with human trophoblastic endovascular progenitor cells show accelerated strut coverage without excessive neointimal proliferation in a porcine model. <i>EuroIntervention</i> , 2014, 10, 709-716.	1.4	8
1634	Vascular healing and integration of a fully bioresorbable everolimus-eluting scaffold in a rabbit iliac arterial model. <i>EuroIntervention</i> , 2014, 10, 833-841.	1.4	20
1635	Different serial changes in the neointimal condition of sirolimus-eluting stents and paclitaxel-eluting stents: an optical coherence tomographic study. <i>EuroIntervention</i> , 2014, 10, 924-933.	1.4	12
1636	Preclinical randomised safety, efficacy and physiologic study of the silicon dioxide inert-coated Axetis and bare metal stent: short-, mid- and long-term outcome. <i>EuroIntervention</i> , 2015, 11, 433-441.	1.4	4
1637	Evaluation of vascular healing of polymer-free sirolimus-eluting stents in native coronary artery stenosis: a serial follow-up at three and six months with optical coherence tomography imaging. <i>EuroIntervention</i> , 2016, 12, e574-e583.	1.4	15
1638	Evaluation of myocardial blood flow and coronary flow reserve after implantation of a bioresorbable vascular scaffold versus metal drug-eluting stent: an interim one-month analysis of the VANISH trial. <i>EuroIntervention</i> , 2016, 12, e584-e594.	1.4	6
1639	Very late scaffold thrombosis after bioresorbable scaffold implantation: an unexpected new enemy on the horizon or just a false alarm?. <i>EuroIntervention</i> , 2016, 12, 1077-1079.	1.4	3
1640	Efficiency and safety of the sirolimus eluting stent in complex coronary artery lesions after cessation of dual antiplatelet therapy: fifteen months clinical outcome of the randomised Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. <i>EuroIntervention</i> , 2007, 3, 309-314.	1.4	3
1641	A pooled safety analysis of data comparing paclitaxel-eluting stents with bare-metal stents. <i>EuroIntervention</i> , 2007, 3, 392-399.	1.4	10
1642	Three-year follow-up of the ARTS-II# " sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. <i>EuroIntervention</i> , 2008, 3, 450-459.	1.4	39
1643	First clinical comparison of Nobori "Biolimus A9 eluting stents with Cypher" Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes. <i>EuroIntervention</i> , 2008, 3, 574-579.	1.4	59
1644	Spelling out risk reduction strategies for intracoronary stenting. <i>EuroIntervention</i> , 2008, 3, 622-626.	1.4	13
1645	Biodegradable-polymer-based, sirolimus-eluting SupralimusÂ® stent: 6-month angiographic and 30-month clinical follow-up results from the Series"l prospective study. <i>EuroIntervention</i> , 2008, 4, 59-63.	1.4	45
1646	One year results of a new in situ length-adjustable stent platform with a biodegradable Biolimus A9 eluting polymer: results of the CUSTOM-II trial. <i>EuroIntervention</i> , 2008, 4, 200-207.	1.4	13
1647	Very late thrombosis in acute myocardial infarction: drug-eluting versus uncoated stents. <i>EuroIntervention</i> , 2008, 4, 324-330.	1.4	5
1648	Long-term safety and efficacy are observed after implantation of Zotarolimus-Eluting Stent in real-world clinical practice. <i>EuroIntervention</i> , 2008, 4, 338-344.	1.4	2
1649	Observational studies of drug-eluting stents " some are more equal than others.. <i>EuroIntervention</i> , 2009, 4, 419-423.	1.4	1

#	ARTICLE	IF	CITATIONS
1650	Meeting report ESC Forum on Drug Eluting Stents, European Heart House, Nice, 27-28 September 2007. <i>EuroIntervention</i> , 2009, 4, 427-436.	1.4	4
1651	The relative safety and efficacy of bare-metal and drug-eluting stents in low and high-risk patient subsets. An epidemiological analysis of three sequential cohorts of consecutive all-comers (n=6129). <i>EuroIntervention</i> , 2009, 4, 464-474.	1.4	19
1652	Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularisation in patients with multivessel coronary artery disease: Insights from ARTS I and ARTS II. <i>EuroIntervention</i> , 2009, 4, 492-501.	1.4	18
1653	Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy. <i>EuroIntervention</i> , 2009, 4, 593-599.	1.4	3
1654	Patient selection to enhance the long-term benefit of first generation drug-eluting stents for coronary revascularisation procedures. Insights from a large multicentre registry. <i>EuroIntervention</i> , 2009, 5, 57-66.	1.4	11
1655	Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme. <i>EuroIntervention</i> , 2009, 5, 67-77.	1.4	28
1656	Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy. <i>EuroIntervention</i> , 2009, 5, 157-165.	1.4	64
1657	Prognostic heterogeneity among patients with chronic stable coronary disease: determinants of long-term mortality after treatment with percutaneous intervention. <i>EuroIntervention</i> , 2009, 5, 239-243.	1.4	4
1658	Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study. <i>EuroIntervention</i> , 2009, 5, 255-264.	1.4	24
1659	The use of drug-eluting stents in ST-elevation myocardial infarction. <i>EuroIntervention</i> , 2009, 5, 494-500.	1.4	2
1660	Impact of sirolimus-eluting stent implantation compared to bare-metal stent implantation for acute myocardial infarction on coronary plaque composition at nine months follow-up: a Virtual Histology intravascular ultrasound analysis. Results from the Leiden MISSION! intervention study. <i>EuroIntervention</i> , 2009, 5, 565-572.	1.4	6
1661	Long-term clinical outcomes with the next-generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial. <i>EuroIntervention</i> , 2010, 5, 692-697.	1.4	39
1662	Drug-eluting stents in saphenous vein graft interventions: a systematic review. <i>EuroIntervention</i> , 2010, 5, 722-730.	1.4	33
1663	Cost effectiveness of coronary revascularisation. <i>EuroIntervention</i> , 2010, 5, 763-767.	1.4	6
1664	Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. <i>EuroIntervention</i> , 2010, 5, 898-905.	1.4	42
1665	Vascular Restoration Therapy: the fourth revolution in interventional cardiology and the ultimate "Rosy" prophecy. <i>EuroIntervention</i> , 2009, 5, F7-F8.	1.4	28
1666	Everolimus-eluting bioabsorbable stent " Abbot Vascular programme. <i>EuroIntervention</i> , 2009, 5, F98-F102.	1.4	15
1667	Design principles and performance of bioresorbable polymeric coronary scaffolds. <i>EuroIntervention</i> , 2009, 5, F15-F22.	1.4	148

#	ARTICLE	IF	CITATIONS
1668	The bioabsorption process: tissue and cellular mechanisms and outcomes. <i>EuroIntervention</i> , 2009, 5, F28-F35.	1.4	49
1669	Randomised comparison of titanium-nitride-oxide coated stents with bare metal stents: five year follow-up of the TiNOX trial. <i>EuroIntervention</i> , 2010, 6, 63-68.	1.4	17
1670	Coronary angioscopic findings eight months after sirolimus-eluting stent implantation: a comparison between ST-elevation myocardial infarction and stable angina pectoris. <i>EuroIntervention</i> , 2010, 6, 251-256.	1.4	10
1671	A quantitative coronary angiography-matched comparison between a prospective randomised multicentre cutting balloon angioplasty and bare metal stent trial (REDUCE III) and the Rapamycin-Eluting Stent Evaluation At Rotterdam Cardiology Hospital (RESEARCH) study. <i>EuroIntervention</i> , 2010, 6, 400-406.	1.4	11
1672	Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study. <i>EuroIntervention</i> , 2010, 6, 562-567.	1.4	44
1673	Triggering mechanisms of stent thrombosis. <i>EuroIntervention</i> , 2011, 6, 722-728.	1.4	4
1674	Percutaneous coronary interventions with an endothelial progenitor cell capture stent (EPC) for high risk patients with no option for drug eluting stents: long term clinical outcomes of a single centre registry. <i>EuroIntervention</i> , 2011, 6, 826-830.	1.4	6
1675	A clinical risk score for the prediction of very late stent thrombosis in drug eluting stent patients. <i>EuroIntervention</i> , 2011, 6, 949-954.	1.4	16
1676	Atheroma and coronary bifurcations: before and after stenting. <i>EuroIntervention</i> , 2010, 6, J24-J30.	1.4	13
1677	Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study). <i>EuroIntervention</i> , 2012, 7, 1189-1196.	1.4	38
1678	Why the provisional single-stent approach is not always the right strategy; arguments for the development of dedicated bifurcation devices. <i>EuroIntervention</i> , 2012, 7, 1249-1253.	1.4	5
1679	Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting with myocardial infarction: insights from the two-year results of the COMPARE prospective randomised controlled trial. <i>EuroIntervention</i> , 2012, 7, 1376-1385.	1.4	34
1680	Clinical performance of drug-eluting stents with biodegradable polymeric coating: a meta-analysis and systematic review. <i>EuroIntervention</i> , 2011, 7, 505-516.	1.4	32
1681	Early and long-term results of unprotected left main coronary artery stenosis with paclitaxel-eluting stents: the FRIEND (French multicentre registry for stenting of unprotected LMCA stenosis) registry. <i>EuroIntervention</i> , 2011, 7, 680-688.	1.4	15
1682	The Valentines Trial: results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation DIOR paclitaxel drug-eluting balloon for in-stent restenosis treatment. <i>EuroIntervention</i> , 2011, 7, 705-710.	1.4	75
1683	Percutaneous coronary intervention versus bypass surgery for left main coronary artery disease: a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2011, 7, 738-746.	1.4	26
1684	The three year follow-up of the randomised 'all-comers' trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS). <i>EuroIntervention</i> , 2011, 7, 789-795.	1.4	36
1685	Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. <i>EuroIntervention</i> , 2011, 7, 977-984.	1.4	41



#	ARTICLE	IF	CITATIONS
1686	Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial. <i>EuroIntervention</i> , 2012, 7, 1021-1029.	1.4	30
1687	Drug-eluting balloons: future potential indications and applications. <i>EuroIntervention</i> , 2011, 7, K112-K118.	1.4	1
1688	Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study. <i>EuroIntervention</i> , 2012, 8, 109-116.	1.4	47
1689	Vasomotor function and re-endothelialisation after implantation of biodegradable abluminal polymer coated paclitaxel-eluting stents in rabbit iliac arteries: a time-course study. <i>EuroIntervention</i> , 2012, 8, 493-500.	1.4	2
1690	Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and XIENCE V drug-eluting stents. <i>EuroIntervention</i> , 2012, 8, 664-671.	1.4	19
1691	Long-term comparison of everolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for percutaneous coronary intervention of saphenous vein grafts. <i>EuroIntervention</i> , 2014, 9, 1432-1440.	1.4	21
1692	Six-month and one-year clinical outcomes after placement of a dedicated coronary bifurcation stent: a patient-level pooled analysis of eight registry studies. <i>EuroIntervention</i> , 2013, 9, 195-203.	1.4	27
1693	Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial. <i>EuroIntervention</i> , 2013, 9, 328-335.	1.4	20
1694	First-in-human evaluation of the novel BioMime sirolimus-eluting coronary stent with bioabsorbable polymer for the treatment of single de novo lesions located in native coronary vessels - results from the merIT-1 trial. <i>EuroIntervention</i> , 2013, 9, 493-500.	1.4	29
1695	Peri-stent contrast staining and very late stent thrombosis after sirolimus-eluting stent implantation: an observation from the RESTART (REgistry of Stent Thrombosis for review And Re-evaluaTion) angiographic substudy. <i>EuroIntervention</i> , 2013, 9, 831-840.	1.4	9
1696	Drug-eluting stent implantation in patients with acute coronary syndrome - the Activity of Platelets after Inhibition and Cardiovascular Events: Optical Coherence Tomography (APICE OCT) study. <i>EuroIntervention</i> , 2014, 10, 916-923.	1.4	9
1697	Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study. <i>EuroIntervention</i> , 2015, 11, 926-934.	1.4	57
1698	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>EuroIntervention</i> , 2015, 10, 1024-1094.	1.4	251
1699	Five-year clinical outcome of the Nobori drug-eluting coronary stent system in the treatment of patients with coronary artery disease: final results of the NOBORI 1 trial. <i>EuroIntervention</i> , 2015, 11, 549-554.	1.4	17
1700	Patient preference regarding assessment of clinical follow-up after percutaneous coronary intervention: the PAPAYA study. <i>EuroIntervention</i> , 2016, 11, 1487-1494.	1.4	3
1701	Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. <i>EuroIntervention</i> , 2009, 4, 481-484.	1.4	61
1702	A Decline in Platelet Activation and Inflammatory Cell Infiltration is Associated with the Phenotypic Redifferentiation of Neointimal Smooth Muscle Cells after Bare-metal Stent Implantation in Acute Coronary Syndrome. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 675-687.	0.9	18
1703	Bioresorbable everolimus-eluting vascular scaffold in patients with ST-segment elevation myocardial infarction: Optical coherence tomography evaluation and clinical outcomes. <i>Cardiology Journal</i> , 2015, 22, 315-322.	0.5	9

#	ARTICLE	IF	CITATIONS
1705	First- Versus Second-Generation Drug-Eluting Stents in Acute Coronary Syndromes (Katowice-Zabrze) Tj ETQq0 0 0,rgBT /Overlock 10 Tf	0.8	8
1706	TRANSMUTATION OF METAL AT LOW ENERGY IN A CONFINED PLASMA IN WATER. , 2006, , .		1
1707	The Frequency, Treatment and Clinical Outcomes of Stent Thrombosis after Use of TAXUSâ„¢ Stent. Korean Circulation Journal, 2007, 37, 641.	0.7	3
1708	Trombose dos stents com fármacos: o retorno de um antigo pesadelo?. Revista Brasileira De Cardiologia Invasiva, 2007, 15, 07-10.	0.1	0
1711	â†—3/4æ,£ç”ç©¶ã®é€²æ©(â3/4âç”oâ™”â† 2007â1’ã®é€²æ©). Journal of JCS Cardiologists, 2007, 15, 305-311.	0.1	0
1712	Perfil de seguranÃ§a dos stents farmacolÃ³gicos nas sÃndromes coronÃrias agudas: dados do Registro INCOR. Revista Brasileira De Cardiologia Invasiva, 2008, 16, 289-294.	0.1	1
1713	Controversies and future approaches. , 2008, , 69-76.		0
1715	Perfil de risco de reestenose em pacientes submetidos a implante de stents coronarianos convencionais. Revista Brasileira De Cardiologia Invasiva, 2008, 16, 155-159.	0.1	0
1716	A Fatal Case of Simultaneous, Very Late Thrombosis Involving Three Drug-Eluting Stents in Three Coronary Arteries. Korean Circulation Journal, 2008, 38, 564.	0.7	3
1717	Why donâ€™t we return to bare metal stents?. EuroIntervention, 2008, 4, 36-41.	1.4	0
1718	Interventional cardiology in Switzerland 2006. Cardiovascular Medicine, 2008, 11, 187-195.	0.2	2
1719	Controversies and future approaches. , 2009, , 79-88.		0
1720	â†—3/4æ,£ç”ç©¶ã®é€²æ©(â3/4âç”oâ™”â† 2008â1’ã®é€²æ©). Journal of JCS Cardiologists, 2008, 16, 319-325.	0.1	0
1721	Overview, Rationale, and Lexicon: Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. , 2009, , 1-8.		1
1722	Bioabsorbable Materialâ€”Containing Phosphorylcholine Group-Rich Surfaces for Temporary Scaffolding of the Vessel Wall. Tissue Engineering - Part A, 0, , 110306231138043.	1.6	0
1723	Predictors for very late stent thrombosis after drug-eluting stent implantation in diabetic patients. EuroIntervention, 2009, 4, 485-491.	1.4	5
1724	Very late stent thrombosis of DES implanted patient during noncardiac surgery - A case report -. Korean Journal of Anesthesiology, 2009, 57, 800.	0.9	0
1725	OPCAB after Placement of Drug-Eluting Stent: A Case of Cardiac Tamponade Developing after Resumption of Ticlopidine Administration in the Early Postoperative Period. Japanese Journal of Cardiovascular Surgery, 2009, 38, 197-200.	0.0	0

#	ARTICLE	IF	CITATIONS
1726	2. Sirolimus-Eluting Stent (SES) and antiplatelet therapy. Japanese Journal of Thrombosis and Hemostasis, 2009, 20, 355-359.	0.1	0
1728	AterotrombÃ³za: antiagregaÃ§Ã£o. Cor Et Vasa, 2009, 51, 19-21.	0.1	1
1730	Drug-eluting stents for saphenous vein graft lesions: useful or harmful?. EuroIntervention, 2010, 5, 647-648.	1.4	0
1731	Manejo de los antiagregantes en el perioperatorio. , 2010, , 123-140.		0
1733	AplicacÃ£o intracoronÃ¡ria de nanopartÃculas de paclitaxel durante intervenÃ§Ã£o percutÃ¡nea para supressÃ£o da hiperplasia intimal apÃ³s implante de stents nÃ£o-farmacolÃ³gicos. Revista Brasileira De Cardiologia Invasiva, 2010, 18, 140-150.	0.1	1
1737	Stent selection in patients with acute coronary syndromes and unstable coronary lesions. Interventional Cardiology, 2010, 2, 545-557.	0.0	1
1738	Coronary artery stenting. , 2010, , 412-428.		0
1739	Is coronary artery bypass grafting the treatment of choice for diabetic patients with multivessel disease? Yes. BMJ: British Medical Journal, 2010, 341, c6961-c6961.	2.4	1
1741	Catheter Intervention for Coronary Artery Disease: the Present Situation and Future of Percutaneous Coronary Intervention in Japan. Journal of the Nihon University Medical Association, 2011, 70, 29-31.	0.0	0
1743	The Drama of Drug-eluting Stent Thrombosis: Dr. Jekyll and Mr. Hyde. Translational Medicine (Sunnyvale, Calif), 2011, 01, .	0.4	0
1747	Coronary angioplasty: some historical remarks. EuroIntervention, 2011, 7, K8-K10.	1.4	2
1748	EvoluÃ§Ã£o tardia de pacientes com infarto agudo do miocÃrdio tratados com stents farmacolÃ³gicos na prÃ¡tica diÃ¡ria do mundo real: subanÃ;lise do Registro DESIRE (Drug-Eluting Stent In the REal World). Revista Brasileira De Cardiologia Invasiva, 2011, 19, 244-254.	0.1	0
1749	Clopidogrel Therapy Discontinuation Following Drug Eluting Stent Implantation in Real World Practice in Israel. Cardiology Research, 2012, 3, 67-72.	0.5	3
1751	Percutaneous Coronary Intervention in Patients with Diabetes and Multivessel or Left Main Disease â€“ a Review. Interventional Cardiology Review, 2012, 7, 37.	0.7	0
1752	Oral Rapamycin to Reduce Intimal Hyperplasia After Bare Metal Stent Implantation - A Prospective Randomized Intravascular Ultrasound Study. , 0, , .		0
1753	Drug-eluting Balloons in Coronary Artery Disease: Past, Present and Future. The European Journal of Cardiovascular Medicine, 2012, 11, .	1.0	0

#	ARTICLE	IF	CITATIONS
1757	Intracoronary Stenting Strategies. , 2013, , 497-529.		0
1758	Occurrence and Prognosis for the Thrombosis in the Drug-Eluting Stents and Bare-Metal Stents. The Journal of the Korea Contents Association, 2012, 12, 273-283.	0.0	0
1759	Percutaneous Coronary Intervention in Patients with Diabetes and Multivessel or Left Main Diseaseâ€™A Review. US Cardiology Review, 2012, 9, 108-111.	0.5	0
1760	Antithrombotic therapy for atherothrombotic disease. Japanese Journal of Thrombosis and Hemostasis, 2013, 24, 30-37.	0.1	0
1761	Management of Perioperative Antiplatelet Therapy. Korean Journal of Medicine, 2013, 85, 22.	0.1	1
1762	Prozedurale Komplikationen. , 2013, , 21-82.		0
1763	Modeling of stent expansion dynamics and resultant arterial wall and lesion stresses in a stenosed artery. International Journal of Design and Nature and Ecodynamics, 2013, 8, 226-238.	0.3	0
1764	Clinical Outcomes of Stent Thrombosis after Drug-Eluting Coronary Stent Implantation. The Journal of the Korea Contents Association, 2013, 13, 880-892.	0.0	3
1767	Periprocedural antithrombotic management. Journal of the Korean Medical Association, 2014, 57, 419.	0.1	0
1768	Interventional Management of Diabetic Coronaropathy and Diffuse Coronary Artery Disease. , 2014, , 1-20.		0
1769	Bioabsorbable Vascular Scaffolds Eluting with Everolimus: for Percutaneous Coronary Intervention of Patients with de-novo Coronary Artery Lesion: Our Experiences at a Tertiary Hospital. Cardiovascular Journal, 2014, 6, 122-126.	0.0	0
1770	Current representation of endovascular treatment of patients with left main coronary artery disease. Cardiosomatics, 2016, 7, 56-59.	0.2	0
1771	Estudo OPTIMIZE: Suban�lise dos Pacientes Tratados no Instituto Dante Pazzanese de Cardiologia. Revista Brasileira De Cardiologia Invasiva, 2014, 22, 233-239.	0.1	0
1775	Peri-stent Contrast Staining. , 2015, , 181-187.		0
1776	Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation. Interventional Cardiology Review, 2015, 10, 139.	0.7	0
1777	Drug-Eluting Stents and Coronary Artery Disease. , 2015, , 495-524.		0
1778	Coronary Stent Thrombosis in 2015: A Comprehensive and Uptodated&nbsp;Review. AIMS Medical Science, 2015, 2, 131-149.	0.2	0
1779	Interventional Management of Diabetic Coronaropathy and Diffuse Coronary Artery Disease. , 2015, , 2253-2270.		0

#	ARTICLE	IF	CITATIONS
1780	Drug-induced Agranulocytosis and Repeated Stent Thrombosis in a Patient Undergoing Stent Implantation: Case Report. <i>Journal of the Japanese Coronary Association</i> , 2016, 22, 273-277.	0.0	0
1781	Long-Term Follow-Up of Patients after Percutaneous Coronary Intervention with Everolimus-Eluting Bioresorbable Vascular Scaffold. <i>Arquivos Brasileiros De Cardiologia</i> , 2016, 108, 109-115.	0.3	0
1782	Current Catheter Intervention for Various Cardiovascular Diseases. <i>Juntendo Medical Journal</i> , 2016, 62, 197-208.	0.1	0
1783	Type of revascularization and outcome in patients with ischaemic cardiomyopathy and multivessel coronary disease. <i>Srce I Krvni Sudovi</i> , 2017, 36, 238-244.	0.1	0
1784	Analysis of 12 Months Clinical Outcomes Associated with Implantation of Ultrathin (60 Î¼m) Bare Metal Stent in an Unselected Real-world Population with Coronary Artery Disease. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2017, 11, OC12-OC16.	0.8	4
1785	Current consensus and future perspective of anti-thrombotic therapy for coronary artery disease. <i>Journal of the Japanese Coronary Association</i> , 2018, 24, 161-165.	0.0	0
1787	A case of acute intrastent thrombosis accompanied by arterial thrombosis in the lower extremities after percutaneous coronary intervention. <i>Anatolian Journal of Cardiology</i> , 2018, 19, 82-83.	0.5	1
1788	Acute stent thrombosis in myocardial infarction complicated by cardiogenic shock in the presence of type 2 diabetes mellitus. <i>MÃ¼nchener Medizinische Wochenschrift</i> , 2018, 140, 776-782.	0.1	0
1789	Long-term results of stenting unprotected left main of the left coronary artery in patients with a stable ischemic heart disease using different types of stents with antiproliferative coating. <i>Kardiologicheskii Vestnik</i> , 2019, 14, 33.	0.1	0
1790	Drug Eluting Stents versus Bare Metal Stents in ST- Segment Elevation Myocardial Infarction. <i>Konuralp Tip Dergisi</i> , 0, , 62-68.	0.1	1
1791	Trials Comparing Percutaneous And Surgical Myocardial Revascularization: A Review. <i>Reviews on Recent Clinical Trials</i> , 2019, 14, 95-105.	0.4	1
1792	Clinical Outcomes in Diabetic Patients with Stable Coronary Artery Disease Treated with Second-Generation Drug Eluting Stents (Short and Mid-Term Follow Up). <i>The Egyptian Journal of Hospital Medicine</i> , 2019, 77, 4832-4839.	0.0	0
1794	Capturing Endothelial Cells by Coronary Stents - From Histology to Clinical Outcomes. <i>Serbian Journal of Experimental and Clinical Research</i> , 2019, .	0.2	1
1795	Ethnic Differences in Oral Antithrombotic Therapy. <i>Korean Circulation Journal</i> , 2020, 50, 645.	0.7	13
1796	Antithrombotic therapy in coronary artery disease patients complicated with atrial fibrillation. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2020, 31, 562-570.	0.1	0
1797	Identification of Patient-Related Factors in Stent Thrombosis. <i>Circulation Journal</i> , 2020, 84, 1464-1466.	0.7	3
1798	Magmaris resorbable magnesium scaffolds: Are they here to stay?. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2020, 39, 427-429.	0.2	0
1799	Stent thrombosis during and after acute coronary syndromes: patient-related factors and operator-related factors. <i>Anatolian Journal of Cardiology</i> , 2020, 24, 274-279.	0.5	2

#	ARTICLE	IF	CITATIONS
1800	Determinants and Clinical Outcomes of Extended Dual Antiplatelet Therapy over 3 Years after Drug-Eluting Stent Implantation: A Retrospective Analysis. <i>Yonsei Medical Journal</i> , 2020, 61, 597.	0.9	2
1801	Role of stent oversizing in patients undergoing primary percutaneous coronary intervention. An open-labeled randomized controlled trial. <i>Minerva Cardiology and Angiology</i> , 0, , .	0.4	0
1802	Safety and performance of the EverPro™ everolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario. <i>World Journal of Cardiology</i> , 2020, 12, 615-625.	0.5	1
1803	Efficacy and Safety of Dual-Drug-Eluting Stents for de Novo Coronary Lesions in South Koreaâ€”The Effect Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 69.	1.0	2
1804	Vascular Biology of Smooth Muscle Cells and Restenosis. , 2020, , 117-139.		1
1805	Prozedurale Komplikationen. , 2020, , 25-98.		0
1806	Coronary Stents and Metal Allergy. , 2020, , 1-13.		0
1807	Republication deÂ: Accidents hÃ©morrhagiques graves sous antiplaquettairesÂ: que faireÂ?. <i>Journal Europeen Des Urgences Et De Reanimation</i> , 2020, 32, 14-19.	0.1	0
1810	Coronary Stents and Metal Allergy. , 2021, , 1171-1183.		1
1811	Impact of Neointimal Condition and Platelet Reactivity on Intrastent Thrombus at Long-Term Follow-up After 2nd- and 3rd-Generation Drug-Eluting Stent Implantationâ€”Insights From a Coronary Angioscopy and Pharmacodynamic Study â€•. <i>Circulation Journal</i> , 2020, 84, 2244-2252.	0.7	0
1813	Metabolic syndrome and coronary artery disease in Ossabaw compared with Yucatan swine. <i>Comparative Medicine</i> , 2010, 60, 300-15.	0.4	108
1814	Advances in drug eluting stents - focus on the Endeavor(Â®) zotarolimus stent. <i>Medical Devices: Evidence and Research</i> , 2009, 2, 1-8.	0.4	0
1815	Simultaneous very late stent thrombosis in multiple coronary arteries. <i>Texas Heart Institute Journal</i> , 2012, 39, 630-4.	0.1	6
1816	Drug-eluting stents versus bare metal stents in ST elevation myocardial infarction at a follow-up of three years or longer: A meta-analysis of randomized trials. <i>Experimental and Clinical Cardiology</i> , 2012, 17, 169-74.	1.3	9
1817	Should antiplatelet therapy be interrupted in drug eluting stent recipients throughout the pericardiac period? A very late stent thrombosis case report and review of the literature. <i>Journal of Geriatric Cardiology</i> , 2014, 11, 274-7.	0.2	0
1818	Vessel healings after stenting with different polymers in STEMI patients. <i>Journal of Geriatric Cardiology</i> , 2016, 13, 306-11.	0.2	0
1819	Five-year major clinical outcomes between first-generation and second-generation drug-eluting stents in acute myocardial infarction patients underwent percutaneous coronary intervention. <i>Journal of Geriatric Cardiology</i> , 2018, 15, 523-533.	0.2	5
1820	Real-Life Outcomes of Coronary Bifurcation Stenting in Acute Myocardial Infarction (Zabrzeâ€”Opole) Tj ETQq1 1 0,784314 rgBT /Over	0,8	2

#	ARTICLE	IF	CITATIONS
1821	Role of stent oversizing in patients undergoing primary percutaneous coronary intervention. An open-labeled randomized controlled trial. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 513-521.	0.4	0
1822	A Narrative Review of Ultrathin-strut Drug-eluting Stents: The Thinner the Better?. <i>Heart International</i> , 2021, 15, 84.	0.4	6
1823	JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease. <i>Circulation Journal</i> , 2022, 86, 477-588.	0.7	38
1824	Store-Operated Calcium Entry in the Cardiovascular System. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1349, 303-333.	0.8	2
1825	A Comparative Analysis of Two Biolimus-Eluting Biodegradable Stents: Evaluation of the Equivalence of 6 Months Versus 12 Months of DAPT Following Biolimus-Eluting Stent Implantation in Acute Coronary Syndrome (EQUUS)., 2022, 1, 61.		0
1826	Antithrombotic Therapy After Acute Coronary Syndromes or Percutaneous Coronary Interventions in East Asian Populations. <i>JACC Asia</i> , 2022, 2, 1-18.	0.5	15
1827	Laser vaporization of atherothrombotic burden before drug-coated balloon application in ST-segment elevation myocardial infarction: Two-year outcomes of the laser-DCB trial. <i>Catheterization and Cardiovascular Interventions</i> , 2022, , .	0.7	2
1828	Sulfur-Mediated Polycarbonate Polyurethane for Potential Application of Blood-Contacting Materials. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 874419.	2.0	2
1829	DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm. <i>Current Atherosclerosis Reports</i> , 2022, , .	2.0	0
1830	Real-World Long-Term Clinical Outcomes of Ultrathin Strut Biodegradable Polymer Drug-Eluting Stents in Korean ST-Segment-Elevation Myocardial Infarction (STEMI) Patients with or without Acute Heart Failure Undergoing Primary Percutaneous Coronary Intervention. <i>Journal of Clinical Medicine</i> , 2021, 10, 5898.	1.0	2
1831	3D-printed polymer nanocomposites with carbon quantum dots for enhanced properties and in situ monitoring of cardiovascular stents. <i>Polymers for Advanced Technologies</i> , 2022, 33, 980-990.	1.6	6
1832	Clinical Outcomes of Drug-Coated Balloon Treatment After Successful Revascularization of de novo Chronic Total Occlusions. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 821380.	1.1	9
1833	Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2022, , .	0.4	5
1839	Impact of Drug-Eluting Stent-associated Coronary Artery Spasm on 3-Year Clinical Outcomes: A Propensity Score Matching Analysis. <i>Indian Heart Journal</i> , 2022, , .	0.2	0
1841	Evaluation of Efficacy and Safety of Paclitaxel and Cilostazol Dual Drug-eluting Coronary Stents. , 0, 1, .		0
1842	Comparative study of neointimal coverage between titanium-nitric oxide-coated and everolimus-eluting stents in acute coronary syndromes. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2023, 76, 150-156.	0.4	2
1846	Comparison of biodegradable and durable polymer drug-eluting stents in acute coronary syndrome: a meta-analysis. <i>BMJ Open</i> , 2022, 12, e058075.	0.8	5
1848	Toward modeling thrombosis and thromboembolism in laminar and turbulent flow regimes. <i>International Journal for Numerical Methods in Biomedical Engineering</i> , 2022, 38, .	1.0	3

#	ARTICLE	IF	CITATIONS
1850	Clinical rationale and experimental feasibility of the first national drug-eluting stent platform. <i>Complex Issues of Cardiovascular Diseases</i> , 2020, 9, 52-62.	0.3	0
1851	Targeted delivery of liver X receptor agonist to inhibit neointimal hyperplasia by differentially regulating cell behaviors. <i>Biomaterials Science</i> , 0, , .	2.6	1
1852	Clinical usefulness of the pattern of non-adherence to anti-platelet regimen in stented patients (PARIS) thrombotic risk score to predict long-term all-cause mortality and heart failure hospitalization after percutaneous coronary intervention. <i>PLoS ONE</i> , 2022, 17, e0274287.	1.1	2
1853	Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e31158.	0.4	1
1854	Recurrent simultaneous two-vessel very late stent thrombosis. <i>Cor Et Vasa</i> , 2022, 64, 522-525.	0.1	0
1855	Structural and temporal dynamics analysis on drug-eluting stents: History, research hotspots and emerging trends. <i>Bioactive Materials</i> , 2023, 23, 170-186.	8.6	14
1856	Beneficial effects of high-density lipoprotein (HDL) on stent biocompatibility and the potential value of HDL infusion therapy following percutaneous coronary intervention. <i>Medicine (United States)</i> , 2022, 101, e31724.	0.4	1
1857	Analysis of the incidence and influencing factors associated with binary restenosis of target lesions after drug-coated balloon angioplasty for patients with in-stent restenosis. <i>BMC Cardiovascular Disorders</i> , 2022, 22, .	0.7	1
1858	Contemporary Drug-Eluting Stents and Vascular Response. <i>European Medical Journal (Chelmsford, England)</i> , 2023, 0, , 85-93.	3.0	0
1859	Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial. <i>Circulation: Cardiovascular Interventions</i> , 2023, 16, .	1.4	2
1860	Pro-Con Debate: Are Patients With Coronary Stents Suitable for Free-Standing Ambulatory Surgery Centers?. <i>Anesthesia and Analgesia</i> , 2023, 136, 218-226.	1.1	3
1861	Drug-Eluting Stent Restenosis: Modern Approach to a Classic Challenge. <i>Current Cardiology Reviews</i> , 2023, 19, .	0.6	1
1862	“Spongy skin” as a robust strategy to deliver 4-octyl itaconate for conducting dual-regulation against in-stent restenosis. <i>Biomaterials</i> , 2023, 296, 122069.	5.7	2
1864	Late and Very Late Stent Thrombosis in the Era of Second-Generation Drug-Eluting Stents. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 85-93.	3.0	0
1865	A Review of Systemic Hematological Manifestations and Stent Thrombosis. <i>Cardiology in Review</i> , 0, Publish Ahead of Print, .	0.6	0
1866	Procedural Complications. , 2023, , 25-95.		0